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I. Abstract 
Berberine (BBR), an herbal originated compound, has lipid-lowering activity. However, 
its low bioavailability and poor absorption characteristics have limited its clinical 
application. The aim of this research study was to investigate the lipid lowering effect 
of a novel berberine derivative, namely berberine8998, and its properties and 
underlying mechanisms.  
For the purpose of this study, the pharmacodynamics of berberine8998 was evaluated 
on a hamster model of hypercholesterolemia by a high-fat diet. Our results showed that, 
compared with the other structurally related derivatives of the berberine group, 
berberine8998 significantly lowered the serum lipid levels in hamsters. Berberine8998 
stimulated the uptake of low-density lipoprotein (LDL) in HepG2 cells in a dose-
dependent manner. Isobaric tags for the relative and absolute quantitation (iTRAQ) 
labeling proteome methods was applied, using a TripleTOF 5600 mass spectrometer to 
compare the pharmacological basis of both berberine and berberine8998. The 
mechanisms of the actions of these two compounds were investigated by identifying 
and quantifying the differences in the proteins that were expressed (with respect to the 
untreated animals) in the liver tissues of hamsters treated with the compounds. The 
result of proteome study showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) 
and long-chain fatty acid—CoA ligase 1 (ACSL1), involved in fatty acid metabolism, 
were regulated by using berberine and berberine8998. Moreover, western blot 
validation results showed that ACOX1 and ACSL1, which are proteins involved in fatty 
acid metabolism, were expressed differently in the berberine8998 group than in the 
untreated group and the berberine treatment group. Biochemistry results showed that 
berberine8998 significantly lowered the non-esterified fatty acid (NEFA) levels, which 
may lead to a reduction in TG levels in the berberine8998 treatment group and the 
differences observed in proteomics analyses. Furthermore, a pharmacokinetic study 
was applied to investigate the absorption of two formulations of berberine8998. 
These findings suggested that berberine8998 lowered cholesterol and lipid levels via 
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different mechanisms from berberine, and its improved absorption made it a promising 
therapeutic candidate for the treatment of hypercholesterolemia and obesity. 
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1. General Introduction 
1.1 Atherosclerosis 
At present, the high incidence of atherosclerosis related cardiovascular disease imposes 
an enormous burden on healthcare systems. Atherosclerosis is a chronic disease of the 
arterial wall, and is characterized by intimal deposition of lipid in the arteries and its 
progression into atherosclerotic plaques. The progression of atherosclerosis may cause 
acute myocardial infarction, stroke and peripheral vascular diseases (Hansson, 2005, 
Libby et al., 2011). It is the primary cause of coronary artery and cerebrovascular 
diseases, two of the leading causes of death and morbidity worldwide (Vishram, 2014, 
Draisci et al., 2001). Lipoproteins that contain apolipoprotein B (apoB) — for example, 
low-density lipoproteins (LDL) —are the major risk factors for atherosclerosis (Orso 
and Schmitz, 2017). Experiments and other studies on humans (Hansson, 2005, Libby 
et al., 2011, Orso and Schmitz, 2017, Vishram, 2014) found that atherosclerosis occurs 
at sites in the arterial tree where laminar flow is disrupted by atherogenic lipoproteins 
like LDL. In particular, LDL levels are clearly correlated with the risk of cardiovascular 
events in humans, as well as individual susceptibility to atherosclerosis and its 
complications. High plasma LDL levels and modifications, such as oxidation, 
glycosylation, carbamylation and glycoxidation, have been experimentally shown to be 
proatherogenic both in vitro and in vivo (Alique et al., 2015). The arterial wall gradually 
thickens to form an atherosclerotic plaque, resulting in narrowing of the artery lumen. 
The process can be summarized into four stages: 1. The initial stage of atherosclerosis 
includes the entrance of LDLs into tunica intima that is lined by a monolayer of 
endothelial cells. There they are modified by oxidation or enzymatic activity, and 
aggregate within the extracellular intimal space, thereby increasing their phagocytosis 
by macrophages (Fig 1.1a). 2. The migration of vascular smooth muscle cells (SMCs) 
contribute to the lesion progression by secreting large amounts of extracellular-matrix 
components like collagen (Fig 1.1b). 3. Plaque macrophages and SMCs can die in the 
advancing lesions, resulting in release of cellular debris and crystalline cholesterol. 
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Moreover, SMCs can form a fibrous cap that enables blood coagulation components to 
come into contact with tissue factors in the plaque’s interior (Fig 1.1c). 4. If the plaque 
does not rupture and the lesion continues to grow, the infiltrating inflammatory cells 
can interact with the intrinsic arterial cells, promoting lesion formation, etc. The lesion 
can in turn encroach on the lumen, so that the blood supply to the organ is reduced, 
resulting in a clinically obstructive disease of (mostly) the heart or brain (Fig 1.1d). 
Plaques can rupture abruptly, causing blood clots, and often myocardial infarction or 
stroke (Stary, 2000). 
 
Figure 1.1 Initiation and progression of atherosclerosis. A lesion begins as a fatty streak 
(a), and develop into an intermediate lesion (b), and then into a lesion that is vulnerable 
to rupture (c), and finally into an advanced obstructive lesion (d) (Rader and Daugherty, 
2008) 
 
However, in the development of atherosclerosis, the pathogenesis of plaques and the 
progressions of the lesion are highly complex processes, and many aspects of the 
mechanistic links between lipids and atherogenesis remain unclear. The main approach 
to threat atherosclerosis is to alleviate hypertension and hyperlipidemia and/or control 
hemostasis, so that thrombotic complications can be avoided (Weber and Noels, 2011). 
Observational data and experimental results support the argument that LDL is the major 
cholesterol-carrying lipoprotein in plasma, and therefore responsible for many forms of 
coronary heart diseases (Fig 1.2) (Nabel, 2003). After administration of lipid lowering 
drugs, cardiovascular events as well as progression of atherosclerosis in humans are 
significantly reduced, regardless of the baseline LDL concentrations (Orso and Schmitz, 
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2017). Numerous lipid-lowering therapies have established that reducing LDL levels 
lowers the risk of developing clinical multiple cardiovascular diseases, including 
atherosclerosis (Weber and Noels, 2011, Nabel, 2003, Lusis, 2000). Accordingly, LDL 
is the main target in lipid-lowering therapies for cardiovascular diseases and its 
lowering is the key strategy. 
 
Figure 1.2 Synthesis, metabolism and deposition of cholesterol leading to 
atherosclerotic lesions by LDL (Nabel, 2003) 
 
1.2 LDLR target lipid lowering drugs (statins) 
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, 
collectively known as statins (Table 1.1), are the most commonly prescribed agents for 
lipid lowering because of their high efficacy in reducing LDL and excellent tolerability 
and safety (Simoens and Sinnaeve, 2013). The development of statins has 
revolutionized the treatment of cardiovascular disease such as atherosclerosis. 
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Table.1.1 Statins market shares in Belgium (Simoens and Sinnaeve, 2013) 
Ranking 
Generic 
Name 
Company Trade Name Source 
1 Atorvastatin 
Pfizer & 
Daiichi 
Sankyo 
Lipitor, Torvast Synthesis 
2 Rosuvastatin 
Astra 
Zeneca & 
Chiesi 
Crestor Synthesis 
3 Simvastatin 
Merck & 
Co EMS  
Zocor, Lipex 
Natural 
extraction 
4 Pravastatin 
Daiichi 
Sankyo & 
Nichi-Iko 
Pravachol, 
Selektine, Lipostat 
Natural 
extraction 
5 Fluvastatin Novartis Lescol, Lescol XL Synthesis 
 
 
Studies of familial hypercholesterolemia characterized by very high LDL levels and 
early coronary heart disease have helped to unravel the pathways regulating plasma 
cholesterol metabolism. Such understandings are important for the development of 
cholesterol-lowering drugs. The most convincing evidence for a potential therapeutic 
target is when a human genetic condition from simple mendelian genetics is associated 
with an altered risk of the disease. An example is homozygous familial 
hypercholesterolemia, which is caused by mutations in the gene encoding the low-
density lipoprotein receptor (LDLR). The observation that this disease is associated 
with markedly premature atherosclerosis led to the understanding that increased 
concentrations of LDL cholesterol in plasma can cause atherosclerosis, and the concept 
that increasing LDL-receptor expression can reduce LDL concentrations and thus the 
risk of atherosclerosis.  
Statins exert a pleiotropy of anti-inflammatory actions, improve endothelial function 
and reduce plaque lipids and thrombogenicity, thereby limiting and stabilizing 
atherosclerotic plaques (Ray and Cannon, 2005). It can inhibit HMG-CoA reductase, 
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the enzyme that catalyzes the intermediate (mevalonate) which is the rate-limiting step 
in cholesterol biosynthesis (Endo et al., 1977). Statins also inhibit hepatic synthesis of 
apolipoprotein B-100 and decrease the synthesis and secretion of triglyceride-rich 
lipoproteins (Grundy, 1998). 
Simultaneously, the primary mechanism for LDL lowering is an accelerated clearance 
of LDL and LDL precursors from the circulation via LDL receptors (LDLR). The 
resulting reduction in hepatocyte cholesterol concentration triggers SREBP-2, 
stimulation of which increases expression of hepatic LDLR (Raal et al., 1997).  These 
lipid lowering mechanisms of statins are illustrated in Fig 1.3. 
 
Figure 1.3 The lipid lowering mechanisms of statins 
 
Statins can effectively lower serum LDL levels and modestly raise serum HDL levels. 
Cholesterol-lowering potency varies between different statins: third-generation statins 
such as atorvastatin or rosuvastatin are more effective than earlier generation statins, 
such as the off-patent and less expensive agent simvastatin or pravastatin (Simoens and 
Sinnaeve, 2013). The comparative efficacy and potency of statins on lipids and 
lipoproteins in patients without hypertriglyceridemia are shown in table 1.2. In general, 
LDL is reduced by an additional 7 percent with each doubling of the dose (Maron et al., 
2000). Recently there is some concern that statins are not always well tolerated, and 
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there are known differences in safety. The major adverse effect of statins is myopathy, 
defined as muscle pain or weakness associated with an elevated serum level of creatine 
kinase (Sacks et al., 1996). Symptoms may include fever and malaise, and some cases 
have been associated with elevated serum statin drug levels (Pierce et al., 1990).  
In contrast, statins have a number of pleiotrophic beneficial effects leading to reduction 
in inflammation, slowing the progression of atherosclerosis, and plaque stabilization. 
At least one-quarter of the high-risk patients who received intensive statin therapy have 
LDL levels above the guideline mandated goals (Pierce et al., 1990). New biological 
targets such as Proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged, 
and they could lead to incremental lowering of LDL levels to a greater degree than that 
achieved by high-dose statin therapy.  
 
Table 1.2 Comparative efficacy of six statins on the percentage LDL and HDL 
changes in patients without hypertriglyceridemia (Maron et al., 2000) 
Statin Drug, mg 
Change in LDL and 
HDL 
Atorvastatin Simvastatin Lovastatin Pravastatin Fluvastatin LDL HDL 
  10 20 20 40 
（+）
27% 
（+）4-8% 
10 20 40 40 80 
（+）
34% 
（+）4-8% 
20 40 80    
（+）
41% 
（+）4-8% 
40 80     
（+）
48% 
（+）4-8% 
80         
（+）
55% 
（+）4-8% 
 
 
1.3 Development of PCSK9 target lipid lowering drugs 
The discovery of Proprotein convertase subtilisin kexin type 9 (PCSK9), initially called 
NARC1 (Neural Apoptosis Regulated Convertase1), in 2003 and the demonstration of 
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its unique functional activity to degrade LDL-R has made it a subject of intense research 
for possible treatment of hypercholesterolemia as an alternative to statin and other drugs 
(Seidah et al., 2003). Increased level of PCSK9 functional activity leads to an 
accumulation of cholesterol in the blood - a high risk factor for cardiovascular disease 
(Basak et al., 2012). Treatment with PCSK9 Inhibitors can reduce cardiovascular 
inflammation and its consequences (Bonaventura et al., 2017). 
 
Genetic studies have shown that mutations in the gene that encodes PCSK9 augment 
LDLR levels on cell surfaces, thereby boosting LDL clearance as well as yielding lower 
serum LDL concentration, and is associated with a form of autosomal dominant 
hypercholesterolemia (Cohen et al., 2006). Individuals with loss-of-function variants in 
PCSK9, who are exposed to lower levels of LDL from childhood than those with the 
common genotype for this enzyme, seem to be protected from atherosclerotic events 
even when they have other cardiovascular risk factors (Brown and Goldstein, 2006). 
PCSK9 is thus a highly attractive target for reducing LDL-cholesterol concentrations. 
Mechanistic studies show that PCSK9 functions by reducing the amount of LDLR at 
the cell surface of hepatocytes. More specifically, after catalysing its own cleavage, 
PCSK9 is secreted and binds to the cell-surface LDLR, thereby targeting them for 
degradation rather than recycling (Horton et al., 2007). A patch of residues in the 
catalytic domain of PCSK9, that binds to the extracellular domain of the LDLR, is 
located in the first epidermal growth factor-like repeat homology domain (EGFA) of 
the LDLR and is closely associated with the molecular interactions within the PCSK9-
LDLR complex (Zhang et al., 2007). PCSK9 binds to LDLR by two possible routes, 
one extracellular, where PCSK9 exits the cell and binds LDLR on the cell surface. The 
second route may involve an intracellular route where PCSK9 enters the endosome 
directly from the golgi and binds to LDLR, and then rerouting it to the lysosome, 
thereby enhancing receptor degradation (Bottomley et al., 2009). Critical observations 
have provided evidence that increase of PCSK9 disrupts the normal recycling of the 
LDLR, consequently increasing the serum LDL levels (Lambert et al., 2012). The above 
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mentioned findings promise PSCK9 to be a potential therapeutic target, and have 
prompted biopharmaceutical companies to develop interventions for lowering serum 
LDL levels. (Fig 1.4) 
LDLR
PCSK9
LDL
LDLR
degradation
LDLR
recycle
Figure 1.4 Mechanism by which PSCK9 redirects degradation of LDLR. (See text for 
details) 
 
In recent years, studies have greatly supplemented our understanding of the 
pathological role of PCSK9 in human biology. Clinical development programs for 
monoclonal antibodies against PCSK9 have advanced rapidly with completion of 
comprehensive phase 1 and 2 trials with both REGN727/SAR236553 (REGN727) and 
AMG 145 (Stein and Swergold, 2013). Completed phase 2 trials in more than 1,500 
patients have confirmed the advantage of early lowering of LDL efficacy and 
demonstrated potential added benefit from reduction of lipid levels. 
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1.4 Pharmacology of berberine 
1.4.1 New perspectives of berberine 
Berberine is a quaternary ammonium salt belonging to the protoberberine group 
of benzylisoquinoline alkaloids (Fig 1.5) and the main active constituent of Coptis 
chinensis French (Yin et al., 2008). As a traditional medicine or dietary supplement in 
China, some prescriptions contain large concentrations of berberine because in 
conjunction with its long history of treatment in clinical practice, people have always 
believed that it has very low toxicity and superior effects for treating many diseases. 
The berberine-rich herb has been used for the treatment of many chronic and acute 
diseases including diarrhea, cancer, depression, hypertension, hypercholesterolemia, 
and diabetes mellitus, as recorded in many ancient Chinese traditional medicinal works 
(Hashemzaei et al., 2017, Pirillo and Catapano, 2015, Zhang et al., 2008). 
 
Figure 1.5 Chemical structure of berberine 
 
It has also been shown to have significant lipid-lowering activity. Treatment of 
hypercholesterolemia patients with orally administered berberine reduced serum levels 
of cholesterol, triglycerides, and low-density lipoprotein (LDL) by 29%, 35%, and 25%, 
respectively. For hyperlipidemic hamsters, berberine treatment reduced serum total 
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cholesterol (TC) by 40% and LDL by 42% (Kong et al., 2004). Berberine has also 
shown some promise of curing type 2 diabetes and dyslipidemia (Zhang et al., 2008). 
 
1.4.2 Molecular pathways of how berberine regulates LDL  
As mentioned, LDL is a major risk factor for atherosclerosis and coronary heart disease, 
and is the main target of lipid-lowering drugs (Nabel, 2003, Canto and Iskandrian, 
2003).  Several mechanisms have been proposed for explaining the cholesterol-
lowering effects of berberine. Berberine increases the abundance of LDL receptor 
(LDLR) in the liver by stabilizing its transcription (Kong et al., 2004, Li et al., 2009). 
LDLR is responsible for the binding and cellular uptake of apolipoprotein (apo)B- and 
apoE-containing lipoproteins; dysregulation of this process results in 
hypercholesterolemia. Upregulation of LDLR on the hepatocyte surface by genetic or 
pharmacological means has been shown to increase hepatic clearance and reduce serum 
levels of LDL-cholesterol (Defesche, 2004, Fass et al., 1997, Jeon and Blacklow, 2005). 
The level of LDLR expression is therefore considered as a key factor determining LDL-
cholesterol concentration in the circulation. 
Berberine also increases the abundance of hepatic LDLRs by reducing the level of 
PCSK9 which binds the EGFA of the LDLR at the hepatocyte surface, thereby 
promoting their lysosomal degradation (Cameron et al., 2008, Zhang et al., 2007). 
Berberine treatment may have also revealed multiple mechanisms by which this 
compound exerts its cardioprotective effects. Moreover, the advent of proteomics 
analysis has permitted effective expression measurement of large sets of samples. 
 
1.4.3 Pharmacokinetic studies of berberine8998 
There are problems associated with the use of berberine. The hyperlipidemia patients 
have to take 1 g/ day or above to lower the lipid levels. Patients compliance can play a 
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role (Zhang et al., 2008). Pharmacokinetic study in animal models has revealed that 
berberine has a poor bioavailability profile, which means that a relatively high dose is 
necessary in order for berberine to yield its efficacy in vivo (Cheng et al., 2010). To 
address this problem, the berberine derivatives dihydroberberine (Cheng et al., 2010) 
and berberrubine (Li et al., 2010) have been synthesized, but their absorption profiles 
turned out to be limited. Accordingly, there is a need for berberine derivatives having 
better bioavailability profiles.  
 
1.5 Proteomic research 
1.5.1 Protein extraction and sample preparation. 
General cell lysis methods for protein extraction are listed in Table 1.3. Lysis buffer 
contained a chemotropic agent, a reducing agent, a buffer solution and a surface active 
agent (Ahmed, 2009).  
Table 1.3 Methods for performing cell lysis and their impact on the level of 
breakdown 
Lysis intensity Methods 
Low Osmosis schizolysis, Enzymatic digestion, Eradicator 
schizolysis 
Middle Homogenate, Freeze-thawing circles, Mechanical crushing 
High Stress break, Bead grinding, Sonication crushing 
 
For archival of formalin-fixed, paraffin-embedded (FFPE) tissues, the protein 
extraction required tissue boiling in a retrieval solution of Tris-HCl containing 2% SDS 
(Shi et al., 2006). To extract integral membrane proteins (IMPs), the use of 1-butyl-3-
methyl imidazolium tetrafluoroborate (BMIM BF4) cloud significantly improved the 
large-scale identification of IMPs (Sun et al., 2011). 
Systematic detection of low-abundance proteins that may be putative disease 
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biomarkers is complicated by an extremely wide range of protein abundances. Hence, 
depletion of major proteins is one potential strategy for enhancing detection sensitivity. 
Commercialized HPLC columns could be used to remove the high abundant proteins 
in the blood (Echan et al., 2005). Another method is based on using protein equalizer 
technology to sharply reduce the concentration of the most abundant components, while 
simultaneously enhancing the concentration of the most dilute species (Boschetti and 
Righetti, 2008, Righetti et al., 2006). The Proteo Miner (Bio-Rad) can be applied in the 
protein equalizer arena as a non-depleting tool for discovering low-abundance species. 
Digestion and depletion of abundant proteins also can improve proteomic coverage 
(Fonslow et al., 2013, Fonslow et al., 2014). 
Protein digestion is a critical and time consuming step. The current conventional in-
solution or in-gel protein digestion has usually been performed using trypsin in a 
buffered medium overnight, which is considerably slower and limits large scale 
proteome analysis. New approaches such as microwave assisted technology and 
pressure cycling technology could accelerate the protein digestion process (Lopez-
Ferrer et al., 2008, Lin et al., 2008). 
Using multiple proteases for large-scale mass spectrometry-based proteomics on 
complex samples could improve both protein identification and protein characterization. 
This method relies on the combined use of different proteases (Table 1.4) to 
enzymatically digest complex protein mixtures to generate a collection of peptides for 
mass spectrometric analysis (Swaney et al., 2010). Multiple proteases approach could 
increase the chances for successful identification of peptides but it is limited to 
discovery of proteins. 
Table 1.4 Summary of proteases cutting sites 
Proteases Proteases cutting site 
Trypsin 
C terminus of K,R (last amino acid is 
not P) 
Endoproteinase Lys-
C 
C terminus of K 
Endoproteinase Arg-
C 
C terminus of R 
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Endoproteinase Asp-
N 
N terminus of R 
Endoproteinase Glu-
C 
C terminus of E 
 
1.5.2 Column separation strategy for the recovered peptides 
For bottom-up proteome analyses of digested peptides obtained from a proteome 
sample, it is by now generally considered that at least two dimensions of separation (2D 
LC) are needed to cover a proteome in reasonable depth. The 2D LC separation is 
usually performed using a SCX column in series with a RP column for reducing the 
complexity and dynamic range of the samples (Davis et al., 2001). In the course of the 
analysis, tryptic peptides are eluted stepwise by injecting salt plugs of increasing ionic 
strength from the SCX column in the first dimension. In the second dimension these 
peptides are first trapped on a RP enrichment column and finally separated on an 
analytical RP column by nanoscale liquid chromatography (nanoLC) systems (Yamana 
et al., 2013). Many different configurations have been developed to optimize RP 
nanoLC. The most basic design consists simply of the analytical column operating at 
nanoliter flow rates where a few microliters of the sample are directly loaded onto the 
column (Masuda et al., 2011, Thakur et al., 2011). By combining two different LC 
techniques with individual peak capacities between 50 and 100, it should theoretically 
be possible to achieve total capacities of 2500–10,000 peaks (Nagele et al., 2004). 
 
1.5.3 Conditions for mass detection 
In the past three decades, startling new developments in two ionization methods — 
matrix-assisted laser desorption (MALDI) and electrospray (ESI) — have been 
introduced by Karas et al. and by Fenn et al., respectively (Karas and Hillenkamp, 1988, 
Fenn et al., 1989). Their work, which won the Nobel prize in 2002, demonstrated that 
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these techniques, under appropriate experimental conditions, have high sensitivity and 
wide mass range, extending to hundreds of thousands of daltons and beyond (Costello, 
1997). Thus, these ionization methods can be applied to proteomics studies. MALDI 
ions source analysis usually requires off-line separation strategy.  
Peptide sequencing is the key step in commonly employed approaches within mass 
spectrometry-based proteomics. The current method of choice for peptide sequencing 
for MS/MS spectra is collision induced dissociation/collision activated dissociation 
(CID/CAD). Compared with traditional, ion-trap-based collision-induced dissociation 
(CID), a more recent method of fragmentation, namely HCD (higher energy collisional 
dissociation), provides beam type CID tandem MS with detection of fragment ions at 
high resolution in the orbitrap mass analyzer (Jedrychowski et al., 2011). Development 
of alternative fragmentation techniques such as electron transfer dissociation (ETD) has 
extended the possibilities within tandem mass spectrometry (Frese et al., 2011). 
Moreover, electron-driven dissociation methods, namely by electron capture 
dissociation (ECD) or electron transfer dissociation (ETD) and their application in 
phosphor peptide analysis, have also been evaluated (Boersema et al., 2009). These 
techniques are useful for in large-scale proteomics studies. 
The most common fragment spectrum acquisition mode is data dependent acquisition 
(DDA), which is a serial process of peptide selection and fragmentation. During a DDA 
experiment, fragmentation spectra are acquired by sequentially isolating and 
fragmenting peptide ions providing that certain criteria (set a priori) related to the 
precursors have to be satisfied (Shliaha et al., 2013). The fragment ion (MS2) spectra 
for selected precursor ions detectable in a survey (MS1) scan are generated (Domon 
and Aebersold, 2006). There is another approach, so called data independent acquisition 
(DIA) method, which is to fragment a group of precursors covering a mass window of 
specific size in the cyclic recording throughout the LC time range (Gillet et al., 2012). 
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1.5.4 The development of labelled peptides proteomics techniques  
The small molecule compound exerts its pharmacological effects through binding to 
proteins directly or affecting its transcription, translation, post-modification indirectly. 
Therefore, a technique to elucidate these effects may be needed to profile the proteins 
that involved in its biological effects. Proteomics, which studies proteins on large scale, 
is a research hotspot in this century (Tubaon et al., 2017). In this type of analysis, MS 
based isotope labelling proteomic technology is applied for identification and 
determination of concentration ratios of proteins expressed in animal tissues of different 
states, especially with respect to effect of a drug against absence of the drug, to 
understand the function of various proteins. 
The first MS-based isotope labeling proteomic technology was ICAT (Gygi et al., 1999). 
It was quickly commercialized for quantitative proteomics of cells and tissues. The 
approach of ICAT involves cysteine specific tagging of intact proteins, proteolytic 
digestion, ICAT peptides labelling, chromatographic separation followed by MS 
analysis (Yu et al., 2004). However, it has not been widely used because of limitation 
in determining the cysteine free proteins.  
In recent years, the development and commercialization of the alternative chemical 
labelling method ICPL harnesses NHS ester groups to derivatise primary amino groups 
in intact proteins. The major advantage of ICPL (in contrast to ICAT) is its reliance on 
the generally abundant lysine residues in proteins, which results in multiple labelling 
sites and increasing in MS sensitivity for the labelled peptides (Sarioglu et al., 2006, 
Wiese et al., 2007). 
In summary, the technique involves a reporter group, which is used to identify the amino 
acids within the digested peptides by means of MS analysis. The iTRAQ reagents attach 
to stable isotopes, providing derivatives of the digested peptides. The iTRAQ 
technology also exploits, similar to ICPL, the link to the NHS ester, forming a derivative 
with the reporter group (Ross et al., 2004). One advantage of having isobaric mass 
design of the iTRAQ reagents is that differently labelled peptides appear as single peaks 
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in the MS scans, thus reducing the possibility of peak overlapping (Wiese et al., 2007). 
There are eight different iTRAQ reagents available, and hence a comparative analysis 
of a set of two to four samples is feasible within a single MS run. More importantly, the 
iTRAQ approach is more reliable and effective on cation exchange chromatography 
separation. The labelled peptides in ICPL, ICAT and iTRAQ techniques all require 
separation by two-dimensional LC. Adequately labelled peptides digested from each 
protein are then used to evaluate the results and summarized for analysis of the proteins 
using statistical methods based on peptide quantization information (Molina et al., 
2005). 
 
1.6 Research hypothesis 
Berberine8998 (Fig1.6) is a novel berberine derivative. The hypothesis of this study is 
that berberine 8998 exerts greater LDL-c and TG lowering effect than berberine in 
vivo. Furthermore, we hypothesize that berberine shares similar mechanisms with 
berberine in their LDL-c lowering effect. The mechanism of its TG lowering effect 
will be examined via proteomics. 
 
 
Figure 1.6 Chemical structure of berberine8998 
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1.7 Research aims and experiment design  
1.7.1 Research aims 
In the present study, a novel berberine derivative, namely berberine8998, with a view 
to preparing a compound that will have better pharmacological and bioavailability 
profile. The aims cover the following: 
1. Investigate the acute oral toxicity (Lethal Dosage 50) of berberine8998 
2. To evaluate the in vivo lipid lowering effects in a hamster model of 
hypercholesterolemia induced by a high-fat diet.  
3. To compare the in vitro lipid uptake promoted by berberine and berberine8998 in   
HepG2 cell line, as determined by the amount of Dil-LDL uptake. 
4. Explore the molecular pharmacology mechanisms of berberine and berberine8998   
using proteomic methods. 
5. Establish a LC/MS/MS method to analyse serum levels of branched amino acids. 
6. Measure serum levels of NEFA and validate related expressed proteins. 
7. Determine the serum concentration of berberine by LC/MS/MS 
8. Compare different formulations of berberine8998. 
 
1.7.2 Experiment design 
The main experimental protocol (not including the aims 1, 2, 6 and 8) is shown in Fig 
1.7. The pharmacodynamic effects of berberine and berberine8998 were evaluated by 
measuring the weight, as well as the serum TC, TG, LDL and the non-esterified fatty 
acids (NEFA) levels in hamsters that were divided into untreated control, berberine and 
berberine8998 treated groups. Liver tissue samples from hamsters were also collected 
and the different expression of proteins was analyzed by isobaric tags for the relative 
and absolute quantitation (iTRAQ) to determine the mechanisms of action of the two 
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compounds. The intensity (a.u.) of Dil-LDL in HepG2 cells was screened to compare 
the lipid uptake amount of positive control group (Pravastatin), berberine group and 
berberine8998 group. Western blot analyses were applied to evaluate the LDLR 
expression. 
 
 
 
 
Figure 1.7 Schematic representation of the main experimental protocol. A) Blood and 
tissue analyses of untreated and BBR- and BBR-B8898-treated hamsters. B) Cell-based 
analyses of untreated and BBR- and BBR-8898-treated HepG2 cells.  
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2. Materials and Methods 
2.1 Chemicals, regents and instruments 
2.1.1 Chemicals and regents 
Product name (alphabetical) Supplier 
A  
Amino Acid Analyzer RP C18 Column AB SCIEX Inc 
AA 45/32 amino acid amounts kit AB SCIEX Inc 
Acetonitrile (HPLC grade) DIKMA Co Ltd 
Anti-LDLR Abcam 
Anti-PCSK9 Abcam 
Anti-ACOX1 Abcam 
Anti- ACSL1 Abcam 
  
B  
BCA assay Beyotime Ltd 
BerberineShifangJubang Plant Materials Co Ltd. 
Berberine8998 (derivative of berberine) Shanghai Institute of Materia Medica 
Protein assay dye reagent concentrate Bio-Rad 
BSA (Bovine Serum Albumin) Merck Inc 
  
C  
Carvedilol (Internal Standard) Salutas Pharma GmbH 
CAPCELL PAC C18 2.0×100mm，5μm Thermo Co Ltd 
C18 4.0×3.0mm，5μm Phenomenex Co Ltd 
  
D  
DiI (1,1'-dioctadecy l-3,3,3',3'– BiotiumInc 
tetramethylindocarbocyanine perchlorate)  
Dialysis bag Spectrum Co Ltd  
Dimethylcarbinol (HPLC grade) DIKMA Co Ltd 
DMEM (Dulbecco's Modified Eagle 
Medium) 
Life (invitrogen) Inc 
DMSO (Dimethyl sulfoxide) AmerscoInc 
  
F  
FBS (Fetal Bovine Serum) Life (invitrogen) Inc 
Fenofibrate ShangqiuChemry Chemicals Co Ltd 
Formic acid (HPLC grade) CWN Co Ltd 
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H  
High density lipoprotein cholesterol assay kit  Wako Pure Chemical Industries Ltd 
  
I  
Isoflurane Sinopharm Chemical Reagent Co Ltd 
Isopropanol Sinopharm Chemical Reagent Co Ltd 
iTRAQ reagent AB SCIEX Inc 
  
L  
Low density lipoprotein cholesterol assay kit  Wako Pure Chemical Industries Co Ltd 
NEFA-HA Test kit Wako Pure Chemical Industries Co Ltd 
  
P  
Polysulfoethyl column Nest Group Inc 
PVDF membrane for protein blotting BioRadInc 
  
S  
Sep-Pak Cartridge Waters Inc 
SCX chromatography The Nest Group Inc 
Sodium carboxymethyl cellulose (CMC-Na) Sinopharm Chemical Reagent Co Ltd 
  
T  
Total cholesterol assay kit Wako Pure Chemical Industries Co Ltd 
Triglyceride assay kit Sichuan Maker Biotechnology Co Ltd  
Trypsin Sigma Aldrich Inc 
  
Z  
Zorbax 300SB-C18 reversed-phase column Agilent Technologies Inc 
 
All the other regents/chemicals were purchased from Sinopharm Chemical Reagent Co 
Ltd 
 
2.1.2 Instruments 
(1) Name: Mass Spectrometer 
Model: Applied Biosystems API 3000™ LC/MS/MS System 
Manufacturer: Applied Biosystems Co. Ltd. 
 
(2) Name: HPLC system 
Model: SIL-HTc Autosampler (X1);  
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LC-20AD Pump (X2);  
DGU-20A3; Auto Degassing apparatus (X1);  
CTO-20A column heater (X1) 
Manufacturer: Shimadzu Co. Ltd. 
 
(3) Name: Computer 
Model: Intel (R) Pentium (R) 4 CPU 3.20/3.19GHz, 1.00GB of RAM 
Manufacturer: DELL Co. Ltd 
 
(4) Name: Balance  
Model: CP225D 
Manufacturer: Sartorius Co. Ltd 
 
(5) Name: Centrifuge 
Model: MIKRO 22R (with 1195-L rotor) 
Manufacturer: Hettich Co. Ltd 
 
(6) Name: Turbine mixer 
   Model: Vortex-2 
Manufacturer: Scientific Industries Co. Ltd 
 
(7) Name:Pipettor 
Model: Eppendorf Research (0.5-10μL，10-100μL，20-200μL，100-1000μL) 
Manufacturer: Eppendorf Co.Ltd 
 
(8) Name: Magnetic Stirrers 
Model: RCT basic IKAMAG 
Manufacturer: IKA 
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(9) Name: Automatic Biochemical Analyzer 
Model: 7020 
Manufacturer: Hitachi (China), Ltd. 
 
(10) Name: Filter Unit 
Model: Millex-GP, 0.22 µm, polyethersulfone, 33 mm, gamma sterilized 
Manufacturer: Millipore Ireland, Ltd. 
 
(11) Name: Ultracentrifuge 
Model: CP100MX 
Manufacturer: Hitachi (China), Ltd. 
 
(12) Name: Microplate Reader 
Model: Spectra Max M2e 
Manufacturer: Molecular Devices, Ltd 
 
(12) Name: Electrophoresis tank 
Model: Mini-Protean Tetra System 
Manufacturer: Biorad, Ltd 
 
(13) Name: Semi-dry transfer unit 
Model: Trans-Blot SD Cell 
Manufacturer: Biorad Ltd 
 
(14) Name: Electrophoresis Imaging Cabinet 
    Model: Chemi DOCTM XRS+ 
    Manufacturer: Biorad Ltd 
 
 
(15) Name: HPLC system (For 2.5.2) 
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Model: 20AD HPLC system 
Manufacturer: Shimadzu Inc 
 
(16) Name: Nano LC system (For 2.5.2) 
    Model: Ekspert™ nanoLC 415 
    Manufacture: Eksigent Technologies Inc 
 
(17) Name: Mass Spectrometer (For 2.5.3) 
Model: TripleTOF 5600 mass spectrometer 
Manufacturer: Applied Biosystems Co. Ltd 
  
(18) Name: Mass Spectrometer (For 2.6.1) 
    Model: AB 3200 QTRAP 
Manufacturer: Applied Biosystems Co.Ltd. 
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2.2 Animals 
2.2.1 Mice 
Male and female 8-week old C57BL/6 mice (50 males and 50 females, weighing 18-22 
g) were obtained from Shanghai Institute of Materia Medica (SIMM), Chinese 
Academy of Science. The animals were kept at standard housing conditions (22±2°C, 
50-60% humidity with a range of 40-80% and 12/12 light/dark cycle). They were fed 
with standard laboratory chow (normal diet: MO2-type Feed, Table 2.1) and water ad 
libitum. 
Table 2.1 The nutrient and other content of MO2-type Feed (Lys: lysine, Met: 
methionine, Cys: cysteine) 
MO2 Water protein Fat ash fiber Ca P Lys Met&Cys other Kcal/g 
% 9.7 20.5 4.62 6.2 4.35 1.23 0.91 1.3 0.68 50.51 3.45  
 
2.2.2 Hamsters 
Golden hamsters (Mesocricetus auratus, 16 weeks old, weighing 80-100g) were 
obtained from SIMM. The animals were kept at standard housing conditions (22±2°C, 
50-60% humidity with a range of 40-80% and 12/12 light/dark cycle). Two dietary 
regimens were used in this study: hamster fed a standard laboratory chow (normal diet: 
MO2-type Feed) and water ad libitum, and left to acclimatize before the 
experiment. During the experiment, selected group of hamsters were fed a high-fat diet 
(high-fat diet: MO-2type Feed with 20% lard).  
 
2.2.3 Sprague Dawley (SD) Rats 
SD Rats (Rattus norregicus, 8 weeks old, weighing 200-250g) were obtained from 
SIMM. The animals were kept at standard housing conditions (22±2°C, 50-60% 
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humidity with a range of 40-80% and 12/12 light/dark cycle). They were supplied with 
standard laboratory chow (normal diet: MO2-type Feed, Table 2.1) and water ad libitum. 
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2.3 Cell culture 
2.3.1 HepG2 cell 
HepG2 cell cultures (ATCC® HB-8065™) were originally derived from the liver tissue 
of a 15-year-old Caucasian American male with a well-differentiated hepatocellular 
carcinoma. They are a suitable in vitro model system for the study of polarized human 
hepatocytes. In this study, HepG2 were seeded into either 12-well or 24-well plates and 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 8% fetal 
bovine serum (FBS), 100 U/ml penicillin-streptomycin, and 0.1 mM nonessential 
amino acids (Gibco, Grand Island, NY). Cells were grown for 72 h at 37 Celsius Degree 
in an atmosphere of 5% CO2 in a humidified incubator. 
 
2.4 Pharmacological studies of berberine8998 
2.4.1 Acute oral toxicity study of berberine8998 
2.4.1.1 Preliminary experiment 
Berberine8998 powder (99%) was obtained from Youhong Hu of the SIMM group and 
the preliminary study was aimed at determination of the acute oral toxicity median 
Lethal Dosage (LD50) for this compound. The value of the median Lethal Dosage (LD50) 
stands for the acute oral toxicity of test compounds. All the mice were raised to 
acclimatize for 2 weeks before the experiments. To explore the possible LD50 range for 
berberine8998, 20 mice were randomly divided into 5 groups. Each group contained at 
least 2 female mice and 2 male mice. The weights of these mice are recorded in Table 
2.2. 
Table 2.2 Body weight of mice utilized in the preliminary experiment to determine the 
LD50 for berberine8998. 
Group No Female (g)  Female (g) Male (g) Male (g)  
1 21.5 20 27.8 24.5 
38 
 
2 19.2 19.5 22.9 22.4 
3 19.1 19.5 23.6 25.9 
4 20.9 19.4 23.6 26.8 
5 17.8 18.7 24.7 25.7 
 
Table 2.3 Dosage used for the five groups included in the preliminary experiment. 
Group No Dosage(mg/kg)  
1 1000 
2 800 
3 600 
4 500 
5 400 
 
After being without dietary exposure for 16 h, intragastric administration of 5 different 
berberine8998 in CMC-Na formulations were administrated orally using a stainless 
steel feeding tube. The gavage process was performed under light anesthesia using 
isoflurane. The dose of 5 groups were randomly set up from 400mg/kg to 1000mg/kg. 
 
2.4.1.2 Further acute toxicity analysis of berberine8998 
The preliminary experiment indicated the LD50 value to be between the maximum 
1.0mg/g and the minimum 0.5mg/g. Subsequently, a second experiment was conducted 
with 25 male mice and 25 female mice randomly divided into five groups (Group A, B, 
C, D and E) (n=10, 5 male and 5 female in each group). All mice were fasted overnight 
(12 h) before treatment. Mice were administered intragastrically (i.g) with 500 mg/kg 
(Group A), 595 mg/kg (Group B), 707 mg/kg (Group C), 841 mg/kg (Group D) and 
1000 mg/kg (Group E), respectively. The dose number was depend on the death number 
of preliminary experiment. The number of animals dead was recorded after 24 h of 
treatment. The suspected death reason of mice was intestinal obstruction. 
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All animal experimental procedures were carried out in accordance with international 
guidelines for care. The uses of laboratory animals were approved by the Institutional 
Ethical Committee of Shanghai Institute of Materia Medica. IACUC Number: 2014-
08-WYP-18 
 
2.4.2 DiI-LDL uptake by HepG2 cells via Low Density Lipoprotein Receptors 
(LDLRs) 
2.4.2.1 Preparation of Phosphate Buffered Saline (PBS) and Dialysate 
PBS is a water-based salt solution containing sodium chloride, sodium phosphate, and, 
in some formulations, potassium chloride and potassium phosphate are also included. 
The buffer's phosphate groups help to maintain a constant pH. To prepare PBS solution, 
7.9g NaCl, 0.2g KCl, 0.24g KH2PO4 and 1.8g K2HPO4 were weighted and dissolved in 
800ml distilled water. Then the solution was transferred to a 1L volumetric flask. 
Distilled water and HCl were added to that solution to provide a final volume of 1L and 
pH of 7.4.The PBS solution (0.01M) was stocked at 4℃. 
Tris Dialysate is a solution used to remove ions (NaBr) out of the serum. Serum is 
placed in a dialysis bag surrounded by dialysate. Diffusion then occurs, whereby the 
ions move out of the serum into dialysate. To prepare the Tris dialysate, 2.42g Tris, 8.5g 
NaCl and 0.2g EDTA were weighted and dissolved in 800 ml distilled water. Then the 
solution was transferred to a 1L volumetric flask. Distilled water and HCl were added 
dropwise to adjust the pH to 7.4, providing a final volume of 1L. The Tris dialysate 
(0.02M) was stored at 4℃in a fridge until required. 
 
2.4.2.2 Preparation of Low Density Lipoprotein (LDL) and Lipoprotein Deficient 
Serum (LPDS) 
LDL is one of the five major group of lipoproteins, which in order of size, largest to 
smallest, are chylomicrons, Very Low Density Lipoprotein (VLDL), Intermediate 
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Density Lipoproteins (IDL), LDL, and High Density Lipoprotein (HDL), that enable 
transport of multiple different fat molecules, including cholesterol, by the water around 
the cells as well as in the water-based bloodstream. 
LPDS is usually prepared by ultracentrifugation, all of the lipoproteins are removed and 
extensively dialyzed. The resultant LPDS is membrane filtered and packaged 
aseptically. Each fraction is evaluated in Human Skin Fibroblast or other cells in culture 
with LDL and [I125] LDL (or DiI-LDL and DiO-LDL) to determine the degree of up 
regulation of LDL receptors. Typical fractions led to a 3 to 4 fold increase in [I125] LDL 
binding. The LPDS is not diluted and the typical protein concentration for the bovine 
LPDS is 75 -120 mg/ml and for the human LPDS it is ~50mg/ml. 
The human serum was purchased from Shanghai Xuhui Central Hospital. First, it was  
defrosted from -20℃ to 4℃. The density of the serum was adjusted to 1.019 g/ml by 
addition of NaBr. It was moved to a centrifugal tube (Hitachi PA40) and centrifuged at 
250000g, 4℃ for 4 hours. The top layer of the serum, which contained chylomicron 
and VLDL was removed. NaBr was added to the rest to adjust the density to 1.063 g/ml. 
Then the sample was centrifuged at 250000g, at 4℃ for 24 hours. The orange layer of 
the serum contained LDL. 
The density of other serum containing LPDS was adjusted to 1.1g/ml by adding NaBr. 
To separate the remaining LDL and IDL, the sample was centrifuged at 250000g, at 4℃ 
for 18 hours and the top layer removed. Then the serum density was raised to 1.21 g/ml 
and centrifuged at 250000g, at 4℃ for 48 hours. The top layer of the serum was HDL. 
The bottom layer of the serum contained LPDS. 
The LDL serum and the LPDS serum components were separately put into two dialysis 
bags (5kD pore size). The dialysis bags were placed in a beaker containing Tris 
dialysate (0.02M) for 48 hours to remove NaBr (the Tris dialysate was changed every 
8 hours). Then the dialysis bags were moved to a beaker containing PBS (0.01M) for 
another 48 hours. After that process, the LDL serum and the LPDS serum were filtered 
using filter (0.22µm). Finally, they were stored at 4℃ until required. 
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2.4.2.3 Preparation of Dil-LDL 
DiI, also called D282, is a fluorescent lipophilic in docarbocyanine dye, with an 18-
carbon-long alkyl hydrocarbon tail, and a 3-carbon bridge between the indolinenuclei. 
It is used for scientific staining purposes, such as single molecule imaging, fate mapping, 
and neuronal tracing. Dil was used to label LDL by adding 15 mg/ml Dil suspended in 
DMSO to LDL in LPDS (volume ratio 1:2) with gentle mixing. The suspension was 
mixed end-over-end for 18 h at 37℃ in the dark. The density of the suspension was 
increased by the addition of 1.063g KBr/ml of suspension and centrifuged at 250000g 
for 24 h at 10℃. DiI-LDL was removed from the top of the tube, dialyzed against PBS 
(0.01M), and stored at 4℃ in the dark until use. 
 
2.4.2.4 Labeling HepG2 with Dil-LDL 
HepG2 cells were obtained from Shanghai Institutes for Biological Sciences (SIBS). 
These cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) for 24 hours. To improve the 
expression of LDLR, the cells were treated with DMEM supplemented with 2% FBS 
for another 24 hours, and thereafter were incubated with Dil-LDL in DMEM. 
2.4.2.5 Determination of Dil-LDL uptake by HepG2 cells 
(1) Standard Curve: Using Dil-LDL (Section 2.4) and physiological saline to prepare 
different concentrations of Dil-LDL (0ng/ml, 100ng/ml, 200ng/ml, 400ng/ml, 800ng/ml, 
1200ng/ml, 1600 ng/ml). Using Microplate Reader (Molecular Devices, Spectra Max 
M2e, Exciting light: 520nm, Emitted light: 570nm) to determine these seven 
concentration with two replicates to provide the standard curve of Dil-LDL. 
(2) Method to determine the of Dil-LDL uptake: The culture medium in a 24-well plate 
was removed. Cell were left in the 24-well plate. 0.4% BSA (dissolved in PBS w/v) 
was used to wash the plates three times. Fluorescence microscopy was applied to take 
a photo of the plates. Then isopropanol (0.5ml each well) was added to extract Dil-LDL 
taken up by the HepG2 cells. The 24-well plate were placed on an incubating shaker 
for 20 min., then the isopropanol (containing Dil-LDL) was centrifuged at 1960 g for 
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15 min. The 200µl of the top layer was recovered and transferred to the fluorescence 
detector (Exciting light: 520nm, Emitted light: 570nm). 
(3) Calculation: First, the total Dil-LDL endocytic content of HepG2 was determined 
at 37℃ for 2-3h and labeled as A. Then the Dil-LDL bound to the cell membrane of 
HepG2 cells was determined at 4℃ for 2-3h and labeled as B. The amount of Dil-LDL 
uptake is equal to A minus B. All the determinations used a fluorescence detector with 
the methods as described above. 
 
2.4.3 Serum lipid level monitoring in hamsters 
2.4.3.1 Preparations of Sodium Carboxyl Methyl Cellulose (CMC-Na) formulations 
(1) Fenofibrate formulation (30 mg/ml):A solution of CMC-Na (100ml 0.5%) was 
mixed with fenofibate powder (3g). 
(2) Berberine and berberine derivative formulations:  
(60 mg/ml): A solution of CMC-Na (80ml 0.5%) was mixed with 4.8 g berberine 
powder. The mixture was stirred using a magnetic stirrer for 12 hours. 
(30 mg/ml): as above but mixed with 3 g berberine8998 powder. 
(15 mg/ml): as above but mixed with 1.5 g berberine8998 powder.  
 
2.4.3.2 Experimental procedure to determine the effect of berberine and 
berberine8998 on lipid metabolism in hamsters 
In the preliminary study, a high-fat diet induced dyslipidemic hamster model was used 
to study the lipid lowering effects of berberine and berberine8998. Hamsters were 
randomly divided into six groups with 10 hamsters in each group. These were: 
Group 1 (negative control: high-fat diet),  
Group 2 (positive control: high-fat diet + 50mg/kg fenofibrate),  
Group 3 (berberine8998 50mg: high-fat diet + 50mg/kg berberine8998),  
Group 4 (berberine8998 100mg: high-fat diet + 100mg/kg berberine8998),  
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Group 5 (berberine 200mg: high-fat diet + 200mg/kg berberine) and  
Group 6 (control on normal diet).  
All groups of hamsters with the exception of Group 6 were fed with a high-fat diet (15% 
lard, 0.2% cholesterol and MO2 feed) for a total of 4 weeks. 
After being fed the high-fat diets for two weeks, fenofibate (30 mg/ml), berberine8998 
(15 mg/ml and 30 mg/ml) and berberine (60 mg/ml) were given (i.g.) to the appropriate 
groups for the following three weeks via intragastric administration. Food and water 
were changed every day. Blood samples (0.3-0.5 ml) were collected weekly by the 
retro-orbital bleeding of the hamsters maintained without dietary exposure for 16 h. 
Blood samples were centrifuged at 3000g for 15 min to collect the serum sample. Total 
cholesterol, LDL, triglyceride and HDL were analyzed by Automatic Biochemical 
Analyzer (Hitachi 7020). At the end of the experimental period, the hamsters were 
sacrificed, their livers were harvested and cut into small pieces (approximately 3 x 3 
mm) and then immediately separately frozen at -70℃ for further studies (e.g., Western 
blot analysis).  
After the preliminary study, it was considered necessary (clarification provided in 
Chapter 5, Section 5.1.1) to modify the arrangement of the hamster groups: Group 1 
(model: high-fat diet), Group 2 (berberine8998: high-fat diet + 50mg/kg berberine8998) 
and Group 3 (berberine: high-fat diet + 50mg/kg berberine). Group 4-6 were replicates 
of Groups 1-3. However, this was later found to be unnecessary since the same was 
undertaken for 2 weeks of feeding on high-fat diet in the preliminary experiment. 
Unless otherwise stated, the other experimental procedures were the same as in the 
preliminary study detailed above. 
 
All animal experimental procedures were approved by the Ethical Review Committee 
for the use of laboratory animals of the Shanghai Institute of Materia Medica and 
carried out in accordance with international guidelines for care.  
 
44 
 
2.4.4 Western blot analysis 
2.4.4.1 Constituents of the buffers 
(1) 1x RIPA Buffer: 50 mMTris, 150 mMNaCl, 0.1% SDS, 0.5% Sodium Deoxycholate, 
1% Triton X-100 or NP40. 
(2) 1x PBS Buffer: 137 mMNaCl, 2.7 mMKCl, 2.7 mM Na2HPO4, 2.7 mM KH2PO4, 
pH 7.4 
(3) 1.5 M Tris buffer (pH 8.8): 90.68 g Tris-HCl to ddH2O, adjust pH to 8.8 using HCl 
and to final volume 500ml 
(4) 1.0 M Tris ype of samplebuffer (pH 6.8): 60.58 g Tris-HCl to ddH2O, adjust pH to 
6.8 using HCl and to final volume 500ml 
(5) 10% APS: 100 mg AP in 1 ml ddH2O. Prepared before use. 
(6) 10% SDS: 10 g SDS in 100 ml ddH2O. 
(7) 1x Tris-Glycine running buffer: 25 mM Tris, 230 mM Glycine (pH 8.3), 0.1% SDS. 
(8) 3x SDS Protein loading buffer: 150 mM Tris (pH 6.8), 6% SDS, 30% glycerol, 30 
mM EDTA and 0.2% 
(9) 1x TBST: 25 mM Tris (pH 7.5): 0.15 M NaCl, 0.05% Tween-20, 0.001% Thimerosal 
(10) 1x Transfer Buffer: 3 g Tris, 14.4 g Glycine and 200 ml methanol, add ddH2O to 
1L 
 
2.4.4.2 Sample preparation 
(1) Preparation of Hype of epG2 cell samples 
Firstly, the supernatant was removed. The cells were then washed with1X PBS to 
remove residual media. 400 µL-1 ml 1X RIPA buffer/100 mm was added to the cells in 
a culture dish. The dish was incubated on ice for 5-10 min. Then the cells were scraped 
completely and transfer to pre-chilled 1.5 ml microtubes on ice before being 
homogenized (sonicated 15s) thoroughly and centrifuged at 1960g at 4℃for 10-15 min. 
The supernatant was collected for use. Total protein recovered was stored at -20℃ until 
needed. 
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(2) Preparation of hamster liver samples 
The livers were chopped into small pieces. 500-600 μL pre-chilled 1x RIPA buffer/100 
mg tissue was added. The tissue was homogenized using Pellet pestle motor (Axygen), 
before being sonicated for 10s and then centrifuged at 1960g at 4℃ for 15-20 min. The 
supernatant was collected for use. Total protein recovered was stored at -20℃ until 
needed. 
2.4.4.3 Protein quantification 
(1) Bicinchonic acid (BCA) assay  
The protein concentration within the various extracted samples was determined by the 
means of the bicinchonic acid assay kit (BCA assay, Beyotime Ltd.). 1-20 μL of the 
protein samples were used for each measurement in triplicate. Protein standards 
comprised of bovine serum albumin (BSA) in the range 0-0.5 mg/ml (0 mg/ml, 0.025 
mg/ml, 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5mg/ml). Standards 
and samples were added to a 96 well plate, individually mixed with 200 μL of BCA 
working solution. The resultant mixtures were incubated at 37℃ for 30 min to allow 
blue coloration to develop. Absorbance was then measured at 550 nm using a 
Microplate Reader (Molecular Devices, Spectra Max M2e). Protein concentrations 
were obtained by deriving the equation of line of best fit from average standard values 
according to y=mx+c. 
 
(2) Preparations of SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Mini-Protean Tetra casting frame, casting stand, and gel cassette (Bio-Rad Laboratories 
Ltd.) were assembled according to the manufacturer’s instructions. The composition of 
the resolving gels was 6-12% (v/v)43 acrylamide/bisacrylamide, 0.375 M Tris-HCl (pH 
8.8), 0.1% (v/v) sodium dodecyl sulphate (SDS), 0.05% (v/v) ammonium persulfate 
(APS), and 0.02% (v/v) tetramethylethylenediamine (TEMED). Gels were poured, over 
laid with water and set for 30 mins, before removing the water and stacking gels of 
composition 4% (v/v) acrylamide/bisacrylamide, 0.125 M Tris-HCl (pH 6.8), 0.1% (v/v) 
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SDS, 0.05% (v/v) ammonium persulfate (APS), and 0.02% TEMED (v/v) were poured 
on top of the resolving gel. Combs (Bio-Rad Laboratories Ltd.) were inserted and the 
gels set for 5 mins. The gels were usually used immediately, but occasionally stored for 
up to 5 days at 4°C wrapped in wet paper towels and Clingfilm. 
 
(3) SDS-PAGE 
3x SDS Sample Loading Buffer was added to the samples and these were boiled for 
10min. Mini-Protean Tetra Gel Cassette and electrophoresis module (Bio-Rad 
Laboratories Ltd.) was assembled according to the manufacturer’s instructions. 20-40 
μL of each denatured protein sample were loaded and resolved at 80V, in 6-12% (w/v) 
SDS-polyacrylamide gels for 120 min in electrophoresis buffer. 5-10 μL of pre-stained 
molecular weight markers (Thermo, Ltd.) was resolved alongside the protein samples 
serving as a reference for approximate protein size determination.  
 
(3) Electrophoretic protein transfer 
Resolved protein gels were transferred to polyvinylidene fluoride (PVDF) membranes 
(Biorad, Ltd). Trans-Blot SD Cell (BioRad Laboratories Ltd.) were assembled. A PVDF 
membrane was pre-treated in absolute methanol for 5 sec, then washed in 1x transfer 
buffer for 5 min before use. Both gel and membrane were then sandwiched between 
buffer-soaked filter papers X2. Proteins were transferred onto the blotting membrane 
through electrophoretic transfer (conditions: 70 mA) for 1.5hrs using pre-chilled 
transfer buffer. Following the electrophoretic transfer, the blots were trimmed to size 
and submerged in blocking buffer (5% non-fat milk dissolved in 1x TBST) for 2 hours 
at room temperature, prior to probing with antibodies. 
 
(4) Immunoblotting 
Primary antibodies were mouse-monoclonal antibodies against LDLR (1:2000), 
ACOX1 (1:200) and ACSL1 (1:200) (all from Abcam, Cambridge, UK). Antibody was 
diluted in 1X TBST+5% BSA at the recommended dilution and incubated overnight 
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with the membrane at 4℃. Primary antibody was recovered and stored at 4℃. Then, 
membrane was washed with1X TBST 5 times for 10min on a shaker at room 
temperature. Secondary antibody was anti-mouse IgG (1:2000; Bio-Rad). The 
membrane was incubated in dilutions secondary antibody solution (diluted in 1X TBST) 
for 1 hour at RT. It was washed 5 times for 10min in TBST on a shaker at RT. ECL were 
used for conjugated secondary antibody. Photos were taken by Molecular Imager 
ChemiDOCTM XRS+ (Bio Rad). 
 
2.5 Proteomics research 
2.5.1 Protein extraction and sample preparation. 
In this work, fresh liver tissue (3  3 mm) was removed from berberine- and 
berberine8998-treated and untreated control animals and stored at −80°C until required. 
Samples were cut into small pieces (0.1 g). To eliminate the effect of sample variation 
in proteomic analyses, five small pieces from each group were ground together in liquid 
nitrogen to produce 12 test samples (four each for berberine, berberine8998 exposed 
and control tissues) for protein extraction. 
The 12 frozen test samples were dissolved in lysis buffer composed of 7 M urea, 2 M 
thiourea, 65 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride at 4°C, and 
sonicated three times at 70 W for 5 s at 10s intervals, followed by three rounds of 
homogenization using a whirlpool mixer at 10 min intervals. Samples were centrifuged 
at 1960 g for 30 min at 4°C and the protein concentration in the supernatant was 
determined by the Bradford assay, with BSA used to generate the calibration curve. 
Trypsin digestion and isobaric tags for relative and absolute quantitation (iTRAQ) 
labeling were carried out according to the manufacturer’s instructions (Applied 
Biosystems, Foster City, CA, USA). Briefly, 150 μg proteins from each sample were 
reduced and alkylated and then digested overnight at 37°C with trypsin (MS grade; 
Promega, Fitchburg, WI, USA). Samples were labeled with iTRAQ reagent (Applied 
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Biosystems) as follows: berberine, iTRAQ reagent 113/114; berberine8998, reagent 
115/116; and control, reagent 117/118. Two sets of six isobaric tags were applied to the 
12 digested protein samples. 
 
2.5.2 Column separation strategy for the recovered peptides 
In the present work, mixed peptides were fractionated by strong cation exchange (SCX) 
chromatography on a 20AD high-performance liquid chromatography (HPLC) system 
(Shimadzu, Kyoto, Japan) using a polysulfoethyl column (Nest Group, Southborough, 
MA, USA) with the following dimensions: 2.1 × 100 mm, 5 μm, and 300 Å. Mixed 
peptides were desalted with a Sep-Pak Cartridge (Waters, Milford, MA, USA), diluted 
with loading buffer (10 mM KH2PO4 in 25% acetonitrile [ACN], pH 2.8), and loaded 
onto the column. Buffer A was identical in composition to the loading buffer. Buffer B 
was the same as Buffer A except that it contained 350 mM KCl. Peptide separation was 
carried out using a linear binary gradient of 0–50% Buffer B in Buffer A at a flow rate 
of 200 μl/min for 1 h. Absorbance at 214 and 280 nm was monitored, and 30 SCX 
fractions were collected along the gradient, dried, dissolved in Buffer C (5% ACN and 
0.1% formic acid [FA]) and analyzed on a model 5600 mass spectrometer (Applied 
Biosystems, see 2.5.3). Peptides were separated on a Zorbax 300SB-C18 reverse phase 
(RP) column (Agilent Technologies, Santa Clara, CA, USA) with the following 
dimensions: 0.1 × 15 mm, 5 μm, and 300 Å with a gradient of 5%–35% Buffer D (95% 
ACN and 0.1% FA) in Buffer C at a flow rate of 0.2 μl/min for 65 min. 
 
2.5.3 Conditions for mass detection 
In our study, the ESI ion source in series with NanoLC system was chosen. CID/CAD 
peptide sequencing strategy and DDA fragment spectrum acquisition mode were 
selected for detection. Survey scans were acquired from 400 to 1800 cm−1, with ≤ 
four precursors selected for MS/MS from m/z 100–2000 using a dynamic exclusion of 
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30 S for selected ions. The iTRAQ-labeled peptides were fragmented under collision-
induced dissociation conditions to yield reporter ions at 113.1, 114.1, 115.1, 116.1, 
117.1, and 118.1 Th; the ratios of their peak areas reflected the relative abundance of 
the peptides and therefore of the proteins in the samples. Larger, sequence information-
rich fragment ions were also produced under the same MS/MS conditions and provided 
the identity of the protein from which the peptide originated. 
 
2.5.4 Data analysis 
Protein Pilot v4.5 (Applied Biosystems) was used to identify and quantify iTRAQ-
labeled peptides. This software was also used to generate the minimum number of 
identified peptides by removing redundant hits. MS/MS data were searched with 
UniProt. The rat database was used since the corresponding hamster database is not 
available. The precursor and iTRAQ fragment tolerance values were set to 100 ppm 
and 0.6 Da. The parameters for data analysis were: sample type = iTRAQ (peptide-
labeled); Cys alkylation = methyl methanethiosulfonate; digestion = trypsin; instrument 
= time-of-flight 5600 ESI; species = RAT; ID focus = biological modifications; 
database = Swissprot Rat (35672 entries). 
To minimize the occurrence of false positive results, A decoy database search strategy 
was adopted to estimate the FDR < 1% for peptide and protein identification FDR<1% 
was applied to protein identification. At least one peptide with a confidence interval of 
95% was included [29]. Data were considered reliable for P <0.05 and error factor <2. 
Student’s t-test and P-value was used to evaluate the significance of protein expression 
level change. Fold-change ratios <0.7 (down regulated) or >1.3 (up regulated) were 
selected as cutoff values for significant changes in protein expression. Gene Ontology 
(GO, http://www.geneontology.org/) was used to verify the function of proteins that 
were up- or down-regulated by berberine or berberine8998 treatment. The signaling 
pathways of proteins were elucidated by searching the Kyoto Encyclopedia of Genes 
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and Genomes database. MATLAB was used for the mathematical modeling and 
analyzing the KEGG pathways. 
2.6 Proteomics validation 
2.6.1 Validation of results from the proteomic analyses 
2.6.1.1 Sample preparation 
Hamster plasma (40µL) and sulfosalicylic acid (10µL) were mixed in a 1.5 mL 
centrifugal tube and vortexed for 10s. The mixture was then centrifuged at 1000g for 2 
min. Supernatant (10µL) and labeling buffer (40µL) were mixed in a 1.5mL centrifugal 
tube and vortexed for 10s. The mixture was centrifuged at 1000 g for a further 2 min. 
10µL of supernatant was removed for the analysis (denoted as S1). 
A bottle of iTRAQ115 regent was thawed to room temperature and then centrifuged at 
1000g for 2 min. Isopropanol (70µL) was added to dilute the iTRAQ115 reagent. The 
mixture was vortexed for 10s and centrifuged at 1000g for 2min. Diluted iTRAQ115 
reagent (5µL) was mixed with S1. The mixture was left at room temperature for 30 min 
for the derivatization reaction. After 30 min, hydroxylamine solution (5µL) was added 
to stop the derivatization reaction. The sample was vacuum dried at 40°C (denoted as 
P1).  
AA45/32 (1.8mL) internal standard diluted solution was added to dissolve iTRAQ114 
powder. The solution was vortexed for 30-60sec. The solution (32µL) was added to 
dissolve P1 (denoted as S2). The S2 was vortexed for 30 seconds and centrifuge at 
1000g for 2 min. S2 (2µL) was analyzed for determination of the amino acids in the 
serum. 
 
2.6.1.2 LC condition 
AAA C18 (150 mm×4.6 mm, 5 m, AB Sciex) was selected as the column for the 
analysis. C18 (4.0×3.0mm, 5 m, Phenomenex) was chosen to be the protection column. 
Mobile Phase A was water containing 0.01% heptafluorobutyric acid and 0.1% formic 
acid. Mobile Phase B was acetonitrile containing 0.01% heptafluorobutyric acid and 
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0.1% formic acid. LC grads and LC time are listed in Table 2.4 Flow rate was set at 
0.8ml/min. Column temperature was 50°C. The temperature in auto sampler was 
maintained at 4°C. 
Table 2.4 LC gradient conditions for determination of amino acids 
Total Time 
(min) 
Mobile Phase 
A % 
Mobile Phase 
B % 
0 98 2 
9.5 76 24 
11 20 80 
14 20 80 
16 98 2 
25 98 2 
 
2.6.1.3 Mass spectra condition 
ESI ion source was selected for determination. Scan model was set at MRM for positive 
ion.  
Ion source：ESI; Polarity: Positive ion; Scan model: MRM; Ion transitions: See 
Appendix;  
Parameter: GS1 60psi, GS2 60psi, Curtain gas 20psi, Collision gas Medium; Voltage 
1500V. 
An AB 3200 QTRAP (Applied Biosystems/MDS Sciex, Toronto, Canada) was operated 
in the positive ionization mode. Ion transitions of amino acid and IS were set as given 
in the Appendix 1. Highly pure nitrogen was used for mass spectrometry analysis. The 
source/gas parameters were set as: GS1: 60, GS2: 60, Curtain gas 20, ion spray voltage 
1500V. The other analyte parameters are listed in Table 2.5. 
 
Table 2.5 Analyte parameters for amino acid determinations 
DP（V） EP（V） CE（V） CXP（V） 
30 10 30 5 
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2.6.2 Serum levels of NEFAs 
2.6.2.1 Sample collection and preparation 
The serum samples were gathered from 76 hamsters, which were fed for five weeks. 
For the Normal diet group, the hamsters were always fed with normal diet (MO2 feed) 
for five weeks. See 2.4.3.2 for animal grouping. Blood samples (0.3-0.5 ml) were 
collected weekly from the orbit of the hamsters without dietary exposure for 16 h. The 
blood samples were centrifuged at 3000g for 15 min to prepare the serum sample. 
 
2.6.2.2 Analysis by automatic biochemical analyzer 
The model 7020 Hitachi's one of the smallest automatic analyzer yet. It brings great 
flexibility in automatic clinical analysis. Despite its compactness, it offers a 
performance of up to 36 test items simultaneously and up to 200 tests per hour. And 
STAT is achieved through very easy operation. 
Automatic biochemical analyzer was applied with NEFA-HA Test kit to validate the 
proteomic results on protein pathway by testing the 76 hamster serum samples (above 
section 2.6.2.1). There are the four reagents in the NEFA-HA Test kit. (1) Color Reagent 
A: 0.53 U/mL ACS, 0.31 mM CoA,  4.3 mM ATP 4-aminoantipyrine, 2.6 U/mL 
ascorbate oxidase and 0.062% sodium azide  (2) Solvent A: 50 mM phosphate buffer 
PH7.0 and 0.05% sodium azide (3); Color Reagent B: 12 U/mL ACOD and 14 U/mL 
POD. (4) Solvent B:  2.4 mM MEHA. All stored between 2-10℃. Before testing, one 
bottle of Solvent A was added to one vial of Color Reagent A to prepare Color Reagent 
A Solution. One bottle of Solvent B was added to one vial of Color Reagent B to prepare 
Color Reagent B Solution. These two Color Reagent Solutions were placed in the 
automatic biochemical analyzer along with the 76 hamster serum samples from the four 
groups (Normal diet group, High-fat diet group, High-fat diet with Berberine8998 50 
mg group, and High-fat diet with Berberine 50mg group). Data were collected and 
processed by Zhifang Software. 
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2.6.3 Western blots validation of differently expressed proteins 
2.6.3.1 Preparation of buffers 
See section 2.4.5.1 
 
2.6.3.2 Liver sample preparation 
See section 2.4.5.2 
 
2.6.3.3 Protein quantification 
See section 2.4.5.3 
 
2.7 Formulation of berberine8998 
2.7.1 Methods for determination of berberine levels 
 (1) HPLC conditions 
Analytic column: CAPCELL PAK C18，2.0lytimm，5μm 
Protect column: C18（4.0×3.0mm，5μm） 
Mobile phase: Mobile phase A 0.1% formic acid in water,  
Mobile phase B acetonitrile 
Elution program: A: B=69:31, isocratic elution 
Flow rate: 0.3mL/min 
Column temperature: room temperature 
Autosampler temperature: 4℃ 
Sample size: 5μL 
 
The chromatographic separation of berberine and carvedilol (internal standard) was 
carried out on Shimadzu LC-20AD HPLC system (Kyoto, Japan) equipped with two 
LC-20AD pumps, a HIL-HTc auto-sampler and an online DGU-20A3 vacuum degasser. 
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The analytical column was CAPCELL PAK C18 (2.0to-smm 5μm) coupled with a 
C18 protect column (4.0 mm × 3.0 mm, 5 μm). The mobile phase consisted of phase A 
(0.1% formic acid in water) and phase B (acetonitrile). Berberine was eluted at a flow 
rate of 0.3 ml/min with an isocratic elution program of A/B at 69:31 (v/v). Aliquots of 
5 μl was injected for the HPLC analysis. 
 
(2) Conditions for determination of the molecular mass conditions 
Ion source：ESI 
Polarity: Positive ion 
Scan model: MRM 
Ion transitions: Berberine 336.2→320.0amu, IS：407.3 →100.1amu 
Parameter: GS1 60psi, GS2 60psi, Curtain gas 20psi,  
Voltage 5500V, Temperature 550℃ 
 
An API 3000 triple quadrupole tandem mass spectrometer (Applied Biosystems/MDS 
Sciex, Toronto, Canada) equipped with a Turbo Ionspray source was operated in 
positive ionization mode. Ion transitions of m/z 336.2/320.0 were used for quantitative 
detection of berberine, respectively and m/z 407.3/100.1 for IS detection. Highly pure 
nitrogen was used for the mass spectrometry analysis. The source/gas parameters were 
set as: GS1: 60, GS2: 60, Curtain gas 20, ion spray voltage 5500V and the source 
temperature 550 °C. Other mass spectrometry analysed parameters are listed in Table 
2.6. 
Table 2.6 Mass spectrometry analysis parameters for berberine and internal standard. 
Analyte DP（V） EP（V） CE（V） CXP（V） 
Berberine 65 
5 45 
20 
IS 60 10 
 
2.4.2.2 Solution preparation 
2.4.2.2.1 Preparation of stock and working solutions 
(1) Berberine stock solution: Berberine 3.23mg was weighed and dissolved in 50% 
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acetonitrile water solution to form 291μg/mL berberine stock solution. 
(2) Berberine working solution: Berberine stock solution was transferred into 50% 
acetonitrile water solution. 
(3) Internal standard stock solution: Carvedilol 3.41mg was dissolved in 50% 
acetonitrile water solution to provide 308μg/mL carvedilol stock solution. 
(4) Internal standard work solution: Appropriate berberine stock solution was transfered 
into 50% acetonitrile water solution. 
Stock solutions were stored at 4 ℃ and kept stable for 4 weeks.  
The concentration of stock solution was test by LC/MS/MS during four weeks. 
 
2.4.2.2.2 Mobile phase preparation 
Mobile phase A (contain 0.1% formic acid water solution): Formic acid 1mL was 
removed into 1000ml water, mix for 10s. 
Mobile phase B was acetonitrile 
 
2.4.2.3 Preparation of standard curve samples and quality control (QC) sample 
2.4.2.3.1 Standard curve annex solution 
To prepare 5ng/ml, 10ng/ml, 20ng/ml, 40ng/ml, 80ng/ml, 150ng/ml, 300ng/ml standard 
curve solution, 5μl standard curve annex solution was added into 50μl blank serum. For 
equal matrix effect for all the test samples, the concentration here stands for the 
compounds concentration in the matrix (pure serum). 
 
2.4.2.3.2 Solutions for a standard curve 
The highest concentration of stock solution (3000ng/ml) was prepared by means of a 
closed system transfer device (CSTD7-3000 ng/mL). The preparation of other 
standard curve annex solution (CSTD-1500ng/mL, CSTD-800ng/mL, CSTD-
400ng/mL, CSTD-200ng/mL, CSTD-100ng/mL, CSTD-50ng/mL) was accomplished 
by adding 50%-acetonitrile water solution, as shown in Table 2.7. 
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Table 2.7 Preparation of solutions for derivation of the standard curve. 
 
Solution 
type 
Solution 
code 
Transferred solution（µL） 
50% acetonitrile water 
solution（µL） 
Concentration
（ng/mL） 
S
tan
d
ard
 so
lu
tio
n
 
CSTD7 Suitable working solution Suitable 3000  
CSTD6 CSTD7：400 400 1500  
CSTD5 CSTD6：480 420 800  
CSTD4 CSTD5：400 400 400  
CSTD3 CSTD4：400 400 200  
CSTD2 CSTD3：400 400 100  
CSTD1 CSTD2：400 400 50  
 
2.4.2.3.3 Quality control annex solution 
To prepare highest concentration quality control solution (QC3-2000 ng/mL), the 
appropriate stock solution was removed into acetonitrile:water 50:50 solution. The 
preparation of other standard curve annex solutions (QC2-500ng/mL, QC1-150ng/mL, 
QC0-50ng/mL) was adding the required amount of the higher concentration standard 
curve annex solution into 50% acetonitrile water solution as given in Table 2.8. 
Table 2.8 Preparation of quality control annex solutions 
Solution 
type          
Solution 
code                       
Removed solution              
（µL） 
50% acetonitrile water 
solution        （µL） 
Concentration        
（ng/mL） 
QC QC3 Appropriate working solution  Appropriate 2000 
 QC2 QC3：250 750 500 
 QC1 QC2：300 700 150 
 QC0 QC2：300 600 50 
 
2.4.2.3.4 Quality control solutions 
To prepare 5ng/mL (LLOQ, Lower Limit of Quantification), 15ng/mL (LQC, Low QC), 
150ng/mL (MQC, Middle QC), 200ng/mL (HQC, High QC) solutions, removed 5μl 
quality control annex solution into 50μl blank serum. For equal matrix effect for all the 
test samples, the concentration here represents the compounds concentration in the 
matrix (pure serum). 
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2.3.2.4 Serum sample preparation (mice, hamster and rat) 
2.3.2.4.1 Sample preparation for standard curve and quality control analysis 
The standard curve solution (55μl) and the quality control solution (5μl) were added to 
acetonitrile (100μl). The mixture was vortex for 30s, then centrifuged at 1960 g (4℃) 
for 10min. The supernatant was recovered and retained for analysis. 
 
2.3.2.4.2 Sample preparation of quality control solution 
The blank serum (50μl), 50% acetonitrile water solution (5μl) and internal standard 
curve solution/quality control solution (5μl) was removed into 100μl acetonitrile 
solution. The mixture was vortex for 30s, then centrifuged at 1960 g (4 °C) for 10min. 
The supernatant was recovered and retained for analysis. 
 
2.3.2.4.3 Sample preparation of blank serum 
The blank serum (50μl) and 50% acetonitrile water solution (10μl) was removed into 
100μl acetonitrile solution. Mixture was vortexed for 30s, then centrifuged with 1960g 
in g (4°C) for 10min. The supernatant was recovered for analysis. 
 
2.3.2.5 Data analysis 
Data from the berberine analyses were collected and processed by Analyst1.4.2 
software (AB SCIEXInc). Individual pharmacokinetic parameters were assessed by a 
noncompartmental method using DAS version 2.0 (Drug And Statistics). Cmax and Tmax 
were obtained by direct inspection of individual plasma concentration– time profiles. 
The AUC0–t was calculated using the linear-up/log-down trapezoidal method. The 
terminal elimination constant (λz) was estimated from the natural logarithm–
transformed plasma concentration–time curve using linear regression, and the t1/2 was 
calculated as ln2/λz. The AUC0–∞ was calculated as AUC0–t + Clast/λz. Data were 
presented as Mean±SD. 
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2.7.2 Preparation of berberine8998 formulation 
Formulation A (berberine8998 microcrystal suspensions): 0.714g of berberine8998 was 
dissolved in dimethyl sulfoxide (DMSO). This was used to prepare berberine8998 
microcrystal suspension (35 mg/ml, 40ml). 
Formulation R (berberine8998 CMC-Na solution): A solution of CMC-Na (100ml 0.5%) 
was mixed with 1.072 g berberine8998 powder to prepare berberine8998 CMC-Na 
solution (17.8mg/ml, 30ml). The mixture was stirred using a magnetic stirrer for 12 
hours. 
 
2.7.3 Experimental procedure to compare the pharmacokinetic (PK) 
characteristics of formulation 1 with that of formulation 2 
Male Sprague-Dawley (SD) rats (weighing 180-200g, n=10, provided by the Animal 
Center of Shanghai Institute of Materia Medica) were randomly divided into two groups. 
Their weights were recorded before the experiment at Week 1 and Week 2 in Table 2.9. 
After twelve hours of food deprivation, the rats were administered 35mg of berberine 
or berberine8998 intragastrically (i.g.). The washout interval between the two treatment 
periods was 7 days. After the washout period, the rats were given the alternating 
compound in the second period. 
 
Table 2.9 Weights of rats used for the pharmacokinetic study 
Cage No Rat N 
Weight（g） 
Week1 Week2 
1 
1 302 327 
2 291.5 326 
3 282.5 309 
4 280 318.5 
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5 290 330.5 
2 
1 284.5 315 
2 345.5 376 
3 330 358 
4 322 345 
5 298 331.5 
 
Sample collection protocol was identical in the two treatment periods. The serum 
preparation method is described as follows. For all the rats, blood samples (0.5 mL) 
were collected pre-dose and at 0 h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, and 48h after 
dosing in each treatment period. The collected blood samples were centrifuged at 3 
000g for 15 min at 4°C within 30 min of the collection time. Serum samples were stored 
at -70°C before analysis. 
 
3 Acute oral toxicity study of berberine8998 
3.1 Introduction 
Inbred mouse strains are generated by sister-brother mating for 20 or more consecutive 
generations (Green et al., 1963). The most well-known inbred lines include C57BL/6, 
C57BL/10, C3H, CBA and BALB/c strains which are widely used in pharmacological 
research by allowing independent researchers from different labs to perform 
reproducible experiments on the same genetic material (Proetzel and Wiles, 2010).  
The C57BL/6, often referred to as "C57 black 6" or just "black 6" (standard 
abbreviation: B6) is a common inbred strain of laboratory mice. It is the most widely 
used "genetic background" for genetically modified mice for use as models of human 
disease. They are the best-selling inbred mouse strain, due to the availability 
of congenic strains, easy breeding, and robustness (Mekada et al., 2009). 
The value of lethal dosage 50 (LD50) is usually applied to indicate the acute toxicity of 
a test compound (1956). In toxicology, LD50 means the dose required to kill 50% of 
tested animals after specified test duration. This toxicity tenet of LD50 was created by 
J.W. Trevan in 1927 and provides a useful means for comparing toxic properties. It is 
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usually determined by test on animals, like mice. 
Berberine has potential lipid-lowering activity. However, its low bioavailability (poor 
absorption) limits its widespread clinical application. Berberine is a low acute toxicity 
compound and reveals therapeutic effect on acute and chronic hepatic damages (Feng 
et al., 2011). Therefore, in order to overcome the problem of limited absorption of 
berberine, a derivative berberine8998 was synthesized. To test the acute oral toxicity of 
berberine8998, the mice model (C57BL/6) was selected for evaluating the effects of 
oral administration of appropriate berberine8998 formulations (CMC-Na, 0.5%). The 
death numbers were counted for calculating the LD50 of berberine8998. 
. 
3.2 Results 
3.2.1 Formulation preparation 
A reliable berberine8998 liquid formulation was required. Berberine8998 does not 
readily dissolve in water. Sodium carboxyl methyl cellulose (CMC-Na) suspension 
(0.5%) was selected for preparing the suspensions. To ensure the administration 
accuracy, individual formulations were prepared for each group. The final oral amount 
administrated was determined by Weight ×Dosage÷ Concentration. 
 
3.2.2 Establishment of the dose range for berberine8998 
The purpose of the preliminary experiment was to look for the dose range for the 
subsequent main experiment to examine LD50 24 hours after intragastric (i.g.), the  
number of dead mice in each group were counted. These data were calculated, recorded 
and is presented in Table 3.1. These results suggest that the dose range is from 
500mg/kg to 1000mg/kg and should be selected to process the main experiment. 
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Table 3.1 Establishment of the dose range for berberine8998  
Group 
No 
Dosage
（mg/kg） 
Number of 
animals 
Number of animals 
that died 
Death rate of the 
animals（%） 
1 1000 4 3 75 
2 800 4 3 75 
3 600 4 1 25 
4 500 4 1 25 
5 400 4 0 0 
 
3.2.3 LD50 analysis  
The value of lethal dosage 50(LD50) illustrates the acute oral toxicity of the test 
compound. To obtain the LD50 of berberine8998, a single dose of berberine8998 was 
administered to the mice in different dosage groups: 500 mg/kg (Group A), 595 mg/kg 
(Group B), 707 mg/kg (Group C), 841 mg/kg (Group D) and 1000 mg/kg (Group E). 
After 24 hours, the numbers of dead mice in each group were counted and recorded in 
Table 3.2. SPSS probit analysis was used to obtain the LD50 values and the 95% 
confidence limits. As shown in Tables 14 and 15, the LD50 (Probit .500) of 
berberine8998 was 870mg/kg (SPSS Probit analysis). 
Table 3.2 LD50 analysis for berberine8998 
Group Dosage（mg/kg） Number of animals Number of animals that died 
1 1000 10 7 
2 841 10 4 
3 707 10 3 
4 595 10 1 
5 500 10 1 
 
3.3 Discussion 
The main aim of the LD50 experiment was designed to test the acute oral toxicity of 
berberine8998, and it is most important to ensure the accuracy of the amount of the 
orally administered berberine8998. Previous study has demonstrated higher 
bioavailability of berberine8998 in SD rats. 
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SPSS Probit analysis was used in this experiment. It provides fitting probit and logit 
sigmoid dose/stimulus response curves as well as calculating confidence intervals for 
dose-response quantiles such as LD50. The fitted model is assessed by statistics for 
heterogeneity which follows a chi-square distribution. For most systems the probit 
(normal sigmoid) and logit (logistic sigmoid) give the best fitting result. Logistic 
methods are useful in biological assays because the odds ratios can be determined easily 
from the differences between the fitted logits (Finney, 1964, Finney, 1971). 
Existing research has reported 30% death rate following intragastric (i.g.) of 4160mg/kg 
berberine in ICR mice (Kheir et al., 2010). The LD50 of berberine8998 in mice was 
870mg/kg. Therefore, berberine8998 is significantly more toxic than berberine. 
However, compared with the lipid lowering drugs it is a safe candidate and has a good 
potential therapeutic window (Maji et al., 2013). Side effects such as proteinuria and 
hematuria occurred in over 1% of total patients taking statins. Serious side effects such 
as myopathy and rhabdomyolysis, though in low occurance rate, was life threatening. 
The withdrawal of cerivastatin was due to this side effects. Compared with the side 
effects mentioned above, berberine was relatively safe in a long history of clinical 
application (Kheir et al., 2010). One can thus conclude that berberine8998 has relatively 
low toxicity and has the potential of being a good lipid-lowering drug. 
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4 Monitoring lipid levels in hamster serum 
4.1 Introduction 
Hamster (Mesocricetus Auratus) is a small rodent of Middle Eastern origin that is 
excellent for assessment of drugs with combined efficacy on atherosclerosis, weight 
loss, hypertriglyceridemia and hypercholesterolemia (Dalboge et al., 2015).  The 
hamster carries a significant portion of its plasma cholesterol in the LDL lipoprotein 
fraction. In this respect, it is closer to humans than to the rodents (Lock et al., 2005). 
Hamsters have an atherogenic lipoprotein profile with a large proportion of the 
circulating lipoproteins, they possess cholesteryl ester transport protein (CETP), 
receptor mediated uptake of LDL lipoproteins via the LDLR, exclusively hepatic 
production of apolipoprotein (apo) B-100 and intestinal production of apo B-48 
(Tsutsumi et al., 2001, Bishop, 1992, Liu et al., 1991). When fed with high-fat diet, 
hamsters quickly develop hypercholesterolemia and hypertriglyceridemia. Therefore, it 
has been suggested that hamsters fed with high cholesterol and saturated fat diets 
responded similarly to humans in terms of lipoprotein metabolism (Dalboge et al., 
2015). The concentration of LDL in hamster plasma is strongly influenced by the 
amount and the type of lipid in the diet. Previous studies showed that dietary lipids alter 
the plasma LDL concentration in the hamster (Lock et al., 2005, Tsutsumi et al., 2001, 
Nistor et al., 1987). These studies indicated that the high-fat diet-induced dyslipidemic 
hamster model can be applied for lipid lowering drug evaluation. 
The hypothesis that atherosclerosis disease is due to hyperlipidemia has been a 
powerful concept that has fostered the development of lipid-lowering therapeutics 
(Davignon, 2004). Serum LDL levels are commonly considered as the most important 
modulators and biomarkers of atherosclerotic processes (Bahiru et al., 2017, Tsai et al., 
2009). Studies using hamsters to evaluate the effects of diet cholesterol and fat on the 
kinetics of hepatic LDLR-mediated LDL clearance have been well characterized 
(Horton et al., 1993, Ugawa et al., 2002). Hence, as a part of this work and an extension 
of the existing studies, berberine and berberine8998 were analysed to see if these drugs 
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can reduce the LDL levels in hamsters fed with a high-fat diet. 
4.2 Results 
4.2.1 Results of a preliminary pharmacodynamic study 
The lipid metabolic profile was significantly improved through lipid-lowering effects, 
as observed from the changes in the slope of the LDL level (Fig 4.1). The dose range 
was set up based on the data of previous berberine research (Kong et al., 2004). The 
berberine at 200mg/kg dose showed the expected positive effects. However, the 
hamsters in this group (Group 5) became extremely lean and weak. Yellow spots were 
also found in the anuses of these hamsters. Two of these animals died in the weeks three 
and four of the treatment. These experimental results indicated that the oral dose of 
200mg/kg of berberine is too high and can be toxic. The dose was therefore lowered in 
the later experiments.  
Thereafter, it was found that at lower dose both berberine and berberin8998 have 
beneficial effects. As judged by their body weight and hair color, all the hamsters in the 
berberine8998 groups were healthy throughout the experiment. However, there was a 
significant difference (p<0.05) between the treated and control groups. The levels of 
LDL in the 50 mg/kg berberine8998 group reduced by 44.53% (Fig 4.1 Group 3) and 
LDL levels in the 100mg/kg berberine8998 group by 51.07% (Fig 4.1 Group 4). These 
reductions in the LDL levels showed trends (down regulation of the slope) that can be 
considered as an improvement of the metabolic syndrome. The results suggested that 
the given berberine8998 dose is safe and that it has a dose dependent lipid-lowering 
effect. 
 
Group 1 (negative control: high-fat diet) 
Group 2 (positive fenofibrate control: high-fat diet + 50mg/kg fenofibrate) 
Group 3 (berberine8998 50mg: high-fat diet + 50mg/kg berberine8998) 
Group 4 (berberine8998 100mg: high-fat diet + 100mg/kg berberine8998) 
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Group 5 (berberine 200mg: high-fat diet + 200mg/kg berberine)  
Group 6 (control on normal diet) 
 
 
Figure 4.1 LDL levels in treated hamster plasma from a preliminary pharmacodynamic 
study, for the groups 1-6, as described above. N=12 The data were analyzed by two-
way ANOVA with post-hoc testing by compared with high fat diet group. ap<0.05, 
bp<0.01 and cp<0.001. 
 
4.2.2 Results of the second pharmacodynamics study 
Based on the results of the preliminary study, several experimental conditions were 
modified. The lipid lowering trends presented in Fig. 4.2 suggested that the total 
number of experimental groups can be limited to three. To prevent animals dying from 
too-high dosage of berberine, the doses of both berberine and berbeine8998 were set at 
50 mg/kg. This dose was well below the LD50 of 870 mg/kg established in the previous 
experiment. 
To evaluate the lipid-lowering effects of berberine and berberine8998, the weight as 
well as serum LDL TC and TG levels were measured in high-fat diet hamsters treated 
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with berberine, berberine8998, or left untreated. The weights of hamsters in the 
berberine and berberine8998 groups showed no significant difference (Fig 4.2 D). 
Hypercholesterolemia developed slowly in the normal diet group (Fig 4.2A-4.2C), and 
serum lipid levels in the high-fat diet (HFD) group increased significantly (Fig 4.2A-
4,2C). Notably, berberine8998 treatment significantly reduced total cholesterol (Fig 
4.2A) and LDL-c (Fig 4.2B) levels at week 2 and week 3 compared with the HFD group 
(P< 0.05). In contrast, berberine did not alter the LDL-c levels after three weeks of 
treatment (Fig 4.2B). Mean LDL-c levels at week 2 and week 3 were 10.30±3.63 and 
13.15±7.34 mM, respectively for the HFD group and 6.00±1.85 and 8.55±2.59 mM, 
respectively, for the berberine8998 group (Fig 4.2B).  
Given that triglyceride (TG) is an important component of lipids, the serum TG levels 
in hamsters were evaluated. The results showed that berberine8998 treatment 
ameliorated the HFD-induced elevated TG serum levels reducing it by 64% (Fig 4.2C). 
Triglyceride levels were significantly attenuated by week 3 in the berberine (P< 0.05) 
and berberine8998 groups (P< 0.01) (Fig 4.2C). Body weight was not significantly 
different between the treatment, control and normal diet groups, as shown in Fig 4.2D. 
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Figure 4.2 Analysis of (A) LDL and serum (B) TC (C) TG and (D) Body Weight levels 
in hamsters treated with berberine or berberine8998 or left untreated over 3 weeks. The 
data were analyzed by two-way ANOVA with post-hoc testing by compared with high 
fat diet model group. bp<0.05 and cp<0.01 by Two-way ANOVA compared with model 
group. 
 
4.3 Discussion 
For seasonally bred rodents such as the golden hamster, photoperiod tightly regulates 
the timing of the onset and cessation of testicular functions characterized by dramatic 
alterations in steroidogenesis and spermatogenesis (Mukherjee and Haldar, 2016).  
Exposure to long-day photoperiod elevates testicular spermatogenesis and 
steroidogenesis, whereas short-day exposure inhibits testicular functions in 
photoperiodic rodents, thereby fine tuning the seasonal cycle of male fertility (Frungieri 
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et al., 2005). Photoperiod also plays a critical role in the modulation of metabolic stress-
induced variation in steroidogenesis and antioxidant status in hamsters (Mukherjee and 
Haldar, 2015). The impact of energy availability in regulation of testicular 
steroidogenesis and antioxidant status has not been investigated for any seasonal 
breeder in general, especially for golden hamster. High fat-diet induced obesity leads 
to liver damage, so that the liver of high-fat diet hamsters is vulnerable (Huang et al., 
2015). Thus, the temperature and light/dark cycle needed to be strictly controlled in this 
research. 
Previous studies on feeding hamsters diets supplemented with conjugated coconut oil, 
linoleic acid, macademia oil, canola oil, sunflower oil, palm oil, and olive oil were used 
to determine if different oils alter plasma lipids levels (Wilson et al., 2006, Matthan et 
al., 2009, Lecker et al., 2010). However these liquid oils are difficult to make into solid 
fodder. To establish a high-fat diet hamster model with high LDL levels, 10% of lard 
was used in the high-fat diet group in this study. 
The LDL and TC levels in high fat model groups were significantly elevated 
(**P=0.004<0.005) (9 vs 2 mM, 17 vs 7 mM). Berberine and berberine8998 
significantly attenuated the elevation of lipid profiles, especially after three weeks’ 
treatment. But the lipid-lowering effect was not different between the two compounds. 
However, the LDL results in week 5 did not show any statistical difference. This can be 
attributed to the threshold effect. Some hamsters might have reached the treatment 
threshold value in week 5. The weights of the hamsters in the berberine and 
berberine8998 groups also showed no statistical difference, indicating that 
berberine8998 is as safe as berberine with respect to the doses used in this part of the 
study. Treatment with either compound decreased the speed (see Fig 4.2) of serum TC 
and LDL level elevation, with berberine8898 showing a greater effect. Therefore, the 
corresponding mechanisms of lipid lowering effect of berberine8998 were thoroughly 
elucidated. 
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5. DiI-LDL uptake by HepG2 cells 
5.1 Introduction 
Majority of the LDL is removed from the body via the liver (Libby et al., 2002). An 
elevated level of LDL in the plasma is one of the major causative factors of 
hypercholesterolemia, atherosclerosis, and coronary heart diseases. Lowering LDL by 
means of a therapeutic drug is an effective and safer approach for treating vascular 
disease (Bulbulia et al., 2011). More than 70% of circulating LDL is taken up from the 
blood via hepatic LDL receptor (LDLR) mediated endocytosis. The uptake of LDL by 
LDLR plays a major part in the elimination of LDL. Loss of function mutations in the 
LDLR gene has been identified as the major cause of familial hypercholesterolemia 
(FH), which is characterized by elevated levels of plasma LDL-cholesterol (LDL-c) and 
an increased risk of cardiovascular disease (Kong et al., 2006). Enhancement of LDLR 
activity is therefore an effective method for down-regulation the serum cholesterol 
levels. 
Human hepatoma cells (HepG2) are recognized as a good surrogate for adult 
hepatocytes. They are able to reproduce most of the hepatocytic functions (Javitt, 1990). 
The HepG2 cell line has been widely used as a functional model for studying the 
pharmacology of berberine in the last decade. It has been reported that berberine 
increased LDLR expression and LDLR mRNA stability via the SREBP pathway in 
HepG2 cells (Kong et al., 2004). Berberine can also reduce the level of PCSK9 mRNA, 
leading to reduction in the amount of PCSK9 protein secreted into the media in the 
HepG2 cells (Cameron et al., 2008). 
Methods which involve labeling LDL complexes (ep: Dil-LDL) are useful for studying 
the function of LDLR. This labeling renders individual molecules visible by their 
fluorescence and enables the complexes to be used in dynamic studies of LDLR motion 
on living fibroblasts by standard fluorescence techniques. 125I-labeled LDL has 
primarily been the method of choice for rapid quantitation of receptor-mediated LDL 
metabolism since it was first introduced by Brown and Goldstein (Goldstein and Brown, 
70 
 
1974). Compared with the 125I-labeled LDL method, which is reliable and highly 
sensitive, the Dil-LDL method is safer (no radiation) and more cost-effective (Stephan 
and Yurachek, 1993).  
The Dil-LDL method is simple, rapid and nonradioactive, and has a potential of being 
adapted to a high through-put screen of compounds modulating LDLR activity in cells. 
The purpose of this study is to see if berberine8998 is exerting its lipid-lowering effect 
via the Dil-LDL uptake regulation on the HepG2 cell line. 
 
5.2 Results 
5.2.1 DiI-LDL uptake by HepG2 cells via LDLRs 
One study has reported that hamsters that were orally given 100mg/kg berberine could 
convert it to 15μg/ml (44.73μM) for a cell-based experiment (Kong et al., 2004). 
Consequently, two dosages (20μM and 40μM) of berberine8998 were selected in this 
experiment for monitoring its uptake. The results reported in the previous chapter 
indicate that berberine8998 treatment lowered serum LDL levels. To further unveil 
related mechanisms, HepG2 cells were incubated with the test compounds (vehicle 
control, pravastatin, berberine, berberine8998) and DiI-LDL. A fluorescent detector 
was used to scan the intensity of the Dil-LDL uptake. Cells treated with the cholesterol-
lowering agent pravastatin served as a positive control. The results were encouraging 
and berberine8998 (40μM, 2.26 absorption fold of control) was relatively more 
effective for stimulating LDL uptake than berberine (40μM, 1.22 absorption fold of 
control) and pravastatin (5μM, 2.20 absorption fold of control), an effect that was dose-
dependent (Fig 5.1). The images from the fluorescence microscope (Fig 5.2) confirmed 
the findings. 
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Fig 5.1 Average uptake amount of Dil-LDL in HepG2 cell incubated with test 
compounds: Con, control; Pro, pravastatin; BBR, berberine; 8998 berberine8998. N=3 
***p<0.001, compared with control group by Dunnet’s test after one way ANOVA 
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Fig. 5.2 Fluorescence images illustrating the uptake amount of Dil-LDL in HepG2 cells 
with test compounds. (A) Control group, HepG2 cells treated with Dil-LDL. (B) 
Pravastatin group, HepG2 cells treated with Dil-LDL and 5 μM pravastatin. (C) 
Berberine 40 μM group, HepG2 cells treated with Dil-LDL and 40 μM berberine. (D) 
Berberine8998 20 μM group, HepG2 cells treated with Dil-LDL and 20 μM 
berberine8998. (E) Berberine8998 40 μM group, HepG2 cells treated with Dil-LDL and 
40 μM berberine8998. Magnifcation:10X 
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5.3 Discussion 
The Dil-LDL study was designed to verify the hypothesis that berberine8998 is able to 
promote LDL uptake in vitro. To confirm the hypothesis that berberine and 
berberine8998 both increase the uptake amount of LDL, HepG2 cell line was incubated 
with the test compounds and Dil-LDL. A fluorescent detector was used to scan the 
uptake amount of Dil-LDL. 
The Dil-labeled lipoproteins showed specific high affinity to human fibroblasts via the 
LDL (apo-B, -E) receptors (Pitas et al., 1981). LDL bound at 37°C was rapidly 
internalized by the cell in specific membrane areas called coated pits (Orci et al., 1978). 
Dil-LDL is internalized rapidly at 37°C by normal fibroblasts and it depresses the 
activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) 
in a manner similar to that of LDL (Barak and Webb, 1981).  Lipoproteins labeled 
with Dil were suitable for the direct viewing of lipid uptake by cells in vitro. 
Cells treated with the cholesterol-lowering agent pravastatin served as a positive control. 
The results were encouraging and berberine8998 (40μM, 2.26 fold) was relatively more 
effective (***p<0.001) for stimulating LDL uptake than berberine (40μM, 1.22 fold) 
and pravastatin (5μM, 2.20 fold), an effect that was dose-dependent.  
The use of fluorescent labeled lipid provides us a tool to quantify the amount of lipid 
uptake. By using Dil-LDL as a marker, both berberine-8898 and berberine treated cells 
stimulated the up-take of LDL. The intensity (a.u.) of Dil-LDL in HepG2 cells was then 
screened to compare the amount of lipid uptake by the positive control group 
(Pravastatin), and the berberine and berberine8998 groups. In this experiment, 
berberine8998 (40μM) exerted more LDL uptake in HepG2 cells than berberine and 
positive control pravastatin (2.26 vs 1.22, 2.20, p<0.001). This improvement may 
contribute to the lipid lowering effect of berberine8998. In general, the exploration here 
suggests that berberine, and to a greater extent berberine8898, stimulated the uptake of 
LDL in the HepG2 cells, similar to the cholesterol-lowering agent pravastatin. 
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6. Analysis of LDLR and PCSK9 levels 
6.1 Introduction 
Liver low-density lipoprotein receptor (LDLR) plays a central role in manipulating 
cholesterol homeostasis by mediating LDL clearance from the bloodstream. LDLR is a 
membrane-spanning glycoprotein with a highly conserved structure in human and other 
animals. Since LDLR was discovered by Goldstein and Brown in 1974 on cultured 
human skin fibroblasts, extensive study has been undertaken to reveal its structure, 
function, mutation, and physiological as well as pharmacological modulations (Kong 
et al., 2006). The mature form of the human LDLR protein contains 839 amino acid 
residues with a molecular mass of 160 kDa (Tolleshaug et al., 1982).  It is made up of 
six functional domains; the signal sequence, ligand binding domain, EGF precursor-
like domain, O-linked sugar domain, transmembrane domain and the cytoplasmic 
domain (Sudhof et al., 1985). The gene is located on chromosome 19p13.1 and the 
cytoplasm, ligand binding domain, EGF precursor-like domain, mediating LDL 
clearance from the blood (Sudhof et al., 1985, Tolleshaug et al., 1982). Mutations in the 
LDLR give rise to familial hypercholesterolaemia (Heath et al., 2001).  Up-regulation 
of liver LDLR expression has been proven to be one of the most effective ways to lower 
plasma cholesterol level (Bays and Stein, 2003).  
Proprotein convertase subtilisin/kexin type 9 (PCSK9) was discovered in the past 
decade as a novel therapeutic target for the management of patients with 
hypercholesterolemia. This protein can bind to the epidermal growth factor-like repeat 
A site of LDLRs at the hepatocyte surface, leading to their degradation in the liver, 
thereby promoting their lysosomal degradation (Zhang et al., 2007).  Inhibition of 
PCSK9 leads to an increase in LDLR and consequently results in a reduction of LDL 
cholesterol in blood. Berberine has been reported to decrease the level of PCSK9 and 
thus has a positive effect on LDL levels (Cameron et al., 2008). 
Western blotting is an important technique used in analysis of cell and molecular 
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biology (Mahmood and Yang, 2012). It is a protein analysis technique which combines 
protein separation in an electric field with immunochemical methods of protein 
detection. It is widely used to detect, characterize, quantify, and/or isolate specific 
proteins or antibodies in complex biological samples. The technique initially involves 
gel electrophoresis and is used to separate native proteins based on the 3D structure of 
proteins and the molecular size of the polypeptide. This is followed by the 
electrophoretic transfer of the proteins out of the gel to a two-dimensional, protein-
binding membrane (typically PVDF) (Gibbons, 2014). The membrane is then incubated 
with labeled antibodies specific to the protein of interest. The unbounded antibody is 
washed off, leaving only the binding protein-specific antibody or ligands. Finally, the 
bounded antibodies are visualized by developing the film. The LDLR and PCSK9 
expression levels of tissue and cell samples were analysed by Western blot to evaluate 
the lipid lowering effect of berberine8998. 
 
6.2 Results 
6.2.1 Western blot analysis results of LDLR levels in hamster liver samples 
Western blots analysis were applied to analyze the LDLR level in the liver tissue of 
hamsters in 5 groups after 3 weeks of high-fat diet (preliminary pharmacodynamics 
study). Fig 7.1, showed that LDLR levels were low in the negative control group. The 
LDLR level promoting effect of berberine8998 was clearly dose dependent (50mg, 
100mg). The LDLR level promoting effect of berberine8998 (100mg) was higher (as 
exhibited by the darker shade) than that of berberine (200mg) in vivo. 
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Fig 6.1 Western blot analysis of LDLR expression level of hamster liver samples (given 
berberine8998 and berberine for three weeks). Control: n=2, Fenobirate: n=2, 
berberine8998-50 mg/kg n=6; berberine8998-100 mg/kg n=6; berberine-200 mg/kg 
n=4 
 
6.2.2 Western blot analysis of LDLR in HepG2 cells 
LDLR expression in the HepG2 cells was screened by Western blotting. LDLR was up 
regulated dose-dependently upon treatment with berberine and berberine8998 (Fig 7.2), 
with the latter inducing a greater effect. These results confirm that berberine8998 
promotes the uptake of LDL by increasing the expression of LDLR in vitro. 
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Figure 6.2 Western blot analysis of LDLR expression level of HepG2 samples. Neg, 
blank; Pos, pravastatin; BBR, berberine; 8998, berberine8998. 
 
6.2.3 Western blot result for PCSK9 in HepG2 cells 
The PCSK9 lowering effect of berberine8998 on HepG2 cell was tested by the Western 
blot method. Berberine was used as positive control. The results showed that 
berberine8998 has a dose dependent down-regulation of PCSK9 (Fig 7.3). However, 
the PCSK9 down-regulation effect of berberine8998 is more pronounced than that of 
berberine. 
 
 
Figure 6.3 Western blot analysis of PCSK9 expression level of HepG2 samples. Neg, 
blank; Bt, fenofibrate; Pu, pravastatin; BBR, berberine; 8998, berberine8998. 
 
6.3 Discussion. 
Fenofibrate is the most frequently prescribed agent in the treatment of hyperlipidemia 
(Brown, 1987, Tarantino et al., 2017). It is a Peroxisomal Proliferator-Activated 
Receptor (PPARα) agonist. PPARα is a nuclear receptor belonging to the PPAR family 
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of ligand-activated transcription factors (Willson et al., 2000). Fenofibrate is an 
effective lipid lowering agent that can be used safely for hamster experiments. However, 
it cannot influence and regulate liver LDLR levels. This is indicated by the absence of 
any difference in the expression of the LDLR level of the fenofibrate control group and 
the negative control group (Fig. 6.1). 
The Food and Drug Administration (FDA) approved pravastatin in 2006 primarily for 
use in the treatment of dyslipidemia and prevention of cardiovascular disease. 
Pravastatin is in a class of medications called HMG-CoA reductase inhibitors, better 
known as statins. These drugs induce plasma cholesterol lowering by increasing hepatic 
intake of LDL particles, which results from the up-regulation of hepatic LDLR (Mach 
et al., 2014, Sahebkar et al., 2016). Hence pravastatin was chosen as the positive control 
in the HepG2 cell experiment on LDLR. 
LDLR is the most important membrane protein media for lipid uptake. The Western 
blot analysis showed that the up-regulation of LDLR expression was greater in hamster 
liver samples feed with berberine-8898 and in HepG2 cells treated with berberine-8898 
in comparison to berberine, indicating that berberine-8898 has superior lipid-lowering 
effects than the parent molecule in vivo and in vitro. The results also demonstrated that 
berberine8998 can down-regulate PSCK9, another atherosclerotic therapeutic target. 
Both fenofibrate and pravastatin showed no effect on this target (Fig 6.3). This 
suggested that berberine8998 could be improving lipid uptake via a yet unknown 
pathway. 
 
7. Proteomic research using iTRAQ labeled analysis  
7.1 Introduction 
The isobaric tags for relative and absolute quantitation (iTRAQ) method combined with 
2D LC-MS/MS is one of the most powerful methodologies in quantitative proteomics 
(Kristensen et al., 2014, Ray et al., 2011, Qin et al., 2013, Hou et al., 2013). It is a stable 
isobaric labeling multiplexed protein quantization strategy launched by Applied 
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Biosystems (USA) in 2004. It provides relative and absolute measurements of proteins 
in complex mixtures. 
The 2D LC-MS/MS is usually performed using a SCX column in series with a RP 
column. In the course of analysis, tryptic peptides are eluted stepwise by injecting salt 
plugs of increasing ionic strength from the SCX column in the first dimension. In the 
second dimension these peptides are first trapped on a RP enrichment column and 
finally separated on an analytical RP column (Davis et al., 2001). By combining two 
different LC techniques with individual peak capacities between 50 and 100, it is 
theoretically possible to achieve total capacities of 2500–10,000 peaks (Nagele et al., 
2004). Data (MS1 and MS2) is acquired using a mass spectrometry that generates high 
quality spectrums useful for further database searching of peptide and protein 
quantization. This method can be a high throughput quantitative technique and an 
efficient way to screen lipid lowering proteins (Kristensen et al., 2014). In this research, 
proteomes profiles of high fat hamster liver tissues samples with or without 
berberine8998 were simultaneously compared. It was the first time that the iTRAQ 
method was coupled with 2D LC-MS/MS (TripleTOF 5600) for investigating the 
operation mechanisms of berberine and berberine8998.  
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7.2 Results 
7.2.1 Protein identification and quantitation 
To clarify the mechanism of berberine and berberine8998, hamster liver protein 
expression levels were evaluated by iTRAQ analysis. Hamster liver samples from the 
berberine, berberine8998 and high-fat diet model groups were analyzed using iTRAQ 
shot-gun proteomics. High-abundance proteins were depleted prior to analysis. A total 
of 2049 and 2020 proteins were identified by the first and second iTRAQ experiments, 
respectively, with a false discovery rate lower than 1%. Combined results of the two 
replicates identified 2444 proteins, of which 2073 proteins were quantified. A total of 
442 differentially expressed proteins were screened in both runs in the berberine8998 
group, and a total of 268 differentially expressed proteins were screened in both runs in 
the berberine group. 
Untreated, berberine8998 treated and berberine treated hamsters were labeled with 
iTRAQ reagent 113/114, 115/116 and 117/118, respectively. A total of 12 groups of 
hamsters and two iTRAQ labeling experiments were carried out. Thus for each 
treatment, there were 4 biological replicates. Student’s t-test and P-value were used to 
evaluate the significance of protein expression level change among the liver tissue of 
differently treated hamster groups in iTRAQ, and the median of the ratio between each 
the two groups were calculated. The untreated model was taken as a reference. To filter 
the non-significant changes in liver protein expression levels between sample groups, 
fold-changes in median ratios <0.7 (downregulated) or >1.3 (upregulated) were selected 
as cutoff values, and ratios were assessed using Student’s t test. The median values of 
the ratios between the two groups were also calculated. 
A total of 48 proteins exhibited significant changes in the berberine8998 group; 16 
proteins were upregulated, and 32 proteins were downregulated. A total of 53 proteins 
exhibited significant changes in the berberine group; 23 proteins were upregulated, and 
30 proteins were downregulated. The top ten most significant changes in protein 
expression after berberine8998 and berberine treatment are summarized in Table 7.1 
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and Table 7.2. 
Table 7.1. List of differentially expressed proteins after berberine8998 treatment in 
hamsters. The proteins were identified by TOF-AB 5600. (↑, up-regulated; ↓, down-
regulated). 
Protein Name 
Gene 
name 
P-value 
Fold of 
Change 
Protein Function 
Peroxisomal carnitine O-
octanoyl transferase  
Crot 1.57×10-5 0.69↓ 
Beta-oxidation of fatty acids. The 
highest activity concerns the C6 
to C10 chain length substrate. 
Alpha-N-acetyl 
galactosaminidase  
Naga 3.58×10-5 1.71↑ 
Removes terminal alpha-N-
acetylgalactosamine residues 
from glycolipids and 
glycopeptides. 
Heterogeneous nuclear 
ribonucleoprotein K  
Hnrnpk 4.13×10-5 0.67↓ 
One of the major pre-mRNA-
binding proteins. 
Peroxisomal acylcoenzyme 
A oxidase 1  
Acox1 1.24×10-3 0.52↓ 
Catalyzes the desaturation of 
acyl-CoAs to 2-trans-enoyl-
CoAs.  
Acetyl-CoA 
acetyltransferase 
Acta2 1.28×10-3 1.55↑ 
Actins are highly conserved 
proteins that are involved in 
various types of cell motility and 
are ubiquitously expressed in all 
eukaryotic cells. 
Apolipoprotein B-100  Apob 1.45×10-3 0.75↓ 
Apolipoprotein B is a major 
protein constituent of 
chylomicrons (apo B-48), LDL 
(apo B-100) and VLDL (apo B-
100).  
1-phosphatidylinositol-4,5-
bisphosphate 
phosphodiesterase delta-1 
Plcd1 1.58×10-3 1.37↑ 
The production of the second 
messenger molecules 
diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3) 
is mediated by activated 
phosphatidylinositol-specific 
phospholipase C enzymes.  
Guanine nucleotide binding 
protein subunit beta-2-like 1  
Gnb2l1 2.16×10-3 0.69↓ 
Involved in the recruitment, 
assembly and/or regulation of a 
variety of signaling molecules. 
Uricase Uox 2.34×10-3 0.54↓ 
Catalyzes the oxidation of uric 
acid to 5-hydroxyisourate, which 
is further processed to form (S)-
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allantoin. 
40S ribosomal protein S15 Rps15 2.50×10-3 0.52↓ 
Liver regeneration. Ribosomal 
small subunit assembly 
Long-chain-fatty-acid—
CoA ligase 1 
ACSL1 2.10×10-3 0.50 ↓ 
Activation of long-chain fatty 
acids for both synthesis of 
cellular lipids, and degradation 
via beta-oxidation. Preferentially 
uses oleate, arachidonate, 
eicosapentaenoate and 
docosahexaenoate as substrates. 
 
Table 7.2. List of differentially expressed proteins after berberine treatment in 
hamsters. The proteins were identified by TOF-AB 5600. (↑, up-regulated; ↓, down-
regulated). 
Protein 
Name 
Gene 
name 
P-value 
Fold of 
change 
Protein Function 
Cytosol 
aminopepti
dase 
Lap3 1.79×10-4 1.41 ↑  
Catalyzes the removal of unsubstituted N-
terminal amino acids from various peptides 
Ras-related 
protein 
Rab-14  
Rab14 4.09×10-4 1.62 ↑ 
Involved in membrane trafficking between the 
Golgi complex and endosomes. 
Signal 
recognition 
particle 
Srp54 6.17×10-5 0.63 ↓ 
Binds to the signal sequence of presecretory 
protein when they emerge from the ribosomes 
and transfers them to TRAM (translocating 
chain-associating membrane protein). 
Guanine 
nucleotide-
binding 
protein 
subunit 
beta-2-like 
1 
Gnb2l1 1.17×10-3 0.63 ↓ 
Involved in the recruitment, assembly and/or 
regulation of a variety of signaling molecules.  
Acetyl-
CoA 
acetyltransf
erase 
Acta2 1.43×10-3 2.25 ↑ 2acetyl-CoA = CoA + acetoacetyl-CoA. 
Alpha-
actinin-4 
Actn4 1.78×10-3 0.65 ↓ 
F-actin cross-linking protein which is thought to 
anchor actin to a variety of intracellular 
structures. 
Misshapen- Mink1 2.23×10-5 0.68 ↓ Serine/threonine kinase which acts as a negative 
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Protein 
Name 
Gene 
name 
P-value 
Fold of 
change 
Protein Function 
like kinase 
1 
regulator of Ras-related Rap2-mediated signal 
transduction to control neuronal structure and 
AMPA receptor trafficking. 
Carbonyl 
reductase 
[NADPH] 1 
Cbr1 2.34×10-3 1.35 ↑ 
Catalyzes the reduction of a wide variety of 
carbonyl compounds includingquinones, 
prostaglandins, menadione, plus various 
xenobiotics. 
Ras-related 
protein 
Rab-2A 
Rab2a 2.40×10-3 1.33 ↑ 
Required for protein transport from the 
endoplasmic reticulum to the Golgi complex. 
Short-chain 
specific 
acyl-CoA 
dehydrogen
ase 
Acads 2.54×10-3 0.65 ↓ 
Introduces a double bond at position 2 in 
saturated acyl-CoAs of short chain length.  
Long-
chain-fatty-
acid—CoA 
ligase 1 
ACSL1 1.30×10-3 0.52 ↓ 
Activation of long-chain fatty acids for both 
synthesis of cellular lipids, and degradation via 
beta-oxidation. Preferentially uses oleate, 
arachidonate, eicosapentaenoate and 
docosahexaenoate as substrates. 
Peroxisoma
l acyl-
coenzyme 
A oxidase 1 
ACOX1 5.49×10-3 0.64 ↓ 
Catalyzes the desaturation of acyl-CoAs to 2-
trans-enoyl-CoAs. Isoform 1 shows highest 
activity against medium-chain fatty acyl-CoAs 
and activity decreases with increasing chain 
length. Isoform 2 is active against a much 
broader range of substrates and shows activity 
towards very long-chain acyl-CoAs. Isoform 1 
shows optimum activity with a chain length of 
10 carbons while isoform 2 exhibits optimum 
activity with 14 carbons. 
 
7.2.2 Gene Ontology (GO) analysis 
A Gene Ontology (GO) analysis was carried out for the differently expressed proteins 
(Fig. 7.1). The top five enriched molecular functions of upregulated proteins in 
berberine and berberine8998 treated hamsters were metabolic processes, cellular 
metabolic processes, regulation of biological processes, and responses to chemical 
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stimulus. A larger number of proteins in the berberine8898 treated group showed altered 
expressions (Fig 7.1A). Most upregulated proteins were involved in FA metabolism and 
the degradation of the branched-chain amino acids valine/leucine/isoleucine (Fig 7.1B). 
 
Figure 7.1 GO analysis of cellular components (A) and biological processes (B) 
associated with differently expressed proteins in berberine- and berberine8998-treated 
hamsters. 
 
7.2.3 Ingenuity pathway analysis (IPA) 
Differently expressed liver-based proteins of berberine and berberine8998 treated 
hamster were further analyzed by Ingenuity Pathway Analysis (IPA). The most enriched 
canonical pathway of the two group of proteins is LXR/RXR Activation pathway, 
which is involved in the regulation of lipid metabolism, inflammation, and cholesterol 
to bile acid catabolism (Fig. 7.2). ALB, APOA4, APOB and TF were involved in the 
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pathway, and down regulated in both treatment groups. Disease and biological function 
of the proteins is conversion of lipid (Fig. 7.3). ACOX1, ALB, APOB and CROT are 
downregulated in the berberine8898 treated hamsters, and ACOX1, ABHD5, ALB and 
TTPA which were differently expressed in the berberine treated hamsters. ACOX1 was 
chosen for further validation by western blot analysis. 
 
Figure 7.2 LXR/RXR activation pathway. Green labeled molecules were 
downregulated in this work. 
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Figure 7.3 The disease and biological function pathway analysis of conversion of lipid. 
Green labeled proteins were down regulated and red labeled proteins were up regulated 
in berberine-8898 (left) and berberine (right) treated hamsters. 
 
7.2.4 Heatmap analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) 
analysis 
KEGG metabolic pathways were analyzed to determine the major pathways involved 
in berberine and berberine8998 treatment and statistical analysis determined the 
pathways represented in the berberine and berberine8998 treatment groups. As shown 
in Fig 7.4, the major KEGG pathways were fatty acid metabolism, ribosome, pyruvate 
metabolism, propanoate metabolism and butanoate metabolism. The most significant 
metabolic pathway was fatty acid metabolism. These results suggest that berberine8998 
and berberine lowered serum lipid levels via similar metabolic pathways. The major 
KEGG pathways were FA degradation, FA metabolism, and degradation of branched-
chain amino acids that were related to lipid metabolism as well.  
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Figure 7.4 Protein KEGG pathways identified by heat map analysis. Proteins associated 
with FA metabolism and branched-chain amino acid degradation are in the red boxes. 
The colour bar is for the –log(p-value). 
 
7.3 Discussion 
Over the last decade, research in this area has been centered on understanding the 
behavior of proteins. The functions, interplays and changes in the abundance of proteins 
are in response to internal and external cues (Ray et al., 2011). So the iTRAQ method 
combined with 2D LC–MS/MS was used to analyze protein expression in the liver 
tissue of mice maintained on a high-fat diet treated with berberine or beberine8898 in 
order to evaluate the effect of the two drugs. This is among the most powerful 
methodologies in quantitative proteomics (Kristensen et al., 2014, Qin et al., 2013, Hou 
et al., 2013) employing a stable isobaric labeling multiplexed protein quantization 
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strategy to provide relative and absolute measurements of proteins in complex mixtures. 
Using the iTRAQ method, 85 proteins were identified that were expressed differently 
between the treatment and control groups of which 19 were common to both the 
berberine and berberine8998 groups. These 19 proteins have the potential to be the 
target of berberine and berberine8998 therapy.  
Functional similarity of proteins or genes can be estimated by controlled biological 
vocabularies, such as Gene Ontology (GO) (2008). Differently expressed proteins were 
annotated by GO using the DAVID software. The GO terms with computed P-values 
less than 0.05 were considered as significantly enriched. The pathway analysis of the 
protein expression pattern was performed using the Ingenuity Pathway Analysis (IPA) 
software (Ingenuity Systems Inc.). The pathways were identified with the help of 
Ingenuity Knowledge Base which is comprised of known molecular interactions, 
functions, and most promising and relevant biomarker candidates within experimental 
datasets. The GO analysis and IPA analysis showed that proteins that were expressed 
differently in the treatment relative to the control group had similar functions. The 
results of the disease and bio function pathway analysis of conversion of lipid showed 
that ACOX1 and ACSL1 were significantly down regulated by both berberine and 
berberine8998.  
KEGG is a collection of manually drawn pathway maps representing our knowledge on 
the molecular interaction and reaction networks (Kanehisa et al., 2014). It was widely 
used for biological interpretation of genome sequences and other high-throughput data. 
The KEGG pathway enrichment heat map suggested that branched-chain amino acid 
degradation and FA metabolism pathways were specifically activated by the treatment, 
and the detailed mechanisms were analyzed in LC-MS/MS, western blot and NEFA 
assay. 
  
89 
 
8. Serum levels of branched-chain amino acid 
8.1 Introduction 
Amino acids, as the basic units of protein molecules, are closely correlated with 
biological activities. Hence, quantitative plasma amino acid analysis is an essential tool 
for the investigating metabolic disorders linked to these compounds. The use of amino 
acid analysis in neonatal screening programs has allowed the rapid diagnosis of several 
inborn errors of metabolism (IEMs), notable examples of which are phenylketonuria 
(PKU) and maple syrup urine disease (MSUD) (Wojnicz et al., 2016, Woontner and 
Goodman, 2006, Chace et al., 1993, Chace et al., 1995). In addition amino acid analysis 
has been widely applied in the study of a growing number of pathologies including 
hepatic dysfunction, inflammatory bowel disease, cancer, muscle catabolism , 
neurotransmitter disorders, cardiovascular disease and insulin resistance (Peake et al., 
2013). 
Great effort has been put forth in the past 30 years to develop a reliable, rapid, and 
accurate method for the analysis of amino acids. Amino acid analysis methods rely on 
the derivatization procedures. Post-column derivatization techniques based on ion 
exchange separation of the underivatized amino acids are most popular. For optical 
detection, O-phthalaldehyde (OPA), dansyl chloride, 2,4-dinitroflurobenzene (DNFB), 
phenylisothiocyanate (PITC), fluorescein and isothiocyanate (FITC) are used as 
derivatization agent (Sherwood, 2000, Krok and Seaver, 1991). Optical detection of 
amino acids could achieve high sensitivity. However, the specificity and selectivity of 
optical methods are poor. For mass detection, N,O- bis (trimethylsilyl) 
trifluoroacetamide (BSTFA) and N-Methyl-N-tert (butyldimethylsilyl) tri-
fluoroacetamide (MTBSTFA) are usually employed as derivatization agent (Starke et 
al., 2001, Halama et al., 2016). 
An increase in plasma branched chain amino acid (BCAA) concentrations is a hallmark 
of adult obese individuals (Halama et al., 2016). BCCA related metabolic signature was 
found to differentiate obese and lean humans (Newgard et al., 2009). BCAAs have also 
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been shown to contribute to obesity-associated insulin resistance. Moreover, studies 
with obese children and children with type 2 diabetes compared to healthy lean subjects 
has indicated that plasma BCAA levels are related with these diseases (Mihalik et al., 
2012, Wahl et al., 2012). 
In the present investigation, improved analyses of aTRAQ Reagent 115 labeled amino 
acids were developed, permitting the study of 42 amino acids from serum samples in a 
single run. BCAA metabolism is altered in obesity, however, how it is regulated and 
cross-linked to other pathways is still not fully understood. 
 
8.2 Results 
Thirty-six hamsters were maintained on a high-fat diet, divided to three groups (12 in 
each group), one group received no treatment, and the other two groups were treated 
with either berberine or berberine8998 (50 mg/kg each). The hamster serum level of 
Val, Ile and Leu were determined by aTRAQ amino acid test kit. The results are shown 
in Fig 9.1. The serum level of Val, Ile and Leu of both the berberine8998 group and the 
berberine group were not significant higher than that of control group. The results also 
showed no statistical difference (one way ANOVA) between the berberine8998 group 
and the berberine group (Appendix Table 1). It can be concluded that these two 
compounds had similar effect on BCCA. 
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Figure 8.1 A comparison of serum levels of Val, Ile and Leu after treatment of hamsters 
with BBR8998 and BBR against control. N=12, Mean ±SD 
 
8.3 Discussion 
A critical step for amino-acid testing is the sample preparation. The key task of sample 
preparation is to remove the proteins that are in high abundance. Organic solvents such 
as acetone and methanol were first applied to remove high abundance proteins (Arola 
et al., 1977, Lavi et al., 1986). However, organic solvents depressed the extraction 
recovery and decoction sensitivity (Grossie et al., 1993). Ultracentrifugation could be 
another option for removing the high-abundant proteins, but that method is inefficient 
and time consuming (Hubbard et al., 1988). In this study, salicylsulfonic acid was 
selected for recovering the proteins and it proved to be efficient for high extraction 
recovery. 
This LC-MS/MS method (Section 2.6.1) determines the concentration of 42 amino 
acids (branched-chain amino acid, including Val, Ile and Leu) in the hamster serum 
sample. The system suitability test is performed using a standard mixture of aTRAQ 
Reagent 115 to label the amino acids. The retention times of key amino acids was kept 
to within 2 to 11 minutes (Fig 8.2). The total gradient elution time (Section 2.6.1.2) was 
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set at 13 minutes for each run. Both berberine and berberine8998 were observed to have 
slight increases in the serum BCCA level. However, such increase is not significant. 
These results indicate that berberine8998 had similar limited promotion effects on 
BCCA as berberine.  
 
 
Figure 8.2 Retention times of key amino acids, (each colour represents an amino acid 
ion pair)  
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9. Hamster serum levels of NEFAs and validation of relevant protein expressions 
9.1 Introduction 
NEFA (Non-esterified Fatty Acid, Free Fatty Acid) are defined as fatty acids that are 
not bound to any lipid fractions present in biological fluids (e.g. triglycerides, 
phospholipids, cholesterols). These play a pivotal role in the development of non-
alcoholic fatty liver disease (Neuschwander-Tetri, 2010). They are also associated with 
coronary heart disease, recurrent ischemic stroke, and carotid atherosclerosis (Yang et 
al., 2014, Jickling and Spence, 2014, Taniguchi et al., 2002).  
Fatty acids synthesized by the liver are converted to triglycerides and transported to the 
blood as very-low-density lipoprotein (VLDL). In the peripheral tissues, lipoprotein 
lipase digests part of the VLDL into LDL and NEFA, which are taken up for 
metabolism.  LDL can be absorbed via LDLR, providing a mechanism for uptake of 
LDL into the liver. 
Extraction methods are widely used for the colorimetric determination of NEFA. NEFA 
are converted to their cropper salts that are then extracted into an organic solvent. The 
salts are then made to complex with a dye for the purpose of colorimetric measurement 
(Duncombe, 1964, Itaya and Ui, 1965, Novak, 1965). These approaches are time 
consuming, hazardous and not easily automated. The choice of the NEFA 
determinations method is NEFA-HA Test kit: acyl-CoA synthetase (ACS) and acyl-
CoA oxidzase (ACOD) method. This method relies on the production of CoA by the 
fatty acids in the presence of added ACS (Fig 10.1). The acyl-CoA thus produced is 
oxidized by the added ACOD with generation of hydrogen peroxide. Hydrogen 
peroxide, in the presence of peroxidase (POD), permits the oxidative condensation of 
MEHA with 4-aminoantipyrine to form a purple coloured product which can be 
measured at 550nm. 
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Figure 9.1 The principle of NEFA determination 
 
9.2 Results 
9.2.1 Serum levels of NEFAs 
Serum levels of NEFAs were evaluated by means of biochemical analysis. These were 
higher in the high-fat diet group than in the berberine8998 treatment group (4.93 vs. 
4.07 mM; P < 0.05, compared with High Fat Diet Group by Dunnet’s test after one way 
ANOVA; Fig 9.2) and was lower in animals maintained on a normal as compared to a 
high-fat diet (1.45 vs. 4.93 mM; P < 0.001, compared with High Fat Diet Group by 
Dunnet’s test after one way ANOVA). These results suggest that berberine8998 
reverses the increase in serum NEFAs levels induced by a high-fat diet. 
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Figure 9.2 Serum levels of NEFAs. Hamsters were maintained on a normal or high-fat 
diet. In high-fat diet hamsters, one group received no treatment, while the other two 
groups were treated with either berberine (50 mg/kg, n=12) or berberine8998 (50 mg/kg, 
n=12). *p<0.05, compared with High Fat Diet Group by Dunnet’s test after one way 
ANOVA  
 
9.2.2 Validation of differently expressed proteins 
Although the major metabolic pathways were similar in berberine and berberine8998 
treatment groups, the differences in the magnitude of the target proteins were examined. 
Bioinformatics analysis revealed that fatty acid metabolism was the most significant 
pathway involved in the lipid-lowering effects of these agents. Therefore, two of the 
differentially expressed proteins, ACOX1 and ACSL1 were selected for validation by 
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western blotting. ACOX1 and ACSL1 expression in the liver was downregulated in the 
berberine and berberine8998 treatment groups compared to the control group (Figure. 
9.3).  
 
Figure 9.3 Western blot analysis of ACOX1 and ACSL1 expression in hamsters after 
being treated with berberine or berberine8998 vs. untreated controls fed a high-fat diet. 
 
9.3 Discussion 
Serum levels of NEFA play an important role in the development of non-alcoholic fatty 
liver disease (Novak, 1965) and are linked to coronary heart disease, recurrent ischemic 
stroke, and carotid atherosclerosis (Jickling and Spence, 2014, Varin et al., 2015, Yang 
et al., 2014). NEFA levels can be determined by colorimetric methods that induce their 
conversion to copper salts, which are then extracted into an organic solvent and undergo 
complex formation with a dye whose absorbance can be measured (Elphick, 1968, Itaya 
and Ui, 1965, Tinnikov and Boonstra, 1999). Serum levels of NEFAs were decreased 
after treatment with berberine8998. The majority of the differently expressed proteins 
that were found to be associated with the FA metabolism pathway were common to both 
berberine and berberine8998 treatment groups, suggesting that the two compounds 
have similar functional mechanisms. 
The protein expression of ACOX1 and ACSL1 was significantly decreased by 
berberine8998 treatment by approximately 2- to 3-fold while the berberine treatment 
decreased ACOX1 and ACSL1 expression by approximately 1- to 2-fold. Therefore, 
the magnitude of ACOX1 and ACSL1 protein expression varied between the berberine 
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and berberine8998 treatment groups. 
A major function of peroxisomes is β-oxidation of FAs. For this purpose, peroxisomes 
have two forms of ACOX (1 and 2)—which catalyze the second and third steps of β-
oxidation, respectively—as well as two 3-oxoacyl-CoA thiolases (Wanders, 2004). The 
two isoforms of ACOX1 isoforms are distinct with respect to their biochemical 
functions (Oaxaca-Castillo et al., 2007): isoform 1a has the highest activity against 
medium-chain fatty acyl-CoAs, which decreases with increasing chain length, and 
isoform 1b has a broader range of substrates, including long-chain acyl-CoAs 
(Ferdinandusse et al., 2007). We confirmed via Western blotting analysis that the 
expression of ACOX1 was downregulated by treatment with berberine and 
berberine8998, suggesting that these agents can reduce serum levels of NEFAs by 
modulating ACOX1 expression. Since high levels of ACOX1 are associated with 
hepatocellular carcinoma and hepatomegaly (Oaxaca-Castillo et al., 2007, 
Ferdinandusse et al., 2007), these findings highlight the possibility of therapeutic 
applications for berberine8998. 
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10. Method validation of berberine in SD rats by LC-MS/MS 
10.1 Introduction 
The triple quadrupole mass coupled with liquid chromatography (QqQ, LC-MS/MS) is 
the most frequently used highly sensitive and selective spectrometric method for the 
determination of drug levels in biological fluids (Hurtado-Gaitan et al., 2017, 
Schuhmacher et al., 2008). It consists of the first quadrupole (Q1), collision cell (Q2) 
and the third quadrupole (Q3). Therefore, a QqQ mass spectrometer can be operated in 
four different modes with collision-induced dissociation: multiple-reaction monitoring 
(MRM/SRM), product-ion scan, precursor-ion scan, and constant neutral loss. MRM is 
the most common function utilized for quantification and confirmation. In general, a 
product-ion spectrum is first acquired with a reference standard, where MRM 
transitions are defined and selected to perform LC/MS/MS analysis. The newest 
instruments enable us to set short MRM dwell times without loss of sensitivity, making 
multi-target methods possible (Draisci et al., 2001, Zi-Min et al., 2017). LC-MS/MS 
with MRM scan has now been applied by many investigators to identify trace levels in 
biological fluids as a gold standard method. Compared with enzyme-label immunoassay, 
which is already highly sensitive and specific, it has not only better sensitivity and 
specificity but also good accuracy and reproducibility. 
To determinate the berberine levels, multiple detection methods have been developed, 
such as high performance liquid chromatography-fluorescence detection (HPLC-FD) 
(Akao et al., 2000), field desorption mass spectrometry (FDMS) (Lee et al., 2003), gas 
chromatography chemical ionization mass-spectrometry (GC-CIMS) (Miyazaki et al., 
1978) and high performance liquid chromatography–mass spectrometry (HPLC-MS) 
(Lu et al., 2006, Liu et al., 2010). 
However, although these methods have good sensitivity and selectivity, they do not 
provide evidence and procedure for method validation. For this reason, a sensitive and 
reliable liquid chromatography tandem mass spectrometry (LC-MS/MS) method with 
liquid–liquid extraction procedure was developed. The determination of berberine in 
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plasma was undertaken using MRM with carvedilol (It’s characteristic of separation is 
similar to berberine) as internal standard. The methods were validated by verifying 
linearity, lower limit of quantification, intra- and inter-assay precision and accuracy, 
specificity, quality control and stability for berberine in human serum. It was carried 
out according to the Guidance for Industry Bioanalytical Method Validation 
recommended by Food and Drug Administration (Guidance).  
The structures of berberine and berberine8998 (Fig.1.5) are similar. After oral 
administration of berberine8998, it is transformed to berberine (ratio 1:1) in the plasma, 
thus it might work as a prodrug. Hence the method developed here (Chapter2.4.2) could 
also be applied to analyze plasma samples after administration of berberine8998. This 
method was successfully applied to the pharmacokinetic study of berberine for 
evaluating and comparing the formulation of berberine8998. 
 
10.2 Results 
10.2.1 Standard curve analysis 
To verify linearity, a standard curve was established on each validation day. The 
calculated peak area ratios of berberine to the internal standard (IS) versus the nominal 
concentration in rat plasma showed a good linear relationship in the concentration range 
from 5 to 300ng/ml. A typical standard curve was Y= 0.0112X+0.00829 (R=0.9984, 
Fig 10.1), where Y represents the ratio of berberine peak area to that of the IS, 
and X represents the plasma concentration of berberine. For each round, different 
standard curves were carried out (Table 10.1). The mean correlation coefficients (r) of 
all of the curves were all above 0.99, which means that Y and X have strong linear 
positive correlation. Thus, the calibration curves exhibited good linearity within the 
given range. 
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Fig 10.1 A standard curve of berberine 
 
Table 10.1 Standard curves values for the berberine analysis n=6 
 
Analyte Conc.
（ng/mL） 
Calculated Conc.（ng/mL） 
5 4.92 4.79 4.67 5.18 4.8 5.12 
10 11.2 10.1 9.81 10.5 9.91 10.3 
20 26.8 19.4 19.9 20.4 19.7 20.2 
40 40.6 39 39.2 43.5 41 40.4 
80 80.6 80.1 79.9 83 88.9 75.5 
150 153 155 152 149 156 148 
300 282 290 243* 260 291 275 
formula y=0.0112x+0.00829 y=0.0101x+0.00632 y=0.0101x+0.02 
R 0.9984 0.9974 0.9982 
5 4.53 5.05 5.17 4.74 5.23 4.28 
10 10.7 10.4 9.22 10.5 11.3 9.5 
20 20 22.3 20.7 22.3 22.3 22.5 
40 39.5 41.8 36 42.9 39.4 41.9 
80 74.9 87 78.9 79.6 73.9 81.9 
150 137 150 143 156 152 152 
300 248* 268 230* 283 264 267 
formula y=0.0123x+0.0153 y=0.00785x+0.00257 y=0.00775x+0.00989 
R 0.9957 0.9966 0.9935 
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10.2.2 Lower Limit of quantitation (LLOQ) 
The lower limit of quantification (LLOQ), which reflects the signal-to-noise ratio (S/N), 
was more than 6 at 5 ng/ml for berberine (Fig 10.2). The LLOQ, which was set at 
5ng/ml, was sensitive enough for investigating the lowest dose of berberine in the serum 
samples. Acceptable precision and accuracy for the LLOQ were obtained. The average 
accuracy of these data was in the range 94.2%-109% (Table 10.2). The precision (RSD) 
of these data were all lower than 7% (Table 10.3).  
 
 
Fig 10.2 LLOQ result for berberine (5ng/ml) 
  
Table 10.2 Results for accuracy of LLOQ for determination of berberine 
Replicates 
%Accuracy 
5（ng/mL） 
1 99.2 103 94.2 
2 95.8 108 97.6 
3 103 114 111 
4 102 110 110 
5 109 106 110 
6 103 112 107 
Within-     
run 
Mean 102 109 105 
N 6 6 6 
Between-        
run  
Mean 105 
N 18 
 
Table 10.3 Results for precision of LLOQ for determination of berberine 
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Replicates 
Calculated Conc.（ng/mL） 
5 
1 2 3 
1 4.96 5.13 4.71 
2 4.79 5.39 4.88 
3 5.13 5.71 5.53 
4 5.09 5.49 5.49 
5 5.45 5.31 5.52 
6 5.16 5.61 5.33 
Within-      
run 
Mean 5.1 5.44 5.24 
SD 0.22 0.21 0.359 
RSD (%) 4.32 3.85 6.84 
N 6 6 6 
Between-        
run  
Mean 5.26 
SD 0.293 
RSD (%) 5.58 
N 18 
 
 
10.2.3 Intra- and inter-assay precision and accuracy 
The within-run (intra-assay) and between-run (inter-assay) precision and accuracy for 
assays were characterized by the four levels of QCs run on three sequential batches in 
six replicates. All QC samples were randomized daily, processed and analyzed, together 
with calibration samples. The precision was expressed as a relative standard deviation 
(RSD) by calculating the standard deviation as the percentage of the mean calculated 
concentration, while the accuracy of the assay was determined as the percentage of the 
mean with reference to the nominal concentration. The results demonstrated that the 
precision (Table 10.4) and accuracy (Table 10.5) of this assay are within the acceptable 
range, and the method is accurate and precise. 
 
Table 10.4 The precision of results of both the within-run and between-run for 
quantification of berberine in serum samples 
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Calculated Conc.（ng/mL） 
  5（ng/mL） 15（ng/mL） 
Within-      
run 
Mean 5.1 5.44 5.24 14.5 13.1 14.2 
SD 0.22 0.21 0.359 0.683 0.655 0.898 
RSD (%) 4.32 3.85 6.84 4.7 5.01 6.33 
N 6 6 6 6 6 6 
Between-        
run  
Mean 5.26 13.9 
SD 0.293 0.951 
RSD(%) 5.58 6.83 
N 18 18 
  50（ng/mL） 200（ng/mL） 
Within-      
run 
Mean 54.5 50.5 51.1 203 182 201 
SD 1.64 2.08 1.67 6.05 2.42 4.46 
RSD(%) 3 4.12 3.27 2.98 1.33 2.21 
N 6 6 6 6 6 6 
Between-        
run  
Mean 52 195 
SD 2.47 10.8 
RSD(%) 4.76 5.53 
N 18 18 
 
Table 10.5 The percentage accuracy of the results for quantification of berberine in 
serum samples for both the within-run and between-run. 
%Accuracy 
    5（ng/mL） 15（ng/mL） 
Within-      
run 
Mean 102 109 105 97.1 87.2 94.6 
N 6 6 6 6 6 6 
Between-        
run  
Mean 105 92.9 
N 18 18 
    50（ng/mL） 200（ng/mL） 
Within-      
run 
Mean 109 101 102 102 90.9 101 
N 6 6 6 6 6 6 
Between-        
run  
Mean 104 97.7 
N 18 18 
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10.2.4 Interference 
Six different source drug-free serums (rat) were used to prepare blank samples and 
LLOQ samples. The interference peak areas of these samples were all lower than 15% 
of that of LLOQ samples (Table 10.6). It can be concluded that the internal interference 
was acceptable. 
 
Table 10.6 Results of internal interference with determination of berberine in serum 
Replicates 
Peak Area (BBR) 
Blank1 Blank2 Blank3 Blank4 Blank5 Blank6 
blank LLOQ blank LLOQ blank LLOQ blank LLOQ blank LLOQ blank LLOQ 
1  718 6970 180 9240 257 8510 468 6610 262 5870 357 5100 
2  427 6470 435 8760 253 7440 738 8730 330 3940 74.7 7390 
3  886 11900 3380 8690 459 8630 1170 7410 628 7260 871 13900 
Mean 677  8447 1332  8897 323  8193 792  7583 407  5690 434  8797 
%Interference 8.01  15.0  3.94  10.4  7.15  4.94  
 
 
10.2.5 Quality control 
The entire QC samples in three round of analysis were found to be acceptable. The 
accuracies of the QC samples were in a range 86.6% to 107% (Table 10.7). It can be 
concluded that the quality of the measure in all three rounds were good. 
 
Table 10.7 Quality control of berberine determination 
Replicates 
Calculated Conc.（ng/mL） %Accuracy 
15 50 200 15ng/mL 50ng/mL 200ng/mL 
Round1 
QC1 14.3  43.3 196 95.5 86.6 97.8 
QC2 14.9 51.1 210 99.1 102 105 
QC3 14.9 51.8 180 99.6 104 90.1 
Unacceptable Quant./ Total Quant. 0 / 9 
Round2 
QC1 14.5  44.1 187 96.9 88.1 93.4 
QC2 15.4  53.1 184 103 106 92.1 
QC3 16.0  50.2 190 107 100  95.1 
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Unacceptable Quant./ Total Quant. 0 /9 
Round3 
QC1 15.1 46.8 181 101 93.6 90.7 
QC2 14.8 49.8 187 98.4 99.7 93.4 
QC3 14.7 49.5 183 98.2 99.1 91.3 
Unacceptable Quant./ Total Quant. 0 /9 
 
10.2.6 Stability 
The auto-sampler stability was assessed by analyzing the extracted QC samples in the 
auto-sampler at room temperature for 0, 2, and 4 hours. The relative standard deviation 
(RSD) was expressed by calculating the standard deviation as the percentage of the 
mean calculated concentration at the time intervals investigated. These results are 
outlined in Table 10.8. The RSD values of these samples (three different concentrations 
of QC samples) were within 5%. The analytes remained considerably stable under the 
above conditions at all-time intervals investigated. The good stability of the berberine 
simplified the precautions needed for laboratory manipulations during the sample 
preparation. 
 
Table 10.8 Results from stability analysis for determination of berberine  
Analyte     
Conc.           
（ng/mL） 
Bench-Top 
Time           
（h） 
Calculated Conc.                              
（ng/mL） 
Mean SD RSD(%) RE 
15 
0 14.6 14.8 14.8 14.7 0.115 0.784 / 
2 14.5 14.1 13.8 14.1 0.351 2.48 -4.07  
4 14.5 14.2 14.7 14.5 0.252 1.74 -1.81  
50 
0 49.9 49.7 50.2 49.9 0.252 0.504 / 
2 51.2 50.3 51.6 51.0 0.666 1.30 2.20  
4 51.5 49.4 46.8 49.2 2.35 4.78 -1.40  
200 
0 178 179 173 177 3.21 1.82 / 
2 189 182 183 185 3.79 2.05 4.53  
4 191 185 176 184 7.55 4.10 4.15  
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10.2.7 Extraction recoveries and matrix effects  
In this study, four organic precipitation solvents were tried: acetonitrile, methanol, 
acetonitrile and water (1:1,v/v), methanol and water (1:1,v/v). Among them the 
acetonitrile:water solution yielded a good clean-up of the plasma samples and adequate 
recovery of the berberine. Mean results of extraction recoveries of berberine at 5, 15, 
50 and 200 ng/ml were 80.5%, 84.2%,78.6% and 86.3%, respectively (n = 6, Table 
10.9). The extraction recoveries is over 75%. It can be concluded that the extraction 
recoveries by this method were acceptable. 
Mean results of matrix effects of berberine at 5, 15, 50 and 200 ng/ml were 94.4%, 
97.1%,96.1% and 97.6 %, respectively (n = 6, Table 10.9). It indicated that the 
suppression of matrix effects in this method were not significant. 
 
Table 10.9 Extraction recoveries and matrix effects on determination of berberine 
Conc. (ng/ml) 5 15 50 200 
Berberine ER (%) 80.5 84.2 78.6 86.3 
  ME (%) 94.4 97.1 96.1 97.6 
 
10.3 Discussion 
Electrospray ionisation (ESI) and atmospheric pressure chemical ionisation (APCI) 
have evolved as standard techniques for the ionisation of most small molecules in 
biological fluids analyses. In addition, atmospheric pressure photoionisation (APPI) 
which has the similar ionization range as APCI has been developed to increase 
ionisation efficiencies of non-polar compounds (Robb et al., 2000). APPI has been 
shown to be especially advantageous with respect to minimizing matrix effects. In this 
study, ESI which is applicable to polar and medium non-polar analytes that cover a very 
broad mass range was selected. Berberine is an alkaloid and hence a nitrogen atom-
containing compound. To avoid ion-pair effect, hydrophobic ion-pair regents such as 
heptafluorobutyric acid (HFBA), trifluoroacetic acid (TFA), and non-afluoropentanoic 
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acid (NFPA) should be avoided in mobile phase preparation as well as in sample 
preparation (Gustavsson et al., 2001, Codony et al., 2002). 
Internal standard is a known amount of chemical added to an analytical sample, which 
allows calibration of laboratory instruments. It is always used when performing MS 
quantization as quality control for extraction of a compound, HPLC injection and 
ionization variables. The internal standard could be a compound that is very similar, but 
not identical to the chemical species of interest in the samples. In this research, 
carvedilol which has the similar molecule weight to berberine, was selected as the 
internal standard (Fig 10.3). 
 
Fig 10.3 The results of sample (Left 198 ng/mL) and internal standard (Right 
4.29µg/mL) from LC-MS/MS analyses of berberine determination 
 
Sample preparation is a critical step for accurate and reliable LC–MS/MS assays. The 
high selectivity of MS instruments has initially led to the assumption that less effort is 
needed for sample preparation and chromatographic separation prior to MS detection. 
Precipitation is a widely adopted method and often achieves satisfactory extraction 
recoveries of an analytes from biological samples. Compared with liquid-liquid 
extraction and solid phase extraction, precipitation can provide a saving for both time 
and cost. Hence, precipitation was chosen to prepare the samples in this study. 
The matrix effect is a challenge in LC-MS/MS quantitative analyses, especially when 
ESI is used as the interface. Eluting matrix components limits the accuracy of 
quantitative analytical methods by ion suppression/enhancement in the MS ion source 
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through competition for the electrical charges or through affecting the evaporation of 
the ESI droplets and the analyte transfer to the gas phase (Panuwet et al., 2016).  The 
matrix effects can be estimated or determined by comparing the responses of analytes 
in solvent or buffer to those in the presence of matrices (Barrett et al., 2005). More 
specifically, the matrix effect was assessed by comparing the percentage of peak areas 
of berberine in neat QC chemical standards to blank serum samples after extraction.  
The current study described, developed and validated an accurate cost-effective 
sensitive and specific LC/MS/MS method to determine berberine. Therefore, this 
method can also be applied in the pharmacokinetic study of berberine8998 to evaluate 
the absorption and quantification of berberine8998 in different formulations 
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11 Formulation of berberine8998 
11.1 Introduction 
Berberine, an isoquinoline alkaloid, has wide application in many research areas in 
recent years because of its many novel pharmacological functions, such as antioxidant, 
cardiovascular protection, anti-depressant, neuroprotective, anti-diabetic, anti-obesity, 
hepatoprotective, anti-rheumatic, antiangiogenic, anti-clastogenic and anti-cancer 
activities (Wang et al., 2017, Doggrell, 2005, Sun et al., 2009, Tang et al., 2009). 
However berberine’s low oral bioavailability restricts its wide application since it is a 
lipophobic compound, it is restrained from passing through the membranes of intestinal 
cells (Zhang et al., 2012). 
There are several reagents that can be combined with lipophobic drugs to enhance their 
uptake from the gastrointestinal tract. D-α-Tocopheryl polyethylene glycol 1000 
succinate (TPGS) is a water-soluble derivative of natural vitamin E, which is formed 
by esterification of Vitamin E succinate with polyethylene glycol (PEG) 1000. TPGS 
can function as a P-gp inhibitor, solubilizer/absorption and permeation enhancer in drug 
delivery and TPGS-related formulations for nanocrystals, nanosuspensions, 
tablets/solid dispersions, as an adjuvant in vaccine systems, nutrition supplements, 
plasticizer films, anticancer reagents, etc. (Guo et al., 2013). It has been reported that 
TPGS at a concentration of 2.5% can improve the peak concentration (Cmax) and the 
area under the curve (AUC) for berberine by 2.9 and 1.9 times, respectively (Chen et 
al., 2011).  
Chitosan is an attractive polymer for biomedical applications due to its biocompatibility, 
biodegradability, natural origin, and low cost. It is a linear polysaccharide with a 
molecular weight up to ca. 2000 kDa, obtained by partial N-deacetylation of chitin from 
crustacean shells or mushrooms (Younes and Rinaudo, 2015). The mechanism by which 
chitosan enhances mucosal absorption is complicated. The most important factor 
is chitosan’s positive charge which can interact electrostatically with the negatively 
charged sialic acid residues on mucin (Deacon et al., 2000). Formulations containing 
111 
 
0.5%, 1.5%, and 3.0% chitosan have resulted in improvement of AUC0-36 values of 
berberine by 1.9, 2.2, 2.5 times (Chen et al., 2012). 
Sodium caprate, is the sodium salt of the aliphatic saturated 10-carbon MCFA. It is a 
compound already approved as a food additive. Rectal formulations containing sodium 
caprate have been shown to increase the absorption of a range of β-lactam antibiotics 
(Murakami et al., 1993). It increases the flux of many different types of poorly 
permeable agents across intestinal epithelia in vitro (Cho et al., 2002).  The AUC 
values of berberine were increased by 28% compared to in the absence of sodium 
caprate (Lv et al., 2010). The pharmacokinetic study was applied to evaluate the AUC 
of the novel berberine8998 formulation. 
 
11.2 Results 
Method validation results for determination of berberine by LC-MS/MS were shown in 
section 4.2. In order to find out the pharmacokinetic differences between the two 
formulations, a study with 10 rats (two-way crossover) was undertaken. The tolerable 
daily intake limit (TDI) of the two formulations was both set at 100mg/kg according to 
the earlier hamster experiment (Section 4). Pharmacokinetic parameter could reflect the 
absorption of two formulations (administered Formulation R and Formulation A at 
same time). The mean serum concentration versus time profile obtained is presented in 
Fig 11.1. The principal pharmacokinetic parameters of Formulation R and Formulation 
A are summarized in table 11.1 and table 11.2.  The maximum concentration of 
Formulation R and Formulation A in serum (Cmax) was 90.8ng/mL and 155.02ng/mL, 
respectively. The half-life of Formulation R and Formulation A in serum (t1/2) was 
3.42 h and 3.92 h, respectively. The area under the curve (AUC0-48) of Formulation R 
was 727.789 h*ng/mL, and the AUC0-48 of Formulation A was 1702.162 h*ng/mL. 
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Figure 11.1 The mean concentration–time profile of Formulation R and Formulation A 
following a single oral administration of 100 mg/kg berberine8998 to 10 rats (dual 
crossing). N=10, Mean±SD 
 
Table 11.1 The plasma pharmacokinetics parameters of Formulation R following a 
single oral administration of 100mg/kg berberine8998 to 10 rats (dual crossing). 
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Pharmacokinetic parameters (R) 
Rat No T1/2 Cmax Tmax AUC(0-t) AUC(0-∞) 
  H ng/ml h ng/ml*h ng/ml*h 
1 2.754 69.3 2 681.415 681.419 
2 2.802 60.8 1 607.39 607.394 
3 2.92 50.4 1 358.55 358.554 
4 2.84 198 1 703.44 703.444 
5 6.192 136 2 1001.98 1006.04 
6 2.643 92.6 3 875.75 875.754 
7 2.523 72.5 3 840.7 840.704 
8 2.66 78.7 2 627.7 627.704 
9 6.202 58.5 2 798.36 802.519 
10 2.696 91.2 2 782.6 782.604 
Mean 3.423 90.8 1.9 727.789 728.614 
SD 1.466 44.792 0.738 176.824 177.713 
RSD(%) 42.8 49.3 38.8 24.3 24.4 
Table 11.2 The plasma pharmacokinetics parameters of Formulation A following a 
single oral administration of 100mg/kg berberine8998 to 10 rats (dual crossing). 
 
Pharmacokinetic parameters (A) 
Rat No T1/2 Cmax Tmax AUC(0-t) AUC(0-∞) 
 H ng/ml h ng/ml*h ng/ml*h 
1 2.375 203 2 2203.5 2203.503 
2 2.349 174 6 1971.3 1971.303 
3 4.168 185 6 2440.21 2441.249 
4 2.542 223 0.5 1854.5 1854.504 
5 2.449 129 6 1841.95 1841.954 
6 5.283 112 2 1592.7 1596.097 
7 8.836 85.2 3 1330.875 1362.831 
8 6.134 143 0.5 1114.8 1119.18 
9 2.508 147 0.5 1464.26 1464.264 
10 2.6 149 1 1212.52 1212.524 
Mean 3.924 155.02 2.75 1702.662 1706.741 
SD 2.202 41.939 2.383 434.922 431.428 
RSD(%) 56.1 27.1 86.7 25.5 25.3 
 
11.3 Discussion 
Formulation A (berberine8998 microcrystal suspensions) was prepared by another 
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research group, they did not want to provide their preparation method. Highest dose for 
hamster experiment (in section 4) was converted to TDI to a rat value in this study, 
because the conversion coefficient of body surface area (BSA) for hamster and rat are 
very close (hamster 9.1 and rat 9.0) (Ohwada, 1992). Thus, 100mg/kg dose was selected. 
At this dose of berberine8998, good tolerability was observed in all the rats. No related 
adverse effects were observed and no significant decrease in weight was found between 
the week 1 and week 2. 
Pharmacokinetics has been proposed for studying the absorption, distribution, 
biotransformation and elimination of drugs in human and animals (Urso et al., 2002). 
Triple quadrupole tandem mass spectrometer was applied for analysis of the serum 
concentration of berberine and berberine8998. These two compound shared the ion pair 
in MRM scan model. As the chemical structures of berberine and berberine8998 are 
very similar, it is feasible that berberine8998 might be converted to berberine after 
absorption, functioning like a prodrug (might be). Hence the same method as described 
in Chapter 4 was used to determine the serum concentration of berberine8998. The 
serum mass test can prove berberine8998 convert to berberine after taken by hamster 
and rat. However, the place berberine8998 convert to berberine was not found in this 
research. The AUC of Formulation R was 727.789, and the AUC of Formulation A was 
1702.662. In this part of the study, The modified Formulation A greatly improved the 
absorption of berberine8998 by 2.34 times (Formulation A AUC0-48 of berberine8998 / 
Formulation R AUC0-48 of berberine8998). 
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12. General Discussion 
Berberine8998 is a novel berberine derivative with Chinese patent accreditation. This 
study aims was to elucidate the pharmacological effects of berberine8998 on lipid 
profiles and associated mechanisms via proteomic approaches. Tentative toxicological, 
pharmacokinetic and pharmaceutical optimization was also included in this study.  
Toxicological profiles were of high importance in drug development. Therefore, 
acute toxicity was conducted. The results of the previous study showed that the LD50 of 
berberine from intravenous injection and intrapetoneal injections is 9.0386 and 
57.6103 mg/kg, respectively; but no LD50 was found in the intragastric administration 
i.g. (Kheir et al., 2010). The results of the present study showed that the LD50 for 
berberine8998 on C57BL/6 mice (i.g.) was 870mg/kg. Acute toxicity can result from 
interference with signal transduction systems and through chemical reactions that 
damage the organism caused by the administered compound or reactive metabolites 
formed through its metabolism. There is reason to believe that the same 
pharmacological effects of drugs that cause the therapeutic effect can also account for 
much of their acute toxic effects (Svennebring, 2016).  
The pharmacological studies were conducted in this study. The results showed for 
the first time that berberine8998 lowered the lipid profiles to a greater extent. In vivo 
studies showed that berberine8998 significantly lowered the total cholesterol (25%, 
P<0.05), low-density-lipoprotein (51%, P<0.05) and triglyceride levels (60%, P<0.01) 
comparing with the hamster model group, while berberine only lowered total 
cholesterol and triglyceride levels (Fig 4.2, section 4.2.2). Further mechanism studies 
revealed that berberine8998 enhanced hepatic LDL uptake (Fig 5.1) by increasing 
LDLR expression (Fig 6.1 and Fig 6.2). These results explained the LDL-lowering 
effect of berberine8998, but they were unable to unveil its beneficial effect on TG. 
Therefore, iTRAQ method coupled with 2D LC-MS/MS, was conducted.  
The lipid lowering effect of berberine was widely reported (Kumar, A, et al. 2015). 
Treatment of hypercholesterolemic patients with orally administered berberine reduced 
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serum levels of cholesterol and low-density lipoprotein (LDL) by 29% and 25%, 
respectively.  Berberine treatment reduced serum LDL by 42% in hyperlipidemic 
hamsters (Kong et al., 2006). Compared with the effect of berberine, berberine8998 
improved the lipid lowering effect to a greater extent (51% vs 42%), though not 
significant in statistics. Besides, triglyceride levels (60%, P<0.01) were significantly 
reduced comparing with the hamster model group, while berberine only lowered total 
cholesterol and triglyceride levels (Fig 4.2, section 4.2.2). Therefore, extensive studies 
were conducted to unveil the associated mechanisms.  
In terms of LDL-c reduction, DiI-LDL and western blot were conducted on HepG2 
cells and hamster liver tissues. Consistent with the findings in serum LDL-c,  
berberine8998, to a greater extent, stimulated the uptake of LDL in HepG2 cells, which 
is similar to the cholesterol-lowering agent pravastatin (Fig 5.1, 2.26 vs 1.22 fold of 
control). The intensity (a.u.) of Dil-LDL in HepG2 cells was screened to compare the 
lipid uptake amount of the positive control group (Pravastatin), the berberine group and 
the berberine8998 group. The western blot analysis showed that the upregulation of 
LDLR expression was greater in cells treated with berberine8998 as compared with that 
of berberine (Fig 6.2), indicating that berberine8998 induces higher LDLR expression. 
These results illustrated that the berberine8998 lead LDL-c reduction was induced by 
LDLR and PCSK9 pathway.  
For the TG reduction, extensive studies were conducted. This study was the first time 
that the iTRAQ method was coupled with 2D LC-MS/MS (TripleTOF 5600) to 
investigate the mechanisms of action of berberine and berberine8998. In-depth iTRAQ 
proteomics revealed that ACOX1 and ACSL1, proteins involved in fatty acid 
metabolism, were expressed differently in the berberine8998 group compared to the 
control group (Table 7.1 and Table 7.2). Further studies showed that berberine8998 
significantly lowered non-esterified fatty acid (NEFA) levels (Fig 9.2), which may lead 
to a reduction in TG levels in berberine8998 treatment groups. All these studies show 
that berberine8998 lowered TG via induction of fatty acid metabolism which is a newly 
defined mechanism of berberine8998.  
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It was found that berberine8998 can reduce TG and NEFA levels, but berberine can 
only lower TG. Serum FA includes triglycerides, phospholipids, and cholesterol that are 
not bound to lipid fractions of biological fluids. These play an important role in the 
development of non-alcoholic fatty liver disease (Neuschwander-Tetri, 2010, 
Tabeshpour, J, 2017). The lipid lowering effect of berberine on NEFA was not 
significant. That result suggested that berberine8998 lowered NEFA through a unique 
mechanism. TG reduction was observed in some most important LDL lowering drug. 
For example, Statins lower TG by endocytosing TG-rich apoB particles, the TG 
themselves are simply re-compartmentalized by going from plasma into the liver 
(Maron et al., 2000). The TG lowering effect of berberine8998 insure it’s potentail 
therapeutical effect in future study. The observed pharmacological differences between 
berberine and berberine8998 may stem from the polarity variance of the two molecules: 
berberine is a quaternary ammonium salt and berberine8998 is expected to be less polar 
due to its lack of this molecular feature. 
In order to elucidate the possible mechanisms involved, the function, the interplay 
and the changes in abundance of proteins in response to internal and external cues 
should be considered (Ray et al., 2011). Hence, the iTRAQ method was combined with 
two-dimensional LC–MS/MS to analyze protein expressions in the liver tissue of mice 
maintained on a high-fat diet and treated with either berberine or berberine8998 in order 
to evaluate the effect of the two compounds. This is among the most powerful 
methodologies in quantitative proteomics (Hou et al., 2013). Using this iTRAQ method, 
85 identified proteins among the treatment and control groups were differently 
expressed, of which 19 proteins were common in the berberine and berberine8998 
groups. The GO and IPA analyses showed that proteins that were differently (relative 
to the control group) expressed in the treatment group had similar functions. The KEGG 
pathway enrichment heat map suggested that FA metabolism and branched-chain amino 
acid degradation pathways were specifically activated within the treatment group. It is 
found that ACOX1 and ACSL1 were significantly lower in the berberine8998 group, 
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suggesting that these agents can reduce serum NEFA levels by modulating ACOX1 and 
ACSL1 expression. 
The mass quantitative methods were validated by verifying the standard curve, LLOQ, 
intra- and inter-assay precision and accuracy, specificity, matrix interference, quality 
control, stability matrix effect and extraction recovery for berberine in mouse and rat 
serum. It was carried out according to the Guidance for Industry Bioanalytical Method 
Validation recommended by the FDA (FDA Guidance). Berberine8998 (not a 
quaternary ammonium salt) may be transformed into berberine after absorption. 
Therefore, this quantitative method (section 10) could be applied to determine 
berberine8998 in the SD rat pharmacokinetic study. 
Pharmacokinetic study was used to evaluate the two formulations of berberine8998. 
Both formulation R and formulation A were designated for future studies. The AUC0-
48h was the main value reflecting the quality of the formulation. The natural product 
berberine has become a potential drug in the treatment of diabetes, hyperlipidemia, and 
cancer. However, the oral delivery of berberine is challenged by its poor bioavailability. 
It is necessary to improve the oral bioavailability of berberine before it can be used in 
many clinical applications. Understanding the pharmacokinetic characteristics of 
berberine enables the development of suitable formulation that have improved oral 
bioavailability. The key considerations for berberine are how to enhance the drug 
absorption. (Chang-shun L.et, al, 2016) 
In summary, in the current mechanism study, the lipid lowering effect of a berberine 
derivative—berberine8998 was explored. Results from the high-fat diet hamster model 
have shown that berberine8998 significantly lowers the LDL, total TC and TG levels 
in hamsters. Further mechanism studies revealed that berberine8998 can enhance 
hepatic LDL uptake by increasing LDLR expression. NEFA was down-regulated by 
berberine8998. From iTRAQ proteomic analysis, the effect of berberine8998 on TG 
was mediated by NEFA and hepatic ACOX1 expression. This ACOX1-regulated 
mechanism suppresses the in vivo TG and NEFA levels, which is a novel mechanism of 
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berberine8998 in its lipid lowering effect. Consistent with the lipid lowering effect, 
berberine8998 up-regulated (compared with berberine) the bioavailability in SD rats. 
 
13. Future Studies 
Many aspects of the current research for the potential involvement of the berberine and 
berberine8998 are currently speculative, based partly on findings presented here and 
partly on existing recorded evidence. Together with important clinical therapeutic 
concerns associated with berberine and berberine8998, future studies should include: 
Since acute oral toxicity study has been completed, animals such as rats, hamsters and 
beagles can be used to explore the long-term toxicity. In the case of rodents, each group 
should consist of at least ten males and ten females. In the case of non-rodents, each 
group should consist of at least three males and three females. Large animals will 
consume more API of berberine8998. Long-term repeated administration should be for 
more than six months. For rodents, blood samples should be taken before the autopsy. 
For non-rodents, blood samples should be taken before the start of drug administration, 
at least once during the administration period (for studies of longer than one month), 
and before autopsy. For both haematological and blood chemistry examinations, it is 
desirable to include as many parameters as possible. Since liver and kidney are the 
organs of metabolism and excretion, they are easily affected by potentially toxic agents, 
so that their functions should be monitored in long term toxicity studies. These tests 
will provide more specific information about the toxicity of berberine8998. 
In this work, the systemic exposure of berberine8998 was 7.76 fold of that of berberine 
in SD rats but the mechanisms are still not fully clear. Caco-2 cell model can be applied. 
The objective of the future study is to use caco-2 cell to study the permeability of 
berberine8998. When cultured under specific conditions, the Caco-2 cell become 
differentiated and polarized, such that their phenotype, morphologically and 
functionally, resemble the enterocytes lining the small intestine (Hidalgo et al., 1989). 
120 
 
Thus, we can develop a rapid in vitro digestion/Caco-2 cell culture model for assessing 
the relative bioavailabilities of berberine and berberine8998 (Yun et al., 2004). Since 
berberine8998 is not soluble in water, there are three possible way to handle the 
problem: 1) the Microemulsion method, 2) the HP-β-CD method and 3) 
nanosized powder.  
The distribution of berberine8998 may be analyzed in rats to understand the target organ 
for this compound. The metabolism and elimination studies may be conducted to 
characterize the major metabolic pathway and elimination route of berberine8998. 
Nonalcoholic steatohepatitis (NASH) is the most extreme form of NAFLD, and has 
been regarded as a major cause of cirrhosis of the liver. Most people can be treated if 
the condition is caught in its early stages. About 12 to 25% of the people in the United 
States have NAFLD and between 2 to 5% have NASH. It is expected that NASH will 
become the major cause of cirrhosis in China in 2030. Previous study (Hong-Mei et al. 
2015) has revealed that berberine, with its lipid lowering effect, attenuated NAFLD in 
the mouse model. One can thus expect that berberine8998 can be effective on NAFLD 
and NASH. Pre-clinical studies may be conducted to evaluate its efficacy. The NASH 
model includes methionine-choline deficient (MCD) diet model, high-fat diet model in 
mice, etc.  
MS-based quantitative proteomics is an essential tool for elucidating the complex and 
dynamic nature of proteomes, enabling in-depth characterization of changes in protein 
expressions. For further validation and verification of novel proteins discovered in 
comparative proteomics, targeted approaches such as selected reaction monitoring 
(SRM; or multiple reaction monitoring, MRM, as commonly known) offer much higher 
sensitivity and much greater speed of analysis. MRM can precisely quantitate targeted 
proteins with known fragmentation properties in complex backgrounds. Integration of 
the chromatographic peaks for each transition of peptides supports the relative or, if 
suitable heavy isotope–labeled reference standards (SIS) are used, absolute 
quantification of the targeted peptide(s) across different samples robustly with high 
throughput (Addona et al., 2009, Ahn et al., 2015). Developing and validating SRM 
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assays is an extensive process. Once generated for a particular protein, this mass 
spectrometric assay can be deployed for accurate identification and quantification of 
that protein in biological samples. 
 
 
  
122 
 
 
14. References 
1956. J.W. Trevan. Br Med J, 2, 943-4. 
2008. The Gene Ontology project in 2008. Nucleic Acids Res, 36, D440-4. 
ADDONA, T. A., ABBATIELLO, S. E., SCHILLING, B., SKATES, S. J., MANI, D. R., BUNK, D. M., 
SPIEGELMAN, C. H., ZIMMERMAN, L. J., HAM, A. J., KESHISHIAN, H., HALL, S. C., 
ALLEN, S., BLACKMAN, R. K., BORCHERS, C. H., BUCK, C., CARDASIS, H. L., 
CUSACK, M. P., DODDER, N. G., GIBSON, B. W., HELD, J. M., HILTKE, T., JACKSON, 
A., JOHANSEN, E. B., KINSINGER, C. R., LI, J., MESRI, M., NEUBERT, T. A., NILES, R. 
K., PULSIPHER, T. C., RANSOHOFF, D., RODRIGUEZ, H., RUDNICK, P. A., SMITH, D., 
TABB, D. L., TEGELER, T. J., VARIYATH, A. M., VEGA-MONTOTO, L. J., 
WAHLANDER, A., WALDEMARSON, S., WANG, M., WHITEAKER, J. R., ZHAO, L., 
ANDERSON, N. L., FISHER, S. J., LIEBLER, D. C., PAULOVICH, A. G., REGNIER, F. E., 
TEMPST, P. & CARR, S. A. 2009. Multi-site assessment of the precision and reproducibility 
of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol, 27, 
633-41. 
AHMED, F. E. 2009. Sample preparation and fractionation for proteome analysis and cancer biomarker 
discovery by mass spectrometry. J Sep Sci, 32, 771-98. 
AHN, Y. H., KIM, J. Y. & YOO, J. S. 2015. Quantitative mass spectrometric analysis of glycoproteins 
combined with enrichment methods. Mass Spectrom Rev, 34, 148-65. 
AKAO, T., KAWABATA, K., YANAGISAWA, E., ISHIHARA, K., MIZUHARA, Y., WAKUI, Y., 
SAKASHITA, Y. & KOBASHI, K. 2000. Baicalin, the predominant flavone glucuronide of 
scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to 
its original form. J Pharm Pharmacol, 52, 1563-8. 
ALIQUE, M., LUNA, C., CARRACEDO, J. & RAMIREZ, R. 2015. LDL biochemical modifications: a 
link between atherosclerosis and aging. Food Nutr Res, 59, 29240. 
AROLA, L., HERRERA, E. & ALEMANY, M. 1977. A new method for deproteinization of small 
samples of blood plasma for amino acid determination. Anal Biochem, 82, 236-9. 
BAHIRU, E., DE CATES, A. N., FARR, M. R., JARVIS, M. C., PALLA, M., REES, K., EBRAHIM, 
S. & HUFFMAN, M. D. 2017. Fixed-dose combination therapy for the prevention of 
atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev, 3, Cd009868. 
BARAK, L. S. & WEBB, W. W. 1981. Fluorescent low density lipoprotein for observation of dynamics 
of individual receptor complexes on cultured human fibroblasts. J Cell Biol, 90, 595-604. 
BARRETT, B., BOREK-DOHALSKY, V., FEJT, P., VAINGATOVA, S., HUCLOVA, J., NEMEC, B. 
& JELINEK, I. 2005. Validated HPLC-MS-MS method for determination of azithromycin in 
human plasma. Anal Bioanal Chem, 383, 210-7. 
BASAK, A., PALMER-SMITH, H. & MISHRA, P. 2012. Proprotein convertase subtilisin kexin9 
(PCSK9): a novel target for cholesterol regulation. Protein Pept Lett, 19, 575-85. 
BAYS, H. & STEIN, E. A. 2003. Pharmacotherapy for dyslipidaemia--current therapies and future 
agents. Expert Opin Pharmacother, 4, 1901-38. 
123 
 
BISHOP, R. W. 1992. Structure of the hamster low density lipoprotein receptor gene. J Lipid Res, 33, 
549-57. 
BOERSEMA, P. J., MOHAMMED, S. & HECK, A. J. 2009. Phosphopeptide fragmentation and analysis 
by mass spectrometry. J Mass Spectrom, 44, 861-78. 
BONAVENTURA, A., CARBONE, F., VECCHIE, A., DALLEGRI, F., CAMICI, G. G., 
MONTECUCCO, F. & LIBERALE, L. 2017. Treatment with Proprotein Convertase 
Subtilisin/Kexin type 9 (PCSK9) Inhibitors to reduce cardiovascular inflammation and 
outcomes. Curr Med Chem. 
BOSCHETTI, E. & RIGHETTI, P. G. 2008. The ProteoMiner in the proteomic arena: a non-depleting 
tool for discovering low-abundance species. J Proteomics, 71, 255-64. 
BOTTOMLEY, M. J., CIRILLO, A., ORSATTI, L., RUGGERI, L., FISHER, T. S., SANTORO, J. C., 
CUMMINGS, R. T., CUBBON, R. M., LO SURDO, P., CALZETTA, A., NOTO, A., 
BAYSAROWICH, J., MATTU, M., TALAMO, F., DE FRANCESCO, R., SPARROW, C. P., 
SITLANI, A. & CARFI, A. 2009. Structural and biochemical characterization of the wild type 
PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem, 
284, 1313-23. 
BROWN, M. S. & GOLDSTEIN, J. L. 2006. Biomedicine. Lowering LDL--not only how low, but how 
long? Science, 311, 1721-3. 
BROWN, W. V. 1987. Fenofibrate, a third-generation fibric acid derivative. Am J Med, 83, 1-2. 
BULBULIA, R., BOWMAN, L., WALLENDSZUS, K., PARISH, S., ARMITAGE, J., PETO, R. & 
COLLINS, R. 2011. Effects on 11-year mortality and morbidity of lowering LDL cholesterol 
with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. 
Lancet, 378, 2013-20. 
CAMERON, J., RANHEIM, T., KULSETH, M. A., LEREN, T. P. & BERGE, K. E. 2008. Berberine 
decreases PCSK9 expression in HepG2 cells. Atherosclerosis, 201, 266-73. 
CANTO, J. G. & ISKANDRIAN, A. E. 2003. Major risk factors for cardiovascular disease: debunking 
the "only 50%" myth. Jama, 290, 947-9. 
CHACE, D. H., HILLMAN, S. L., MILLINGTON, D. S., KAHLER, S. G., ROE, C. R. & NAYLOR, E. 
W. 1995. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem 
mass spectrometry. Clin Chem, 41, 62-8. 
CHACE, D. H., MILLINGTON, D. S., TERADA, N., KAHLER, S. G., ROE, C. R. & HOFMAN, L. F. 
1993. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and 
tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem, 39, 66-71. 
CHANG-SHUN L., YU-RONG Z., YING-FENG Z., XIAO-YING L., 2016. Research progress on 
berberine with a special focus on its oral bioavailability. Fitoterapia, 109, 274–82. 
CHEN, W., FAN, D., MENG, L., MIAO, Y., YANG, S., WENG, Y., HE, H. & TANG, X. 2012. 
Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine 
in rats. Drug Dev Ind Pharm, 38, 104-10. 
CHEN, W., MIAO, Y. Q., FAN, D. J., YANG, S. S., LIN, X., MENG, L. K. & TANG, X. 2011. 
Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption 
in rats. AAPS PharmSciTech, 12, 705-11. 
124 
 
CHENG, Z., CHEN, A. F., WU, F., SHENG, L., ZHANG, H. K., GU, M., LI, Y. Y., ZHANG, L. N., 
HU, L. H., LI, J. Y. & LI, J. 2010. 8,8-Dimethyldihydroberberine with improved bioavailability 
and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem, 18, 5915-24. 
CHO, S. Y., KIM, J. S., LI, H., SHIM, C., LINHARDT, R. J. & KIM, Y. S. 2002. Enhancement of 
paracellular transport of heparin disaccharide across Caco-2 cell monolayers. Arch Pharm Res, 
25, 86-92. 
CODONY, R., COMPANO, R., GRANADOS, M., GARCIA-REGUEIRO, J. A. & PRAT, M. D. 2002. 
Residue analysis of macrolides in poultry muscle by liquid chromatography-electrospray mass 
spectrometry. J Chromatogr A, 959, 131-41. 
COHEN, J. C., BOERWINKLE, E., MOSLEY, T. H., JR. & HOBBS, H. H. 2006. Sequence variations 
in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 354, 1264-
72. 
COSTELLO, C. E. 1997. Time, life ... and mass spectrometry. New techniques to address biological 
questions. Biophys Chem, 68, 173-88. 
DALBOGE, L. S., PEDERSEN, P. J., HANSEN, G., FABRICIUS, K., HANSEN, H. B., JELSING, J. 
& VRANG, N. 2015. A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of 
Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents. PLoS One, 10, e0135634. 
DAVIGNON, J. 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation, 109, Iii39-43. 
DAVIS, M. T., BEIERLE, J., BURES, E. T., MCGINLEY, M. D., MORT, J., ROBINSON, J. H., 
SPAHR, C. S., YU, W., LUETHY, R. & PATTERSON, S. D. 2001. Automated LC-LC-MS-
MS platform using binary ion-exchange and gradient reversed-phase chromatography for 
improved proteomic analyses. J Chromatogr B Biomed Sci Appl, 752, 281-91. 
DEACON, M. P., MCGURK, S., ROBERTS, C. J., WILLIAMS, P. M., TENDLER, S. J., DAVIES, M. 
C., DAVIS, S. S. & HARDING, S. E. 2000. Atomic force microscopy of gastric mucin and 
chitosan mucoadhesive systems. Biochem J, 348 Pt 3, 557-63. 
DEFESCHE, J. C. 2004. Low-density lipoprotein receptor--its structure, function, and mutations. Semin 
Vasc Med, 4, 5-11. 
DOGGRELL, S. A. 2005. Berberine--a novel approach to cholesterol lowering. Expert Opin Investig 
Drugs, 14, 683-5. 
DOMON, B. & AEBERSOLD, R. 2006. Mass spectrometry and protein analysis. Science, 312, 212-7. 
DRAISCI, R., PALLESCHI, L., MARCHIAFAVA, C., FERRETTI, E. & DELLI QUADRI, F. 2001. 
Confirmatory analysis of residues of stanozolol and its major metabolite in bovine urine by 
liquid chromatography-tandem mass spectrometry. J Chromatogr A, 926, 69-77. 
DUNCOMBE, W. G. 1964. THE COLORIMETRIC MICRO-DETERMINATION OF NON-
ESTERIFIED FATTY ACIDS IN PLASMA. Clin Chim Acta, 9, 122-5. 
ECHAN, L. A., TANG, H. Y., ALI-KHAN, N., LEE, K. & SPEICHER, D. W. 2005. Depletion of 
multiple high-abundance proteins improves protein profiling capacities of human serum and 
plasma. Proteomics, 5, 3292-303. 
ELPHICK, M. C. 1968. Modified colorimetric ultramicro method for estimating Nefa in serum. J Clin 
Pathol, 21, 567-70. 
ENDO, A., TSUJITA, Y., KURODA, M. & TANZAWA, K. 1977. Inhibition of cholesterol synthesis in 
vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase. Eur J Biochem, 77, 31-6. 
125 
 
FASS, D., BLACKLOW, S., KIM, P. S. & BERGER, J. M. 1997. Molecular basis of familial 
hypercholesterolaemia from structure of LDL receptor module. Nature, 388, 691-3. 
FENG, Y., WANG, N., YE, X., LI, H., FENG, Y., CHEUNG, F. & NAGAMATSU, T. 2011. 
Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on 
carbon tetrachloride-induced chronic liver hepatotoxicity in rats. J Ethnopharmacol, 138, 683-
90. 
FENN, J. B., MANN, M., MENG, C. K., WONG, S. F. & WHITEHOUSE, C. M. 1989. Electrospray 
ionization for mass spectrometry of large biomolecules. Science, 246, 64-71. 
FERDINANDUSSE, S., DENIS, S., HOGENHOUT, E. M., KOSTER, J., VAN ROERMUND, C. W., 
L, I. J., MOSER, A. B., WANDERS, R. J. & WATERHAM, H. R. 2007. Clinical, biochemical, 
and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat, 28, 
904-12. 
FINNEY, D. J. 1964. Statistical method in biological assay, New York,, Hafner Pub. Co. 
FINNEY, D. J. 1971. Probit analysis, Cambridge Eng., University Press. 
FONSLOW, B. R., STEIN, B. D., WEBB, K. J., XU, T., CHOI, J., PARK, S. K. & YATES, J. R., 3RD 
2013. Digestion and depletion of abundant proteins improves proteomic coverage. Nat Methods, 
10, 54-6. 
FONSLOW, B. R., STEIN, B. D., WEBB, K. J., XU, T., CHOI, J., PARK, S. K. & YATES, J. R., 3RD 
2014. Addendum: Digestion and depletion of abundant proteins improves proteomic coverage. 
Nat Methods, 11, 347-8. 
FRESE, C. K., ALTELAAR, A. F., HENNRICH, M. L., NOLTING, D., ZELLER, M., GRIEP-
RAMING, J., HECK, A. J. & MOHAMMED, S. 2011. Improved peptide identification by 
targeted fragmentation using CID, HCD and ETD on an LTQ-Orbitrap Velos. J Proteome Res, 
10, 2377-88. 
FRUNGIERI, M. B., MAYERHOFER, A., ZITTA, K., PIGNATARO, O. P., CALANDRA, R. S. & 
GONZALEZ-CALVAR, S. I. 2005. Direct effect of melatonin on Syrian hamster testes: 
melatonin subtype 1a receptors, inhibition of androgen production, and interaction with the local 
corticotropin-releasing hormone system. Endocrinology, 146, 1541-52. 
GIBBONS, J. 2014. Western blot: protein transfer overview. N Am J Med Sci, 6, 158-9. 
GILLET, L. C., NAVARRO, P., TATE, S., ROST, H., SELEVSEK, N., REITER, L., BONNER, R. & 
AEBERSOLD, R. 2012. Targeted data extraction of the MS/MS spectra generated by data-
independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell 
Proteomics, 11, O111 016717. 
GOLDSTEIN, J. L. & BROWN, M. S. 1974. Binding and degradation of low density lipoproteins by 
cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with 
homozygous familial hypercholesterolemia. J Biol Chem, 249, 5153-62. 
GREEN, M. C., GRUENEBERG, H., HERTWIG, P., HESTON, W. E., LYON, M. F., MEDVEDEV, 
N. N., SNELL, G. D. & STAATS, J. 1963. A Revision of the Standardized Genetic 
Nomenclature for Mice. J Hered, 54, 159-62. 
GROSSIE, V. B., JR., YICK, J., ALPETER, M., WELBOURNE, T. C. & OTA, D. M. 1993. Glutamine 
stability in biological tissues evaluated by fluorometric analysis. Clin Chem, 39, 1059-63. 
GRUNDY, S. M. 1998. Consensus statement: Role of therapy with "statins" in patients with 
hypertriglyceridemia. Am J Cardiol, 81, 1b-6b. 
126 
 
Guidance for Industry Bioanalytical Method Validation. 
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/u
cm070107.pdf 
GUO, Y., LUO, J., TAN, S., OTIENO, B. O. & ZHANG, Z. 2013. The applications of Vitamin E TPGS 
in drug delivery. Eur J Pharm Sci, 49, 175-86. 
GUSTAVSSON, S. A., SAMSKOG, J., MARKIDES, K. E. & LANGSTROM, B. 2001. Studies of signal 
suppression in liquid chromatography-electrospray ionization mass spectrometry using volatile 
ion-pairing reagents. J Chromatogr A, 937, 41-7. 
GYGI, S. P., RIST, B., GERBER, S. A., TURECEK, F., GELB, M. H. & AEBERSOLD, R. 1999. 
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat 
Biotechnol, 17, 994-9. 
HALAMA, A., HORSCH, M., KASTENMULLER, G., MOLLER, G., KUMAR, P., PREHN, C., 
LAUMEN, H., HAUNER, H., HRABE DE ANGELIS, M., BECKERS, J., SUHRE, K. & 
ADAMSKI, J. 2016. Metabolic switch during adipogenesis: From branched chain amino acid 
catabolism to lipid synthesis. Arch Biochem Biophys, 589, 93-107. 
HANSSON, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 352, 
1685-95. 
HASHEMZAEI, M., ENTEZARI HERAVI, R., REZAEE, R., ROOHBAKHSH, A. & KARIMI, G. 
2017. Regulation of autophagy by some natural products as a potential therapeutic strategy for 
cardiovascular disorders. Eur J Pharmacol. 
HEATH, K. E., GAHAN, M., WHITTALL, R. A. & HUMPHRIES, S. E. 2001. Low-density lipoprotein 
receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new 
features and mutation analysis. Atherosclerosis, 154, 243-6. 
HIDALGO, I. J., RAUB, T. J. & BORCHARDT, R. T. 1989. Characterization of the human colon 
carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. 
Gastroenterology, 96, 736-49. 
HONE-MEI, Y., MING-FENG, X., YAN, W., XIN-XIA C., XIU-ZHONG Y., SHENG-XIANG R,. 
MENG-SU Z, YIN-FANG T., RU F., WEI-PING J., JUN L., WEI D., JIAN-DONG J., & XIN 
G., 2015. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease, PLOS ONE. 
10,e0134172. 
HORTON, J. D., COHEN, J. C. & HOBBS, H. H. 2007. Molecular biology of PCSK9: its role in LDL 
metabolism. Trends Biochem Sci, 32, 71-7. 
HORTON, J. D., CUTHBERT, J. A. & SPADY, D. K. 1993. Dietary fatty acids regulate hepatic low 
density lipoprotein (LDL) transport by altering LDL receptor protein and mRNA levels. J Clin 
Invest, 92, 743-9. 
HOU, Q., TAN, H. T., LIM, K. H., LIM, T. K., KHOO, A., TAN, I. B., YEOH, K. G. & CHUNG, M. 
C. 2013. Identification and functional validation of caldesmon as a potential gastric cancer 
metastasis-associated protein. J Proteome Res, 12, 980-90. 
HUANG, T. W., CHANG, C. L., KAO, E. S. & LIN, J. H. 2015. Effect of Hibiscus sabdariffa extract on 
high fat diet-induced obesity and liver damage in hamsters. Food Nutr Res, 59, 29018. 
HUBBARD, R. W., CHAMBERS, J. G., SANCHEZ, A., SLOCUM, R. & LEE, P. 1988. Amino acid 
analysis of plasma: studies in sample preparation. J Chromatogr, 431, 163-9. 
127 
 
HURTADO-GAITAN, E., SELLES-MARCHART, S., MARTINEZ-MARQUEZ, A., SAMPER-
HERRERO, A. & BRU-MARTINEZ, R. 2017. A Focused Multiple Reaction Monitoring 
(MRM) Quantitative Method for Bioactive Grapevine Stilbenes by Ultra-High-Performance 
Liquid Chromatography Coupled to Triple-Quadrupole Mass Spectrometry (UHPLC-QqQ). 
Molecules, 22. 
ITAYA, K. & UI, M. 1965. COLORIMETRIC DETERMINATION OF FREE FATTY ACIDS IN 
BIOLOGICAL FLUIDS. J Lipid Res, 6, 16-20. 
JAVITT, N. B. 1990. Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile 
acids. Faseb j, 4, 161-8. 
JEDRYCHOWSKI, M. P., HUTTLIN, E. L., HAAS, W., SOWA, M. E., RAD, R. & GYGI, S. P. 2011. 
Evaluation of HCD- and CID-type fragmentation within their respective detection platforms for 
murine phosphoproteomics. Mol Cell Proteomics, 10, M111 009910. 
JEON, H. & BLACKLOW, S. C. 2005. Structure and physiologic function of the low-density lipoprotein 
receptor. Annu Rev Biochem, 74, 535-62. 
JICKLING, G. C. & SPENCE, J. D. 2014. Free fatty acids to predict recurrent ischemic stroke. 
Neurology, 82, 1110-1. 
KANEHISA, M., GOTO, S., SATO, Y., KAWASHIMA, M., FURUMICHI, M. & TANABE, M. 2014. 
Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res, 
42, D199-205. 
KARAS, M. & HILLENKAMP, F. 1988. Laser desorption ionization of proteins with molecular masses 
exceeding 10,000 daltons. Anal Chem, 60, 2299-301. 
KHEIR, M. M., WANG, Y., HUA, L., HU, J., LI, L., LEI, F. & DU, L. 2010. Acute toxicity of berberine 
and its correlation with the blood concentration in mice. Food Chem Toxicol, 48, 1105-10. 
KONG, W., WEI, J., ABIDI, P., LIN, M., INABA, S., LI, C., WANG, Y., WANG, Z., SI, S., PAN, H., 
WANG, S., WU, J., WANG, Y., LI, Z., LIU, J. & JIANG, J. D. 2004. Berberine is a novel 
cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 
10, 1344-51. 
KONG, W. J., LIU, J. & JIANG, J. D. 2006. Human low-density lipoprotein receptor gene and its 
regulation. J Mol Med (Berl), 84, 29-36. 
KRISTENSEN, L. P., LARSEN, M. R., MICKLEY, H., SAABY, L., DIEDERICHSEN, A. C., 
LAMBRECHTSEN, J., RASMUSSEN, L. M. & OVERGAARD, M. 2014. Plasma proteome 
profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal 
protein vinculin. J Proteomics, 101, 141-53. 
KROK, K. A. & SEAVER, S. S. 1991. Realities of automating OPA HPLC amino acid analyses. 
Biotechniques, 10, 664-70. 
KUMAR, A. 2015. Current knowledge and pharmacological profile of berberine:An update Eur J 
Pharmacol, 761,288–97. 
LAMBERT, G., SJOUKE, B., CHOQUE, B., KASTELEIN, J. J. & HOVINGH, G. K. 2012. The PCSK9 
decade. J Lipid Res, 53, 2515-24. 
LAVI, L. E., HOLCENBERG, J. S., COLE, D. E. & JOLIVET, J. 1986. Sensitive analysis of asparagine 
and glutamine in physiological fluids and cells by precolumn derivatization with 
phenylisothiocyanate and reversed-phase high-performance liquid chromatography. J 
Chromatogr, 377, 155-63. 
128 
 
LECKER, J. L., MATTHAN, N. R., BILLHEIMER, J. T., RADER, D. J. & LICHTENSTEIN, A. H. 
2010. Impact of dietary fat type within the context of altered cholesterol homeostasis on 
cholesterol and lipoprotein metabolism in the F1B hamster. Metabolism, 59, 1491-501. 
LEE, J. H., KIM, J. M. & KIM, C. 2003. Pharmacokinetic analysis of rhein in Rheum undulatum L. J 
Ethnopharmacol, 84, 5-9. 
LI, H., CHEN, W., ZHOU, Y., ABIDI, P., SHARPE, O., ROBINSON, W. H., KRAEMER, F. B. & LIU, 
J. 2009. Identification of mRNA binding proteins that regulate the stability of LDL receptor 
mRNA through AU-rich elements. J Lipid Res, 50, 820-31. 
LI, Y. H., LI, Y., YANG, P., KONG, W. J., YOU, X. F., REN, G., DENG, H. B., WANG, Y. M., WANG, 
Y. X., JIANG, J. D. & SONG, D. Q. 2010. Design, synthesis, and cholesterol-lowering efficacy 
for prodrugs of berberrubine. Bioorg Med Chem, 18, 6422-8. 
LIBBY, P., RIDKER, P. M. & HANSSON, G. K. 2011. Progress and challenges in translating the 
biology of atherosclerosis. Nature, 473, 317-25. 
LIBBY, P., RIDKER, P. M. & MASERI, A. 2002. Inflammation and atherosclerosis. Circulation, 105, 
1135-43. 
LIN, S., YAO, G., QI, D., LI, Y., DENG, C., YANG, P. & ZHANG, X. 2008. Fast and efficient 
proteolysis by microwave-assisted protein digestion using trypsin-immobilized magnetic silica 
microspheres. Anal Chem, 80, 3655-65. 
LIU, G. L., FAN, L. M. & REDINGER, R. N. 1991. The association of hepatic apoprotein and lipid 
metabolism in hamsters and rats. Comp Biochem Physiol A Comp Physiol, 99, 223-8. 
LIU, Y. T., HAO, H. P., XIE, H. G., LAI, L., WANG, Q., LIU, C. X. & WANG, G. J. 2010. Extensive 
intestinal first-pass elimination and predominant hepatic distribution of berberine explain its 
low plasma levels in rats. Drug Metab Dispos, 38, 1779-84. 
LOCK, A. L., HORNE, C. A., BAUMAN, D. E. & SALTER, A. M. 2005. Butter naturally enriched in 
conjugated linoleic acid and vaccenic acid alters tissue fatty acids and improves the plasma 
lipoprotein profile in cholesterol-fed hamsters. J Nutr, 135, 1934-9. 
LOPEZ-FERRER, D., PETRITIS, K., HIXSON, K. K., HEIBECK, T. H., MOORE, R. J., BELOV, M. 
E., CAMP, D. G., 2ND & SMITH, R. D. 2008. Application of pressurized solvents for ultrafast 
trypsin hydrolysis in proteomics: proteomics on the fly. J Proteome Res, 7, 3276-81. 
LU, T., LIANG, Y., SONG, J., XIE, L., WANG, G. J. & LIU, X. D. 2006. Simultaneous determination 
of berberine and palmatine in rat plasma by HPLC-ESI-MS after oral administration of 
traditional Chinese medicinal preparation Huang-Lian-Jie-Du decoction and the 
pharmacokinetic application of the method. J Pharm Biomed Anal, 40, 1218-24. 
LUSIS, A. J. 2000. Atherosclerosis. Nature, 407, 233-41. 
LV, X. Y., LI, J., ZHANG, M., WANG, C. M., FAN, Z., WANG, C. Y. & CHEN, L. 2010. Enhancement 
of sodium caprate on intestine absorption and antidiabetic action of berberine. AAPS 
PharmSciTech, 11, 372-82. 
MACH, F., RIESEN, W. F., RODONDI, N. & VON ECKARDSTEIN, A. 2014. [Statin treatment in 
primary and secondary prevention--a statement]. Rev Med Suisse, 10, 2430-3. 
MAHMOOD, T. & YANG, P. C. 2012. Western blot: technique, theory, and trouble shooting. N Am J 
Med Sci, 4, 429-34. 
MAJI, D., SHAIKH, S., SOLANKI, D. & GAURAV, K. 2013. Safety of statins. Indian J Endocrinol 
Metab, 17, 636-46. 
129 
 
MARON, D. J., FAZIO, S. & LINTON, M. F. 2000. Current perspectives on statins. Circulation, 101, 
207-13. 
MASUDA, T., SUGIYAMA, N., TOMITA, M. & ISHIHAMA, Y. 2011. Microscale phosphoproteome 
analysis of 10,000 cells from human cancer cell lines. Anal Chem, 83, 7698-703. 
MATTHAN, N. R., DILLARD, A., LECKER, J. L., IP, B. & LICHTENSTEIN, A. H. 2009. Effects of 
dietary palmitoleic acid on plasma lipoprotein profile and aortic cholesterol accumulation are 
similar to those of other unsaturated fatty acids in the F1B golden Syrian hamster. J Nutr, 139, 
215-21. 
MEKADA, K., ABE, K., MURAKAMI, A., NAKAMURA, S., NAKATA, H., MORIWAKI, K., 
OBATA, Y. & YOSHIKI, A. 2009. Genetic differences among C57BL/6 substrains. Exp Anim, 
58, 141-9. 
MIHALIK, S. J., MICHALISZYN, S. F., DE LAS HERAS, J., BACHA, F., LEE, S., CHACE, D. H., 
DEJESUS, V. R., VOCKLEY, J. & ARSLANIAN, S. A. 2012. Metabolomic profiling of fatty 
acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for 
enhanced mitochondrial oxidation. Diabetes Care, 35, 605-11. 
MIYAZAKI, H., SHIRAI, E., ISHIBASHI, M. & NIIZIMA, K. 1978. Quantitative analysis of berberine 
in urine samples by chemical ionization mass fragmentography. J Chromatogr, 152, 79-86. 
MOLINA, H., PARMIGIANI, G. & PANDEY, A. 2005. Assessing reproducibility of a protein dynamics 
study using in vivo labeling and liquid chromatography tandem mass spectrometry. Anal Chem, 
77, 2739-44. 
MUKHERJEE, A. & HALDAR, C. 2015. Effect of 2-deoxy-D-glucose induced metabolic stress on 
testicular steroidogenesis and antioxidant status in golden hamster, Mesocricetus auratus: Role 
of photoperiod. J Photochem Photobiol B, 153, 40-50. 
MUKHERJEE, A. & HALDAR, C. 2016. Effect of Naltrexone on photoperiodic regulation of testicular 
steroidogenesis in adult golden hamster, Mesocricetus auratus. Gen Comp Endocrinol, 239, 89-
96. 
MURAKAMI, T., MISAKI, M., KOJIMA, Y., YAMADA, M., YUKI, M., HIGASHI, Y., AMAGASE, 
H., FUWA, T. & YATA, N. 1993. Effect of absorption promoters on subcutaneous absorption 
of human epidermal growth factor in rats. J Pharm Sci, 82, 236-9. 
NABEL, E. G. 2003. Cardiovascular disease. N Engl J Med, 349, 60-72. 
NAGELE, E., VOLLMER, M., HORTH, P. & VAD, C. 2004. 2D-LC/MS techniques for the 
identification of proteins in highly complex mixtures. Expert Rev Proteomics, 1, 37-46. 
NEUSCHWANDER-TETRI, B. A. 2010. Hepatic lipotoxicity and the pathogenesis of nonalcoholic 
steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology, 52, 774-
88. 
NEWGARD, C. B., AN, J., BAIN, J. R., MUEHLBAUER, M. J., STEVENS, R. D., LIEN, L. F., HAQQ, 
A. M., SHAH, S. H., ARLOTTO, M., SLENTZ, C. A., ROCHON, J., GALLUP, D., 
ILKAYEVA, O., WENNER, B. R., YANCY, W. S., JR., EISENSON, H., MUSANTE, G., 
SURWIT, R. S., MILLINGTON, D. S., BUTLER, M. D. & SVETKEY, L. P. 2009. A branched-
chain amino acid-related metabolic signature that differentiates obese and lean humans and 
contributes to insulin resistance. Cell Metab, 9, 311-26. 
NISTOR, A., BULLA, A., FILIP, D. A. & RADU, A. 1987. The hyperlipidemic hamster as a model of 
experimental atherosclerosis. Atherosclerosis, 68, 159-73. 
130 
 
NOVAK, M. 1965. COLORIMETRIC ULTRAMICRO METHOD FOR THE DETERMINATION OF 
FREE FATTY ACIDS. J Lipid Res, 6, 431-3. 
OAXACA-CASTILLO, D., ANDREOLETTI, P., VLUGGENS, A., YU, S., VAN VELDHOVEN, P. P., 
REDDY, J. K. & CHERKAOUI-MALKI, M. 2007. Biochemical characterization of two 
functional human liver acyl-CoA oxidase isoforms 1a and 1b encoded by a single gene. Biochem 
Biophys Res Commun, 360, 314-9. 
OHWADA, K. 1992. Body surface area of the golden Syrian hamster. Jikken Dobutsu, 41, 221-4. 
ORCI, L., CARPENTIER, J. L., PERRELET, A., ANDERSON, R. G., GOLDSTEIN, J. L. & BROWN, 
M. S. 1978. Occurrence of low density lipoprotein receptors within large pits on the surface of 
human fibroblasts as demonstrated by freeze-etching. Exp Cell Res, 113, 1-13. 
ORSO, E. & SCHMITZ, G. 2017. Lipoprotein(a) and its role in inflammation, atherosclerosis and 
malignancies. Clin Res Cardiol Suppl. 
PANUWET, P., HUNTER, R. E., JR., D'SOUZA, P. E., CHEN, X., RADFORD, S. A., COHEN, J. R., 
MARDER, M. E., KARTAVENKA, K., RYAN, P. B. & BARR, D. B. 2016. Biological Matrix 
Effects in Quantitative Tandem Mass Spectrometry-Based Analytical Methods: Advancing 
Biomonitoring. Crit Rev Anal Chem, 46, 93-105. 
PEAKE, R. W., LAW, T., HOOVER, P. N., GAEWSKY, L., SHKRETA, A. & KELLOGG, M. D. 2013. 
Improved separation and analysis of plasma amino acids by modification of the MassTrak AAA 
Solution Ultraperformance(R) liquid chromatography method. Clin Chim Acta, 423, 75-82. 
PIERCE, L. R., WYSOWSKI, D. K. & GROSS, T. P. 1990. Myopathy and rhabdomyolysis associated 
with lovastatin-gemfibrozil combination therapy. Jama, 264, 71-5. 
PIRILLO, A. & CATAPANO, A. L. 2015. Berberine, a plant alkaloid with lipid- and glucose-lowering 
properties: From in vitro evidence to clinical studies. Atherosclerosis, 243, 449-61. 
PITAS, R. E., INNERARITY, T. L., WEINSTEIN, J. N. & MAHLEY, R. W. 1981. Acetoacetylated 
lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence 
microscopy. Arteriosclerosis, 1, 177-85. 
PROETZEL, G. & WILES, M. V. 2010. Mouse models for drug discovery : methods and protocols, 
Totowa, N.J., Humana. 
QIN, X., CHEN, Q., SUN, C., WANG, C., PENG, Q., XIE, L., LIU, Y. & LI, S. 2013. High-throughput 
screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by 
iTRAQ combines lectin-related techniques. Med Oncol, 30, 420. 
RAAL, F. J., PILCHER, G. J., ILLINGWORTH, D. R., PAPPU, A. S., STEIN, E. A., LASKARZEWSKI, 
P., MITCHEL, Y. B. & MELINO, M. R. 1997. Expanded-dose simvastatin is effective in 
homozygous familial hypercholesterolaemia. Atherosclerosis, 135, 249-56. 
RADER, D. J. & DAUGHERTY, A. 2008. Translating molecular discoveries into new therapies for 
atherosclerosis. Nature, 451, 904-13. 
RAY, K. K. & CANNON, C. P. 2005. The potential relevance of the multiple lipid-independent 
(pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll 
Cardiol, 46, 1425-33. 
RAY, S., REDDY, P. J., JAIN, R., GOLLAPALLI, K., MOIYADI, A. & SRIVASTAVA, S. 2011. 
Proteomic technologies for the identification of disease biomarkers in serum: advances and 
challenges ahead. Proteomics, 11, 2139-61. 
131 
 
RIGHETTI, P. G., BOSCHETTI, E., LOMAS, L. & CITTERIO, A. 2006. Protein Equalizer Technology : 
the quest for a "democratic proteome". Proteomics, 6, 3980-92. 
ROBB, D. B., COVEY, T. R. & BRUINS, A. P. 2000. Atmospheric pressure photoionization: an 
ionization method for liquid chromatography-mass spectrometry. Anal Chem, 72, 3653-9. 
ROSS, P. L., HUANG, Y. N., MARCHESE, J. N., WILLIAMSON, B., PARKER, K., HATTAN, S., 
KHAINOVSKI, N., PILLAI, S., DEY, S., DANIELS, S., PURKAYASTHA, S., JUHASZ, P., 
MARTIN, S., BARTLET-JONES, M., HE, F., JACOBSON, A. & PAPPIN, D. J. 2004. 
Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric 
tagging reagents. Mol Cell Proteomics, 3, 1154-69. 
SACKS, F. M., PFEFFER, M. A., MOYE, L. A., ROULEAU, J. L., RUTHERFORD, J. D., COLE, T. 
G., BROWN, L., WARNICA, J. W., ARNOLD, J. M., WUN, C. C., DAVIS, B. R. & 
BRAUNWALD, E. 1996. The effect of pravastatin on coronary events after myocardial 
infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial 
investigators. N Engl J Med, 335, 1001-9. 
SAHEBKAR, A., RATHOUSKA, J., SIMENTAL-MENDIA, L. E. & NACHTIGAL, P. 2016. Statin 
therapy and plasma cortisol concentrations: A systematic review and meta-analysis of 
randomized placebo-controlled trials. Pharmacol Res, 103, 17-25. 
SARIOGLU, H., BRANDNER, S., JACOBSEN, C., MEINDL, T., SCHMIDT, A., KELLERMANN, J., 
LOTTSPEICH, F. & ANDRAE, U. 2006. Quantitative analysis of 2,3,7,8-tetrachlorodibenzo-
p-dioxin-induced proteome alterations in 5L rat hepatoma cells using isotope-coded protein 
labels. Proteomics, 6, 2407-21. 
SCHUHMACHER, R., SULYOK, M. & KRSKA, R. 2008. Recent developments in the application of 
liquid chromatography-tandem mass spectrometry for the determination of organic residues and 
contaminants. Anal Bioanal Chem, 390, 253-6. 
SEIDAH, N. G., BENJANNET, S., WICKHAM, L., MARCINKIEWICZ, J., JASMIN, S. B., STIFANI, 
S., BASAK, A., PRAT, A. & CHRETIEN, M. 2003. The secretory proprotein convertase neural 
apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. 
Proc Natl Acad Sci U S A, 100, 928-33. 
SHERWOOD, R. A. 2000. Amino acid measurement in body fluids using PITC derivatives. Methods 
Mol Biol, 159, 169-75. 
SHI, S. R., LIU, C., BALGLEY, B. M., LEE, C. & TAYLOR, C. R. 2006. Protein extraction from 
formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J 
Histochem Cytochem, 54, 739-43. 
SHLIAHA, P. V., BOND, N. J., GATTO, L. & LILLEY, K. S. 2013. Effects of traveling wave ion 
mobility separation on data independent acquisition in proteomics studies. J Proteome Res, 12, 
2323-39. 
SIMOENS, S. & SINNAEVE, P. R. 2013. Generic atorvastatin, the Belgian statin market and the cost-
effectiveness of statin therapy. Cardiovasc Drugs Ther, 27, 49-60. 
STARKE, I., KLEINPETER, E. & KAMM, B. 2001. Separation, identification, and quantification of 
amino acids in L-lysine fermentation potato juices by gas chromatography-mass spectrometry. 
Fresenius J Anal Chem, 371, 380-4. 
STARY, H. C. 2000. Natural history and histological classification of atherosclerotic lesions: an update. 
Arterioscler Thromb Vasc Biol, 20, 1177-8. 
132 
 
STEIN, E. A. & SWERGOLD, G. D. 2013. Potential of proprotein convertase subtilisin/kexin type 9 
based therapeutics. Curr Atheroscler Rep, 15, 310. 
STEPHAN, Z. F. & YURACHEK, E. C. 1993. Rapid fluorometric assay of LDL receptor activity by 
DiI-labeled LDL. J Lipid Res, 34, 325-30. 
SUDHOF, T. C., GOLDSTEIN, J. L., BROWN, M. S. & RUSSELL, D. W. 1985. The LDL receptor 
gene: a mosaic of exons shared with different proteins. Science, 228, 815-22. 
SUN, L., TAO, D., HAN, B., MA, J., ZHU, G., LIANG, Z., SHAN, Y., ZHANG, L. & ZHANG, Y. 
2011. Ionic liquid 1-butyl-3-methyl imidazolium tetrafluoroborate for shotgun membrane 
proteomics. Anal Bioanal Chem, 399, 3387-97. 
SUN, Y., XUN, K., WANG, Y. & CHEN, X. 2009. A systematic review of the anticancer properties of 
berberine, a natural product from Chinese herbs. Anticancer Drugs, 20, 757-69. 
SVENNEBRING, A. 2016. The connection Between Plasma Protein Binding and Acute Toxicity as 
Determined by the LD50 Value. Drug Dev Res, 77, 3-11. 
SWANEY, D. L., WENGER, C. D. & COON, J. J. 2010. Value of using multiple proteases for large-
scale mass spectrometry-based proteomics. J Proteome Res, 9, 1323-9. 
TABESHPOUR, J., IMENSHAHIDI, M, HOSSEINZADEH, H. 2017. A review of the effects of 
Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med 
Sci, 20, 557-8. 
TANG, J., FENG, Y., TSAO, S., WANG, N., CURTAIN, R. & WANG, Y. 2009. Berberine and Coptidis 
rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. 
J Ethnopharmacol, 126, 5-17. 
TANIGUCHI, A., NAKAI, Y., FUKUSHIMA, M., TERAMURA, S., HAYASHI, R., HAMA, K., 
MARUMOTO, K., WATANABE, T., YOSHIOKA, I., SAKAGUCHI, K., KISHIMOTO, H., 
MATSUSHITA, K., OKUMURA, T., TOKUYAMA, K., NAGASAKA, S. & SAKAI, M. 2002. 
Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role 
of nonesterified fatty acids. Metabolism, 51, 539-43. 
TARANTINO, N., SANTORO, F., DE GENNARO, L., CORREALE, M., GUASTAFIERRO, F., 
GAGLIONE, A., DI BIASE, M. & BRUNETTI, N. D. 2017. Fenofibrate/simvastatin fixed-
dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. 
Vasc Health Risk Manag, 13, 29-41. 
THAKUR, S. S., GEIGER, T., CHATTERJEE, B., BANDILLA, P., FROHLICH, F., COX, J. & MANN, 
M. 2011. Deep and highly sensitive proteome coverage by LC-MS/MS without prefractionation. 
Mol Cell Proteomics, 10, M110 003699. 
TINNIKOV, A. A. & BOONSTRA, R. 1999. Colorimetric micro-determination of free fatty acids in 
plasma using microplate readers. Clin Chim Acta, 281, 159-62. 
TOLLESHAUG, H., GOLDSTEIN, J. L., SCHNEIDER, W. J. & BROWN, M. S. 1982. Posttranslational 
processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia. Cell, 
30, 715-24. 
TSAI, T. Y., CHU, L. H., LEE, C. L. & PAN, T. M. 2009. Atherosclerosis-preventing activity of lactic 
acid bacteria-fermented milk-soymilk supplemented with Momordica charantia. J Agric Food 
Chem, 57, 2065-71. 
133 
 
TSUTSUMI, K., HAGI, A. & INOUE, Y. 2001. The relationship between plasma high density 
lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of 
healthy experimental animals. Biol Pharm Bull, 24, 579-81. 
TUBAON, R. M., HADDAD, P. R. & QUIRINO, J. P. 2017. Sample clean-up strategies for electrospray 
ionization mass spectrometry applications in bottom-up proteomics: Trends from 2012-2016. 
Proteomics. 
UGAWA, T., KAKUTA, H., MORITANI, H. & INAGAKI, O. 2002. Effect of YM-53601, a novel 
squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. Br J 
Pharmacol, 137, 561-9. 
URSO, R., BLARDI, P. & GIORGI, G. 2002. A short introduction to pharmacokinetics. Eur Rev Med 
Pharmacol Sci, 6, 33-44. 
VARIN, A., THOMAS, C., ISHIBASHI, M., MENEGAUT, L., GAUTIER, T., TROUSSON, A., 
BERGAS, V., DE BARROS, J. P., NARCE, M., LOBACCARO, J. M., LAGROST, L. & 
MASSON, D. 2015. Liver X receptor activation promotes polyunsaturated fatty acid synthesis 
in macrophages: relevance in the context of atherosclerosis. Arterioscler Thromb Vasc Biol, 35, 
1357-65. 
VISHRAM, J. K. 2014. Prognostic interactions between cardiovascular risk factors. Dan Med J, 61, 
B4892. 
WAHL, S., YU, Z., KLEBER, M., SINGMANN, P., HOLZAPFEL, C., HE, Y., MITTELSTRASS, K., 
POLONIKOV, A., PREHN, C., ROMISCH-MARGL, W., ADAMSKI, J., SUHRE, K., 
GRALLERT, H., ILLIG, T., WANG-SATTLER, R. & REINEHR, T. 2012. Childhood obesity 
is associated with changes in the serum metabolite profile. Obes Facts, 5, 660-70. 
WANDERS, R. J. 2004. Peroxisomes, lipid metabolism, and peroxisomal disorders. Mol Genet Metab, 
83, 16-27. 
WANG, K., FENG, X., CHAI, L., CAO, S. & QIU, F. 2017. The metabolism of berberine and its 
contribution to the pharmacological effects. Drug Metab Rev, 1-54. 
WEBER, C. & NOELS, H. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 
17, 1410-22. 
WIESE, S., REIDEGELD, K. A., MEYER, H. E. & WARSCHEID, B. 2007. Protein labeling by iTRAQ: 
a new tool for quantitative mass spectrometry in proteome research. Proteomics, 7, 340-50. 
WILLSON, T. M., BROWN, P. J., STERNBACH, D. D. & HENKE, B. R. 2000. The PPARs: from 
orphan receptors to drug discovery. J Med Chem, 43, 527-50. 
WILSON, T. A., NICOLOSI, R. J., SAATI, A., KOTYLA, T. & KRITCHEVSKY, D. 2006. Conjugated 
linoleic acid isomers reduce blood cholesterol levels but not aortic cholesterol accumulation in 
hypercholesterolemic hamsters. Lipids, 41, 41-8. 
WOJNICZ, A., AVENDANO-ORTIZ, J., DE PASCUAL, R., RUIZ-PASCUAL, L., GARCIA, A. G. & 
RUIZ-NUNO, A. 2016. Simultaneous monitoring of monoamines, amino acids, nucleotides and 
neuropeptides by liquid chromatography-tandem mass spectrometry and its application to 
neurosecretion in bovine chromaffin cells. J Mass Spectrom, 51, 651-664. 
WOONTNER, M. & GOODMAN, S. I. 2006. Chromatographic analysis of amino and organic acids in 
physiological fluids to detect inborn errors of metabolism. Curr Protoc Hum Genet, Chapter 17, 
Unit 17.2. 
134 
 
YAMANA, R., IWASAKI, M., WAKABAYASHI, M., NAKAGAWA, M., YAMANAKA, S. & 
ISHIHAMA, Y. 2013. Rapid and deep profiling of human induced pluripotent stem cell 
proteome by one-shot NanoLC-MS/MS analysis with meter-scale monolithic silica columns. J 
Proteome Res, 12, 214-21. 
YANG, N., GUO, S., ZHENG, F., GAN, X., NING, L. & DONG, S. 2014. High plasma fatty acid 
concentrations were present in non-diabetic patients with coronary heart disease. Clin Lab, 60, 
125-31. 
YIN, J., ZHANG, H. & YE, J. 2008. Traditional chinese medicine in treatment of metabolic syndrome. 
Endocr Metab Immune Disord Drug Targets, 8, 99-111. 
YOUNES, I. & RINAUDO, M. 2015. Chitin and chitosan preparation from marine sources. Structure, 
properties and applications. Mar Drugs, 13, 1133-74. 
YU, Y., CUI, J., WANG, X., LIU, Y. & YANG, P. 2004. Studies on peptide acetylation for stable-isotope 
labeling after 1-D PAGE separation in quantitative proteomics. Proteomics, 4, 3112-20. 
YUN, S., HABICHT, J. P., MILLER, D. D. & GLAHN, R. P. 2004. An in vitro digestion/Caco-2 cell 
culture system accurately predicts the effects of ascorbic acid and polyphenolic compounds on 
iron bioavailability in humans. J Nutr, 134, 2717-21. 
ZHANG, D. W., LAGACE, T. A., GARUTI, R., ZHAO, Z., MCDONALD, M., HORTON, J. D., 
COHEN, J. C. & HOBBS, H. H. 2007. Binding of proprotein convertase subtilisin/kexin type 9 
to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor 
recycling and increases degradation. J Biol Chem, 282, 18602-12. 
ZHANG, Y., LI, X., ZOU, D., LIU, W., YANG, J., ZHU, N., HUO, L., WANG, M., HONG, J., WU, P., 
REN, G. & NING, G. 2008. Treatment of type 2 diabetes and dyslipidemia with the natural 
plant alkaloid berberine. J Clin Endocrinol Metab, 93, 2559-65. 
ZHANG, Y., ZHU, H. X. & GUO, L. W. 2012. [Intestinal absorption of berberine alone and in 
combinations by rats single pass intestinal perfusion in situ]. Yao Xue Xue Bao, 47, 233-8. 
ZI-MIN, Y., YUE, C., HUI, G., JIA, L., GUI-RONG, C. & WANG, J. 2017. Comparative 
Pharmacokinetic Profiles of Three Protoberberine-type Alkaloids from Raw and Bile-processed 
Rhizoma coptidis in Heat Syndrome Rats. Pharmacogn Mag, 13, 51-5
135 
 
136 
 
 
  
137 
 
 
